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 Canine neoplasms provide an opportunity to study genetic risk, pathogenesis, clinical 
progression of disease, and novel therapeutics, which may translate to human medicine. Canine B-cell 
chronic lymphocytic leukemia (BCLL) is a common neoplasm in dogs that is defined by an expansion of 
small-sized CD21+ B cells in the peripheral blood. This disease has a similar clinical presentation to 
human chronic lymphocytic leukemia (CLL), and we hypothesize that canine BCLL may be a useful 
natural animal model for human CLL. The aims of this thesis were to evaluate clinical progression and 
molecular features of canine BCLL, including immunoglobulin heavy variable region (IGHV) gene 
mutation status and gene expression profiling. We evaluated breed-specific differences in canine BCLL 
and compared findings to human CLL. Additionally, we identified a syndrome in English bulldogs 
characterized by small cell B-cell lymphocytosis, which is distinct from BCLL.  
 In Chapter 1, we investigated IGHV gene mutation status in canine BCLL. Human CLL is a 
heterogeneous disease, and molecular subtypes of CLL patients are defined by whether IGHV genes in 
malignant B cells have undergone somatic hypermutation. These subtypes, termed unmutated IGHV CLL 
and mutated IGHV CLL have different cellular origins, B-cell activation and clinical outcomes. We 
sequenced immunoglobulin heavy chain VDJ gene rearrangements in 55 canine patients with BCLL, 
including 36 non-Boxer and 19 Boxer dogs, 11 Boxers with large B-cell lymphoma, and 6 healthy control 
dogs (3 Boxers and 3 non-Boxers). The majority of non-Boxer BCLL cases (75%) had mutated IGHV genes, 
which is associated with favorable prognosis in human CLL. The majority of Boxer BCLL cases (79%) had 
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unmutated IGHV genes, which is associated with poor prognosis in human CLL. BCLL IGHV gene usage 
and mutation status were compared to Boxers with large B-cell lymphoma and the normal IGHV 
repertoire of control dogs. IGHV3-41 was preferentially used in Boxers with BCLL, large B-cell lymphoma 
and without lymphoproliferative disease. However, preferential use of unmutated IGHV genes was 
unique to Boxers with BCLL. These results suggest that Boxers with BCLL may be a valuable model to 
investigate unmutated IGHV CLL, and we hypothesized that Boxers would have more aggressive disease. 
 In Chapter 2, we examined clinical outcome in canine BCLL. Previous small-scale BCLL outcome 
studies suggested that BCLL has an indolent clinical course, but there was a wide range in survival times, 
similar to human CLL. We hypothesized that canine BCLL has a heterogeneous clinical progression and 
certain clinical or flow cytometric factors are prognostic. We performed a retrospective study, reviewing 
the medical records for 121 canine BCLL cases from 3 major breed groups: small breed dogs (n=55), due 
to increased risk of BCLL; Boxers (n=33), due to preferential use of unmutated IGHV genes; and other 
breeds (n=33), to compare outcome with small breed cases. We examined clinical data, laboratory data, 
treatment and survival data, and measured cellular proliferation by the percent of Ki67-expressing 
CD21+ B cells by flow cytometry in a subset of cases. The median overall survival time (MST) for all cases 
was 300 days, with a wide range in survival times (1-1644 days). Boxers had significantly shorter survival 
(MST, 178 days) compared to non-Boxers (MST, 423 days), and there was no significant survival 
difference between small breeds and other non-Boxer breeds. Boxers had significantly higher Ki67 
expression than non-Boxers, indicating increased tumor cell proliferation. Cases with high Ki67 (>40% 
Ki67-expressing B cells) had significantly shorter survival (MST, 173 days) than cases with <40% Ki67 
(MST undetermined), irrespective of breed. Additionally, a high presenting lymphocyte count and 
clinical signs at diagnosis were associated with poor prognosis. In summary, BCLL demonstrated a 
heterogeneous clinical course, like human CLL, and Boxer dogs and cases with high Ki67 expression had 
more aggressive disease.  
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 In Chapter 3, we investigated the gene expression profile of canine BCLL, and compared these 
results to the human CLL gene signature. We measured expression of 327 genes relevant to human CLL 
by NanoString analysis in BCLL cases (n=26), large B-cell lymphoma cases (n=23) and sorted control 
lymph node B cells (n=8). We performed RNA Sequencing on 12 BCLL cases and 3 sorted control lymph 
node B cell samples. By both methods, we found that differentially expressed genes in canine BCLL cases 
were significantly enriched for human CLL gene signatures. Canine BCLL was not enriched for gene sets 
from other human B-cell neoplasms, including mantle cell lymphoma, splenic marginal zone lymphoma 
and follicular lymphoma. Canine BCLL had upregulation of cytokine signaling pathways, KRAS signaling, 
NF-κB signaling and B-cell receptor signaling pathways. Additionally, we identified two subgroups of 
BCLL cases by transcriptome analysis: BCLL subgroup 1 and 2. BCLL subgroup 2 had overexpression of 
cell cycle progression and proliferation genes and BCLL subgroup 1 had overexpression of genes 
regulated by NF-κB in response to TNF and ribosome and spliceosome genes. BCLL subgroup 2 had 
significantly higher MKI67 expression and an overrepresentation of Boxers, suggesting this molecular 
subgroup may have poorer prognosis. These results identified similarities in gene expression profiles 
between canine BCLL and human CLL and identified two molecular subgroups of BCLL for further study. 
 In Chapter 4, we investigated a syndrome of small cell B-cell lymphocytosis in English bulldogs. 
We previously found that this breed disproportionally develops an expansion of small B cells, which was 
previously interpreted as BCLL. However, English bulldogs had a unique clinical presentation compared 
to conventional BCLL cases, raising the possibility that these dogs have a different B-cell 
lymphoproliferative disorder. We examined 84 cases of B-cell lymphocytosis in English bulldogs, 
assessing clinical presentation, flow cytometry features, B-cell clonality, and immunoglobulin 
gammopathy patterns. Clonality analysis by the PCR for antigen receptor rearrangement assay 
determined that 70% of cases had polyclonal or restricted polyclonal immunoglobulin gene 
rearrangements, suggesting nonmalignant B-cell expansion. Expanded B cells expressed low levels of 
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class II MHC and CD25. Young male English bulldogs were overrepresented. Splenomegaly was common, 
and the majority of cases had hyperglobulinemia, characterized by IgA +/- IgM polyclonal or restricted 
polyclonal gammopathy patterns. We hypothesize that this syndrome, termed polyclonal B-cell 
lymphocytosis in English bulldogs (PBLEB), has a genetic basis. 
 In conclusion, this dissertation contributes to our understanding of small cell B-cell 
lymphocytosis syndromes in dogs. We examined clinical and molecular heterogeneity in canine BCLL, 
identifying clinical and molecular subgroups of cases, which helps improve management of canine BCLL 
and lays the foundation to further study pathogenesis in this common canine neoplasm. Additionally, 
we identified similarities between canine BCLL and human CLL, supporting the hypothesis that this 
canine population may be a useful translation model for CLL. Finally, we identified a unique B-cell 
syndrome in English bulldogs, broadening our understanding of the spectrum of small B-cell 
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Human non-Hodgkin lymphoma 
Non-Hodgkin lymphomas (NHLs) are comprised of a heterogeneous group of lymphoid tumors, 
including all lymphomas not classified as Hodgkin lymphoma.  Non-Hodgkin lymphoma accounts for an 
estimated 4.3% of all new cancer cases in the United States, with 19.6 NHL cases per 100,000 men and 
women diagnosed per year.1 Lymphomas are classified by the World Health Organization classification 
of lymphoid neoplasms, which was revised most recently in 2016.2,3 This classification system includes 
more than 50 subtypes of NHL. A combination of histology, immunophenotyping, cytogenetics, and 
genetic mutation analysis are used to subtype lymphoma and provide prognosis. Proper classification is 
important as different NHL subtypes have highly variable clinical outcomes and treatment indications. 
Additionally, as targeted therapies have developed, identification of targetable genetic alterations is 
increasingly important.  
Approximately 90% of NHL cases are of B-cell origin, with T-cell and natural killer cell 
lymphomas occurring at lower frequencies.4 The frequency of lymphoma subtypes differs 
geographically. Diffuse large B-cell lymphoma (DLBCL) is the most common subtype in developed 
regions (28.9%), followed by follicular lymphoma (25.5%), marginal zone lymphoma of MALT type (8.8%) 
or nodal/splenic type (3.0%), mantle cell lymphoma (7.8%), and chronic lymphocytic leukemia/small 
lymphocytic lymphoma (CLL/SLL) (7.0%).4 Burkitt lymphoma (a B-cell subtype), precursor B- and T-
lymphoblastic leukemia/lymphoma, and extranodal natural killer/T-cell lymphoma subtypes are 
significantly increased in developing regions, but still account for relatively small proportions of cases.4  
Lymphomas are derived from a clonal expansion of lymphocytes. Neoplastic B cells and T cells 
typically have clonal immunoglobulin (IG) and T-cell receptor (TCR) gene rearrangements, respectively, 
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though immature precursor neoplasms may have clonal cross-lineage rearrangements or clonal 
rearrangements of both IG and TCR loci.5 Clonality of antigen receptors is determined by evaluating the 
size of the gene rearrangements. Historically, the immunoglobulin heavy chain (IGH) and T-cell receptor 
gamma (TRG) loci were evaluated, but more recently clonality assessment has expanded to 
immunoglobulin light chain kappa (IGK) and lambda (IGL) loci and T-cell receptor beta (TRB).6 Antigen 
receptor gene rearrangements are composed of variable (V), joining (J), and in some cases, diversity (D) 
genes. The IGH and TRB loci form a VDJ rearrangement and IGK, IGL and TRG loci form a VJ 
rearrangement.7 The loci contain multiple V, D, and J genes and a recombinase enzyme complex 
containing RAG1 and RAG2 proteins rearrange individual genes in each lymphocyte to form a V(D)J 
rearrangement.8 Nucleotides are then added or subtracted at gene junctions, further adding to the 
diversity of gene rearrangements between lymphocytes. A polyclonal or reactive population of 
lymphocytes will have diverse antigen receptor rearrangements, while a clonal or neoplastic population 
will have identical rearrangements.9 Evaluating the homogeneity of antigen receptor gene 
rearrangements in a lymphocyte population by polymerase chain reaction is the foundation of clonality 
testing.9 Clonality testing is very useful in supporting a diagnosis of lymphoma, particularly in challenging 
cases where histology and/or immunophenotyping are not definitive.  
B-cell lymphoma: cell of origin 
 Different lymphoma subtypes are derived from a clonal expansion of lymphocytes at different 
stages of development. The normal cell counterpart, or cell of origin, has been well-characterized for 
many B-cell lymphoma subtypes. Development of B cells is characterized and guided by the ordered 
rearrangement of IG heavy chain and light chain loci to form a functional B-cell receptor (BCR).7 B-cell 
precursors in the bone marrow rearrange IG genes and undergo negative selection to remove immature 
B cells capable of binding self-antigens. B cells migrate to peripheral lymphoid organs, where mature B 
cells are activated upon binding to foreign antigen. Within the germinal center, B cells expand, undergo 
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somatic hypermutation to increase antibody affinity for antigen, and undergo class switch 
recombination to isotype switch from IgM and IgD to IgG, IgA or IgE. Activated B cells give rise to plasma 
cells, capable of secreting antibody, and memory B cells, which can expand during secondary immune 
responses. Cellular morphology, immunophenotype, mutation status of IG gene rearrangements 
(reflecting somatic hypermutation) and gene expression profiling help to identify the cell of origin for 
lymphoma subtypes.  
A number of B-cell lymphomas are derived from germinal center B cells, likely because of the 
high rate of B-cell proliferation and/or because processes occurring in the germinal center reaction are 
error-prone. Errors during somatic hypermutation and class switch recombination can allow for IG locus 
translocations, which bring proto-oncogenes undergo the control of IG enhancers.10 Follicular 
lymphomas are derived from B cells with germinal center differentiation, and therefore, express 
markers normally found in the germinal center, including CD10, BCL6 and HGAL.11 DLBCL contains two 
major subgroups, derived from germinal center B cells (GCB type) or activated peripheral B cells (ABC 
type), which have different prognoses.12  
The cell of origin for CLL/SLL is still controversial, as there is no known normal B-cell counterpart 
with the immunophenotype of CLL/SLL cells. CLL has two molecular subtypes with different prognoses, 
which are defined by whether the immunoglobulin heavy chain variable (IGHV) genes have undergone 
somatic hypermutation.13,14 This dichotomy in IGHV mutation status suggests that unmutated IGHV CLL 
and mutated IGHV CLL have different origins, derived from pre-germinal center B cells and post-
germinal center B cells, respectively. Gene expression profiling by Seifert et al. suggested that 
unmutated CLL and mutated CLL were most similar to CD5+ B cells, which predominantly have 
unmutated IGHV genes.15 However, this group identified a small subset of normal CD5+ B cells that 
express the memory B-cell marker CD27 and have mutated IGHV genes. They concluded that unmutated 
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CLL is derived from CD5+CD27- B cells and mutated CLL is derived from CD5+CD27+ post–germinal 
center memory B cells.15  
B-cell lymphoma pathogenesis 
 While events such as chromosomal translocations often incite malignant transformation, many 
B-cell lymphoma subtypes are dependent upon BCR signaling and signals from the microenvironment 
for tumor cell survival and proliferation.16 B cells may be stimulated via T-cell dependent or independent 
mechanisms.7 T-cell dependent responses require interaction between CD40 ligand on T helper cells 
with CD40 expressed on B cells, resulting in T cells releasing cytokines that promote B cell proliferation, 
differentiation and class switching. T-cell independent activation can occur when an antigen binds 
pattern recognition receptors, such as Toll-like receptors, or when an antigen binds to and stimulates 
signaling through the BCR. The BCR is composed of surface immunoglobulin molecules and signal 
transduction cofactors (CD79A and CD79B). Following BCR crosslinking, signals are transmitted through 
intracellular tyrosine kinases, which activate downstream messengers such as the RAS/MEK/ERK 
pathway, AKT mTOR pathway, and protein kinase C pathway. Activation alters transcription factors such 
as NF-κB and MYC, which promote B-cell survival and proliferation. Tumors including CLL and mantle cell 
lymphoma are dependent on BCR signaling, as evidenced by the efficacy of BCR pathway inhibitors in 
treating these tumors.17 Additionally, subgroups of unrelated patients have IG gene repertoire biases 
and highly similar BCR amino acid sequences.18,19 These stereotyped BCRs are additional evidence that 
these neoplasms developed under antigen selection.  
 In tumors such as follicular lymphoma and CLL, malignant B cells require interactions with the 
tumor microenvironment to maintain tumor cell survival and proliferation. Follicular lymphoma cells 
require interaction with T cells and follicular dendritic cells in the germinal center.20 Follicular lymphoma 
prognosis is predicted by the gene expression signatures of the non-malignant immune cells in the 
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tumor, highlighting how cells in the microenvironment can modulate tumor behavior.21 CLL cells also 
require signals from the microenvironment in order to proliferate. CLL cells circulating in the peripheral 
blood have a quiescent phenotype.22 Proliferation mainly occurs in proliferation centers within the 
lymph node and bone marrow, which contain CD4+ T cells that can activate CLL cells via CD40-CD40 
ligand binding.23,24 Expanded and highly active proliferation centers are associated with a more 
aggressive clinical course.25 Stromal cells in the marrow support CLL cell survival through integrin 
interaction (VLA-4 and VCAM-1) and secretion of chemokines, such as CXCL12, which interacts with 
CXCR4 on CLL cells.26–28 Nurselike cells found in secondary lymphoid organs activate BCR signaling and 
provide survival signals to CLL cells.29–31 
Chronic lymphocytic leukemia 
 Chronic lymphocytic leukemia is the most common leukemia of adults in western countries.1,32 
This neoplasm is defined by an accumulation of CD5+ B cells in the peripheral blood, bone marrow, and 
secondary lymphoid organs.3 When lymphadenopathy is present and there are <5,000 B cells/µL in the 
peripheral blood, patients are diagnosed with small lymphocytic lymphoma (SLL).33 CLL and SLL are 
considered different manifestations of the same disease. CLL typically affects older patients, with a 
median age at diagnosis of 72 years old.32 Relatives of CLL patients have an increased risk of developing 
this tumor, suggesting a genetic predisposition.34 Genome-wide association studies (GWAS) have 
identified over 20 loci associated with increased risk of CLL, including loci near genes associated with 
apoptosis.35,36 
 CLL is characterized by an expansion of small-sized lymphocytes with mature-appearing 
morphology in the blood.32 CLL is usually diagnosed by immunophenotyping of the peripheral blood, 
which identifies an expansion of CD19+ CD5+ CD23+ B cells with dim CD20 expression.37 Cases rarely 
have lymph node biopsies, except for the minority of cases affected with SLL. Unlike other NHL 
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subtypes, there is no one chromosomal translocation that defines CLL. The four most common genomic 
aberrations include: del13q14, resulting in loss of miR-15a and miR16-1, which regulate function of the 
anti-apoptotic gene BCL2;38,39 trisomy 12, which affects NFAT signaling involved in cell cycle regulation 
and apoptosis;40 del11q22-q23, which affects the tumor suppressor gene ATM involved in DNA damage 
response;41,42 and del17p13, which affects the tumor suppressor gene TP53 and is associated with very 
poor prognosis.43 CLL has high genetic heterogeneity and a large number of somatic mutations have 
been described.44 Some of the most common recurrent mutations affect genes involved in NOTCH 
signaling (NOTCH1), DNA damage and cell cycle control (ATM, TP53), NF-κB regulation (BIRC3), RNA 
processing and export (SF3B1, FUBP1), MYC activity (PTPN11), MAPK-ERK signaling (NRAS, KRAS, BRAF), 
chromatin modification (IKZF3) and inflammatory pathways (MYD88).32,44 Different genomic aberrations 
and recurrent somatic mutations are associated with widely different prognoses, accounting for some of 
the clinical heterogeneity in CLL. A key feature of CLL is the intraclonal heterogeneity of the tumor. 
Different CLL subpopulations are detected in the same patient, and those subclones will alter over time, 
accumulating additional mutations that contribute to progression of disease and resistance to 
therapy.44,45  
 CLL has a remarkably heterogeneous clinical course. Survival times can range from just a few 
months to decades. Approximately one-third of patients never require therapy and achieve a normal 
lifespan.46 A combination of clinical, biological and genetic factors are used to predict prognosis and 
guide therapy. Early staging systems developed by Rai and Binet, which were solely based on physical 
exam findings and hematologic data, were highly prognostic.47,48 These systems identified risk groups 
based on the degree of tumor cell infiltration in the peripheral blood/bone marrow, lymph nodes, liver 
and spleen, and the presence or absence of anemia and thrombocytopenia. The IGHV mutation status is 
prognostic and now routinely performed for CLL patients.46 Cases with unmutated IGHV genes have a 
poor prognosis compared to mutated IGHV cases.13,14 It is hypothesized that unmutated CLL tumors 
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have polyreactive BCRs, which allow for more antigen stimulation and BCR signaling, leading to 
progression of disease.18,49 Additional genetic factors, such as del17p13 or TP53 mutations, NOTCH1 
mutations, and SF3B1 and BIRC3 mutations, are associated with poor prognosis.50 The CLL international 
prognostic index working group identified 5 independent prognostic factors that stratify patients into 4 
risk groups with significantly different survival: TP53 status, IGHV mutational status, β2-microglobulin 
concentration, clinical (Rai/Binet) stage, and age.51 
 Optimal treatment guidelines for CLL, including indications to treat, first-line treatment, and 
treatment for refractory or relapsing patients, continue to evolve.52 Treatment with alkylating-based 
chemotherapies were shown to have no benefit in treating CLL and recent studies tracking mutations in 
CLL subclones over time demonstrate that early chemotherapy can be detrimental, promoting 
expansion of chemotherapy-resistant clones.44,45,53 The development of inhibitor molecules, including 
ibrutinib, idelalisib and venetoclax, has revolutionized CLL treatment and started to replace 
chemotherapy.32 Ibrutinib and idelalisib target BTK and PI3Kδ, respectively, to block BCR signaling and 
proliferation and induce CLL cell apoptosis.54 Venetoclax blocks the function of the anti-apoptotic 
protein, BCL2.55 As the number of novel therapies increases, the challenge comes in determining which 
drugs should be used in which settings. Many of these drugs are used in combination, and as patients 
become refractory, clinicians reach for different drugs throughout the course of disease. Determining 
the optimal combinations of drugs and order of administration in patient groups with different risk is an 
ongoing effort. Additionally, recent efforts to sequence patients over the course of therapy have 
revealed the acquisition of mutations and expansion of drug-resistant subclones over time. For example, 
patients on ibrutinib therapy can develop resistance mutations in the BTK gene, which may be detected 
before relapse.56 Further work is needed to determine how to incorporate this sequencing data into 
practice; for example, whether treatment protocols should be switched in patients that have developed 
resistance mutations but are still in clinical remission. Dogs with naturally occurring CLL could provide a 
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useful model for preclinical assessment of novel treatments and study of different drug regimens as first 
or second line therapy.   
Dogs as a natural model for human cancer 
 The field of comparative oncology studies the comparison of canine and human cancers, to 
investigate genetic risk, study mechanisms of tumor development, and assess novel therapies.57–59 There 
are over 75 million pet dogs in the US, and cancer is the leading cause of death in dogs, accounting for 
45% of deaths in dogs over 10 years old in one study.60,61 This population provides an opportunity to 
study naturally occurring cancers, to improve human and animal health.  
 Dogs spontaneously develop many of the same cancer types seen in people, and tumor 
progression follows a similar course across species. This natural cancer model allows us to study 
environmental and genetic risk factors for different tumor types. Because dogs and humans usually live 
in a shared environment, they have similar environmental exposures. The practice of dog breeding to 
maintain stringent standards has generated purebred breeds with restricted genetic variation, providing 
an opportunity to study genetic risk.57 Certain dog breeds have increased risk for different tumor types. 
For example, specific breeds have increased risk for particular hematopoietic neoplasms, including small 
breed dogs for B-cell chronic lymphocytic leukemia, Boxers for CD4+ peripheral T-cell lymphoma, Golden 
retrievers for T-zone lymphoma, and German shepherds for acute myeloid leukemia.62–66 These high-risk 
breeds may be investigated through GWAS, to identify risk alleles for specific cancer types. Because of 
the genetic homogeneity within a purebred breed, these studies may be performed with smaller sample 
sizes in dogs compared to humans.67 Genome-wide association studies have identified risk alleles for 
histiocytic sarcoma in Bernese mountain dogs, squamous cell carcinoma of the digit in standard poodles, 




 Naturally occurring spontaneous cancers in dogs are also useful in studying clinical progression 
and response and resistance to therapy. Dogs frequently have a similar clinical presentation and disease 
course compared to people, with significant heterogeneity among patients with the same tumor type. 
Given their shorter lifespan, it is easier to follow disease progression and assess response to therapies, 
particularly for indolent cancers, which may progress over decades in humans. Dogs provide an 
opportunity to study the interactions between tumor cells and the immune system and investigate 
changes in the tumor microenvironment within the primary tumor and distant metastases. Because 
similar pathways are often dysregulated in human and canine cancers, dogs provide a valuable natural 
model to test novel targeted therapies which block or alter these pathways.72 There is a large system in 
place for canine cancer clinical trials, making it feasible to test therapies and study acquired resistance 
to therapies. This data can help inform human studies and ultimately benefit both dogs and people. 
 Canine lymphoma/leukemia 
 Lymphoid neoplasms are among the most common tumor types diagnosed in dogs, accounting 
for 13% of all tumor diagnoses in a more recent study.73 Fewer subtypes are recognized in dogs 
compared to people, but several subtypes have been established in both species.74 In veterinary 
medicine, lymphoma subtyping is most commonly performed by flow cytometry immunophenotyping 
and/or histopathology. Many lymphoma subtypes can be identified by flow cytometry alone, while 
some require a histologic diagnosis. As in human medicine, clonality testing is a very useful adjunct 
diagnostic tool to support a diagnosis of lymphoid neoplasia. The PCR for antigen receptor 
rearrangements (PARR) assay is used routinely to assess the clonality of lymphoid expansions.75 
The frequency of different lymphoma/leukemia subtypes varies between dogs and people 
(Figure 1). In dogs, B-cell lymphomas are most common, accounting for 64%-80% of hematopoietic 
neoplasms across large-scale histologic studies.76,77 Diffuse large B-cell lymphoma is the most common 
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subtype in both species,76–78 and recent studies have compared the mutations and dysregulated 
pathways between human and canine DLBCL.79–82 Other B-cell neoplasms recognized in dogs include 
marginal zone lymphoma (nodal and splenic forms), mantle cell lymphoma, follicular cell lymphoma and 
B-cell chronic lymphocytic leukemia. T-cell lymphomas are more common in dogs than people. 
Peripheral T-cell lymphoma-not otherwise specified is a rare aggressive neoplasm in people that is 
common in Boxer dogs, providing a valuable model to study this disease. Other T-cell neoplasms, such as 
T-zone lymphoma and CD8+ T-cell chronic lymphocytic leukemia, are common in dogs but quite rare in 
people. Acute leukemias of lymphoid and myeloid origin are aggressive precursor neoplasms recognized 
in dogs and people. 
 
Figure 1. Distribution of canine lymphoproliferative diseases. Data represent lymphoma/leukemia 
diagnoses from approximately 25,000 unique canine cases submitted to the Colorado State University-
Clinical Immunology laboratory. Diagnoses were determined by flow cytometry immunophenotyping.  
The broad distribution of cases by acute/precursor neoplasm, B-cell lineage or T-cell lineage is presented 
on the left. The distribution of subtypes is presented on the right. B-cell neoplasms are most common, 
and B-cell CLL accounts for approximately 10% of all cases. The B-cell other category includes the most 
common lymphoma subtype, diffuse large B-cell lymphoma. Common canine T-cell subtypes include T-
zone lymphoma and peripheral T-cell lymphoma. 
    
 Canine CLL can be of B-cell (BCLL) or T-cell lineage. This contrasts with human classification 
systems, where the historical entity of T-cell CLL has been replaced by T-cell prolymphocytic leukemia 
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(small-cell variant), and therefore, the term CLL strictly refers to a neoplasm of B cells.2,83 In dogs, BCLL is 
one of the most common lymphoid neoplasms and accounts for 10% of canine samples submitted to the 
Colorado State University-Clinical Immunology laboratory with a suspicion of lymphoproliferative 
disease (Figure 1).  
 There are currently no defined consensus criteria for BCLL diagnosis. In general, BCLL is 
diagnosed by an expansion of small-sized mature-appearing lymphocytes in the bone marrow and/or 
peripheral blood. Immunophenotyping is performed by flow cytometry or 
immunocytochemistry/immunohistochemistry to determine B-cell origin. Canine BCLL cells do not 
express the CD5 antigen like human CLL cells. Some canine BCLL studies have excluded cases with 
lymphadenopathy and/or splenomegaly, due to concerns that these cases may have a different B-cell 
lymphoma subtype with extension into the blood (stage V), rather than BCLL, which was historically 
considered a disease of the blood and bone marrow.84 However, human CLL/SLL involves secondary 
lymphoid organs and exclusion of canine cases with lymph node or spleen involvement likely excludes 
true cases of BCLL. Differentials for B-cell lymphoma subtypes with a leukemic component include 
CLL/SLL, mantle cell lymphoma, follicular lymphoma and splenic marginal zone lymphoma.2 The latter 
three subtypes appear quite rare in dogs according to several large-scale histologic studies.76–78 
Diagnostic criteria for BCLL in our laboratory include: >5,000 lymphocytes/µL in the peripheral blood, a 
homogeneous expansion (>60%) of CD21+ lymphocytes, and small size by flow cytometry (forward light 
scatter ratio of B cells to neutrophils <0.60). This definition may include cases of other B-cell lymphoma 
subtypes, and work is needed to define BCLL criteria and identify markers to discriminate this tumor 
from other subtypes. 
Despite its prevalence, there are only a small number of studies in the veterinary literature 
describing BCLL. One study from our laboratory evaluated the clinical presentation and breed 
distribution of BCLL in 491 dogs.62 BCLL cases had a median age of 11 years at diagnosis, corroborating 
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other studies that show BCLL generally affects older patients, similar to human CLL.62,66,84 Approximately 
half of cases had peripheral lymphadenopathy and splenomegaly, 26% had anemia, and 
thrombocytopenia was rare. Twelve breeds had significantly increased odds of BCLL compared to mixed 
breed dogs, and 10/12 were small breeds.62 When compared to Labrador retrievers, 16 breeds had 
increased risk and 12/16 were small breeds. The 4 larger breeds were English bulldogs, Boxers, Pit bulls 
and Dobermans. English bulldogs had a unique clinical presentation, including a younger age at 
diagnosis (median, 6 years old) and significantly lower class II MHC and CD25 expression on B cells, 
raising the possibility that bulldogs have a different manifestation of BCLL or a different B-cell disorder.62 
Two small-scale studies evaluating outcome in 17 and 21 BCLL patients found that BCLL 
generally has an indolent clinical course.84,85 However, there was a wide range in survival times in both 
studies, suggesting that canine BCLL may have a heterogeneous clinical course similar to human CLL. 
Comazzi et al. found that young age was associated with poor prognosis.84 A larger scale outcome study 
is needed to evaluate the spectrum of clinical outcomes in BCLL and assess additional prognostic factors. 
Additionally, investigation of IGHV mutation status, gene expression profile, and underlying mutations 
are needed to further characterize canine BCLL and evaluate similarities to human CLL. A previous study 
assessing copy number change in canine BCLL identified a loss of the region containing miR-15a and 
miR16-1, similar to the del13q14 aberrancy seen in human CLL.86 Larger studies are needed to 
investigate the range of mutations in canine BCLL and evaluate functional effects. 
Conclusions 
 Canine BCLL shares a similar clinical presentation with human CLL, but further work is needed to 
evaluate the dog as a model for CLL. A canine BCLL model may be useful in studying genetic risk, 
pathogenesis of disease, novel therapeutics, and acquired resistance to therapy. Genetic risk factors 
could be investigated in high-risk small breeds. Additionally, human CLL tumor cell stimulation and 
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proliferation occurs in lymph nodes, which are not routinely sampled in human patients. Dog owners are 
often highly motivated to participate in clinical trials, and collection of lymph node samples, particularly 
at different time points, may be more feasible in canine patients. These samples could provide an 
opportunity to study mechanisms of tumor development and progression in the lymph node 
microenvironment, and assess changes in subclones and the mutational landscape over time. Finally, as 
the number of novel therapies for CLL expands, dogs could provide a useful preclinical model to assess 
response to therapy and evaluate combinations of different agents.  
 The goals of this thesis were to assess molecular features and outcome in canine BCLL, and 
compare these findings to human CLL. We investigated the role of IGHV mutation status in canine BCLL, 
performed a large-scale BCLL outcome study, and performed gene expression profiling. Additionally, we 
investigated English bulldogs with small cell B-cell lymphocytosis and identified a new syndrome, termed 
polyclonal B-cell lymphocytosis of English bulldogs (PBLEB). This work advances our understanding of 
BCLL in dogs, to improve the diagnosis and treatment of canine patients, and helps establish the dog as 





CHAPTER 1: Preferential use of unmutated immunoglobulin heavy variable region genes in Boxer dogs 
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Summary 
 
Human chronic lymphocytic leukemia (CLL) is a clinically heterogeneous disease, and 
immunoglobulin heavy variable region (IGHV) gene mutational status is an important prognostic marker. 
IGHV mutational status has not been previously examined in canine CLL. We sequenced the IGHV-D-J 
rearrangements from 55 canine patients with CLL, including 36 non-Boxer and 19 Boxer dogs. The 
majority of non-Boxers (75%) had mutated IGHV genes, whereas the majority of Boxers (79%) had 
unmutated IGHV genes. IGHV3-41 and IGHV3-67 gene usage was significantly higher in Boxers with CLL 
compared to non-Boxers. Additionally, 11 Boxers with large B-cell lymphoma and the normal IGHV 
repertoire of 6 control dogs (3 Boxers and 3 non-Boxers) were sequenced. IGHV3-41 was preferentially 
used in Boxers with other forms of lymphoma and without lymphoproliferative disease. However, 
preferential use of unmutated IGHV genes was unique to Boxers with CLL, suggesting Boxers may be a 
valuable model to investigate unmutated CLL. 
Introduction 
 
Human chronic lymphocytic leukemia (CLL) is the most common leukemia of adults in the 
Western world.2,87 The disease has a variable clinical course, with wide ranges in time to progression and 
survival.88 Analysis of the immunoglobulin genes has been crucial in understanding CLL pathogenesis and 
identifying subsets of patients with different clinical courses. Early studies identified restricted 
immunoglobulin heavy variable region (IGHV) gene usage in CLL compared to normal B cells.89 Later, 
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studies demonstrated that the mutational status of the IGHV genes is highly prognostic and divides 
patients into subsets with different clinical outcomes.13,14 Patients with mutated IGHV genes have a 
more favourable clinical course, while patients with unmutated IGHV genes have a poorer prognosis. 
Subsequently, subsets of unrelated CLL individuals were found to have highly similar to identical B-cell 
receptor immunoglobulins (stereotyped BCR),90 which allowed for further stratification of patients and 
prognostication for certain subsets.  
IGHV mutational status continues to be a major prognostic factor in human CLL51 and more 
recently was shown to predict response to therapeutic agents.91 The European Research Initiative on CLL 
has established standard methods for accurate analysis of mutational status.92,93 Mutational status is 
determined by amplifying and sequencing the IGHV region, aligning the sequence to immunoglobulin 
gene databases, and calculating the percent identity between the case sequence and closest germline 
IGHV gene. Germline identity >98% is consistent with unmutated CLL, while cases with <98% identity 
constitute mutated CLL cases. 
 Canine B-cell chronic lymphocytic leukemia (BCLL) shares many features with human CLL. The 
disease is characterized by a clonal expansion of small B cells in the peripheral blood. In people, the 
expanded B-cell population usually co-expresses CD5 and CD23.33 Canine BCLL cells do not express the 
CD5 antigen and a CD23 antibody is not available in dogs. However, the clinical presentation and clinical 
course in dogs appear similar to that seen in human patients. The disease affects older dogs, with a 
median age at diagnosis ranging from 10-11.9 years.62,66,84 Lymphadenopathy and splenomegaly are 
common, affecting approximately 50% of patients.62 Cytologic review reveals the majority of 
lymphocytes are small with condensed chromatin and no apparent nucleoli, with fewer yet variable 
numbers of pro-lymphocytes. Anemia is relatively common, affecting 25-53% of patients across two 
studies, and thrombocytopenia and neutropenia are rare.62,84 While it appears that many patients have 
indolent disease,84,85 one study found a wide range in survival times (25 to >1000 days).85   
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 IGHV gene usage and mutational status have not previously been studied in canine BCLL 
patients. Bao et al. characterized the canine immunoglobulin heavy chain variable region, identifying 80 
IGHV genes, 6 IGHD genes, and 3 IGHJ genes.94 These gene names have been modified to adhere to the 
conventions of the international ImMunoGeneTics (IMGT) information system (http://imgt.cines.fr,95–97), 
and the new names are used in this study (personal correspondence from M-P Lefranc; unreferenced). 
IGHV genes were classified into three subgroups, with 76/80 genes belonging to subgroup IGHV3 
(previously VH1). Recently, Martin et al. expanded the canine immunoglobulin locus annotation, 
describing 83 IGHV genes and 6 IGHJ genes.98 Three studies have shown that canine IGHV-D-J 
rearrangements predominantly use IGHV3 subgroup genes,94,99,100 with IGHV3-38 (previously VH1-44) 
and IGHV3-19 (previously VH1-62) preferentially used in one study.94 Heavy chain complementarity-
determining region 3 (CDR3) length ranged from 7 to 17 amino acids (AA) in one study,94 and 5 to 27 AA 
in another.99 IGHV gene usage and mutational status were investigated in canine diffuse large B-cell 
lymphoma, where IGHV3-38 was most frequently used.101,102 
We investigated IGHV gene usage and mutational status in a cohort of canine BCLL patients, and 
compared the repertoire to patients with large B-cell lymphoma and to normal B-cells. We hypothesized 
that canine BCLL patients would have a skewed IGHV gene repertoire and variable mutational status. 
Methods 
Diagnostic criteria for BCLL cases 
BCLL cases were selected from peripheral blood samples submitted to the Colorado State 
University-Clinical Immunology (CSU-CI) laboratory for flow cytometric immunophenotyping. Flow 
cytometry was performed as previously described and antibody combinations are listed in Table 1.65 
BCLL cases were defined as having >5,000 lymphocytes/µL, with a homogeneous expansion (>60%) of 
small lymphocytes expressing the B-cell marker CD21. Antibodies for CD19 and CD20 are not available in 
the dog but anti-CD21 reliably detects B cells when combined with T-cell antibodies. Intracellular flow 
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cytometry with CD79A and PAX5 antibodies is also available in the dog to detect B cells, but these 
antibodies are not used in routine immunophenotyping in our laboratory. B-cell size was classified as 
small when the ratio of the geometric mean of B-cell to neutrophil forward scatter (FS) was <0.60, which 
correlates to a B-cell FS value <400 on our flow cytometer. In previous studies, dogs meeting these 
diagnostic criteria predominantly had an indolent clinical course85 and clinical characteristics62 similar to 
mutated human CLL. 
Table 1. Antibody panels used for immunophenotyping. Unless otherwise noted, all antibodies were 
purchased from Bio-Rad, Hercules, CA. Clones are as follows: CD45, YKIX716.13; CD18, YFC118.3 (human 
CD18); CD4, YKIX302.9; CD8, YCATE55.9; CD5, YKIX322.3; CD21, CA2.1D6; CD22, RFB4 (human CD22, 
purchased from AbCam, Cambridge, MA); CD3, CA17.2A12; CD14, UCHM (human, used in panel 1) and 
CD14, TUK4 (human, used in panel 2); class II MHC, YKIX334.2; CD34, 1H6; CD25, P2A10 (purchased from 
eBioscience, San Diego, CA). 
Tube Antibody specificity and fluorochrome 
Panel 1 (two color)a 
1 None 
2 Mc IgG1-FITC/CD45-PE 





8 Class II MHC-FITC/CD34-PE 
Panel 2 (multicolor)b 
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1 M IgG1-FITC/M IgG1-PE/M IgG1-Alexa 647/M IgG1-Alexa 700/M IgG1-PE-
Alexa-750/M IgG1-Pacific Blue 
2 CD3-FITC/CD25-PE/CD5-APC/CD8-Alexa 700/CD4-Pacific Blue 
3 Class II MHC-FITC/CD22-PE/CD21-Alexa 647 
4 Class II MHC-FITC/CD34-PE/CD5-APC/CD14-PE-Alexa 750 
5 Class II MHC-FITC/CD18-PE/CD5-APC/CD14-PE-Alexa 750/CD4-Pacific Blue 
6 CD5-FITC/CD45-PE/CD21-Alexa 647 
aPanel 1 samples were analyzed using a single laser Coulter XL (Beckman Coulter Inc., Brea, CA). bPanel 2 
samples were analyzed using a 3-laser Coulter Gallios (Beckman Coulter Inc., Brea, CA). cM, mouse. 
 
Clonality was confirmed in all cases using a PCR-based assay termed the PCR for antigen receptor 
rearrangements (PARR) assay,75,103 which detects clonal immunoglobulin gene rearrangements based on 
size and is similar to the method used in people.9  
BCLL cases were selected at random from the CSU-CI database initially, with additional Boxers 
sequenced after discovering preferential IGHV gene usage in this breed. 
Case selection for large B-cell lymphoma and control dog cohorts 
Cases with large B-cell lymphoma were identified among lymph node aspirate samples 
submitted to the CSU-CI laboratory for immunophenotyping. To meet the criteria for large B-cell 
lymphoma, >60% of the large cells in the sample expressed CD21,104 and the median FS of the CD21+ 




Control dogs without evidence of lymphoproliferative disease were identified at necropsy or 
biopsy and lymph node sections were collected. 
Characterization of the canine IGHV locus 
In this study, we annotated the 80 germline genomic IGHV genes previously identified 94 using 
the guidelines established by the IMGT information system (http://imgt.cines.fr,95–97). A subset of these 
annotations are depicted in Figure 2. Functional rearrangements used for analysis had these conserved 
IMGT AA and motifs, and an open reading frame absent of stop codons or frameshift mutations. 
 
 
Figure 2. Dog IG V-REGION depictions in germline genomic DNA (A) and rearranged genomic DNA (B). 
(A) The V-DOMAIN of canine IGHV3-38 is shown as an example. IMGT standardized labels are shown, 
including framework regions (FR), complementarity determining regions (CDR), and the four conserved 
positions: 23 (1st-CYS), 41 (CONSERVED-TRP), 89 (hydrophobic) and 104 (2nd-CYS). Other labels include: 
the OCTAMER in the 5’UTR of the V-GENE; INIT-CODON, initiation codon (ATG sequence); L-PART1, first 
exon of the leader sequence; DONOR and ACCEPTOR SPLICE sites flanking the INTRON; L-PART2, second 
part of the leader sequence; V-HEPTAMER and V-NONAMER, recombination sites. (B) An IGHV-D-J 
rearrangement from a BCLL case is shown as an example. The location of the PCR sequencing primers 
are shown, including the forward primer (used for both amplification protocols) and the reverse primers 
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for protocol 1 (reverse 1) and protocol 2 (reverse 2) (Table 2). Below, the genomic sequence and amino 
acid translation are shown for a portion of the rearrangement. The conserved position, 118 (J-PHE or J-
TRP), and G-X-G motif of the J-REGION are shown. 
 
Additionally, we identified new IGHV and IGHJ genes compared to previous annotations.94,98 
Contiguous germline DNA sequence from dog chromosome 8 (NCBI Reference Sequence: 
NW_003726071.1) encoding all previously identified IGHV genes through the immunoglobulin heavy 
constant mu (IGHM) gene was analyzed using the Geneious ‘Dotplot’ function with consensus IGHV and 
IGHJ gene probes generated via multiple sequence alignments (http://www.geneious.com, version 
5.5.8105). All identified genes were compared to those reported previously.94,98 Newly identified genes 
were confirmed using BLAST search of dog genomic sequences (available at 
ncbi.nlm.nih.gov/projects/mapview,106) and/or dog BLAT search (available at genome.ucsc.edu,107), 
using the CanFam3.1 assembly (GenBank Assembly ID GCA_000002285.2). 
Sequencing of canine IGHV genes 
For BCLL cases, genomic DNA was extracted from 200 µL peripheral whole blood using the 
QIAamp DNA mini kit (Qiagen, Germantown, MD). DNA was amplified by PCR with a consensus IGHV3 
subgroup-specific forward primer binding the leader exon (L-PART1) and either a pool of reverse primers 
binding the IGHJ intron regions (protocol 1) or the IGHJ coding regions (protocol 2) (Table 2; Figure 2). 
Earlier cases were sequenced using IGHJ intron primers, but these primers did not amplify 
rearrangements as effectively as IGHJ coding region primers, so the majority of cases were sequenced 
with protocol 2. While either leader primers or FR1 region primers may be used to amplify the IGHV 
region, leader primers were selected because they allow analysis of the whole IGHV gene, while FR1 
primers exclude the 5’ portion.92 Amplified products were purified using the DNA Clean & Concentrator-
5 kit (Zymo Research Corp, Irvine, CA), ligated into a pDrive T-vector (Qiagen, Germantown, MD) and 
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transformed into competent TG1 bacteria (Zymo Research Corp, Irvine, CA). Inserts were directly 
sequenced by Sanger sequencing from multiple independent clones (8-16 total). Tumor-associated 
IGHV-D-J rearrangements were identified as predominant repeated sequences with identical CDR3 
sequences and a nucleotide length equal to the fragment size detected in the PARR assay. The cloning 
and sequencing protocol was identical for large B-cell lymphoma cases, except that DNA was isolated 
from fresh lymph node aspirates. 
Table 2. PCR amplification primer sequences and cycling conditions for IGHV sequencing. 






Denaturation step of 15 minutes at 
95oC, followed by 10 cycles of 94oC 
for 30 seconds, 64oC for 30 seconds 
with the temperature decreasing 
0.5oC every cycle, and 72oC for 1.5 
minutes each, followed by 30 cycles 
of 94oC for 30 seconds, 59oC for 30 
seconds and 72oC for 1.5 minutes 
each, and final extension step of 7 
minutes at 72oC. 





















Denaturation step of 5 minutes at 
95oC, followed by 40 cycles of 94oC 
for 30 seconds, 60oC for 1 minute 
and 72oC for 1 minute each, and 
final extension step of 10 minutes at 
72oC. 




J-REGION IGHJ2, IGHJ4 
J-REGION IGHJ6 
aProtocol 1 reverse primer pool: amplification was first attempted with a pool of IGHJ2, IGHJ4, and IGHJ6 
primers. If the clone was not identified, amplification was attempted in a second wave with a pool of 
IGHJ1, IGHJ3, and IGHJ5 primers. These primer sequences are located in the introns downstream of the 
IGHJ genes (see Figure 2B). L-PART1: first exon, encoding the first part of the leader sequence in an IGHV 
gene; J-REGION: coding region of the IGHJ genes (see Figure 2B). 
 
For control dogs without lymphoproliferative disease, more IGHV-D-J rearrangements were 
sampled per dog, since there was not a clonal B-cell population present. For each case, the PCR and 
cloning conditions were the same, except that DNA was extracted from a section of fresh whole lymph 
node and 100 independent clones were selected for sequencing, rather than 8-16 clones.  
Alignment and determination of mutational status and CDR3 length 
Patient sequence from the first nucleotide of FR1 through the conserved 2nd-CYS in FR3 was 
queried against the CanFam3.1 assembly using NCBI BLAST (https://blast.ncbi.nlm.nih.gov). The most 
similar reference nucleotide sequence identified in this BLAST search was compared to our annotated 
library of germline reference IGHV genes (Supplemental table S1) to determine IGHV gene usage in the 
patient. When more than one reference germline IGHV gene was identified as a possible match, the 
intron sequence was used to confirm the patient IGHV gene identity. 
 Mutational status was determined using guidelines adapted from human medicine.92 The 
percentage of identity was calculated based on the number of nucleotide differences between the 
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patient sequence and reference sequence in the V-REGION. Percent identity was calculated from the 
first nucleotide of FR1 to both the 2nd-CYS108 and to codon 105,92 but this boundary difference only 
changed the mutational status for one of the 389 sequences analyzed in this study. The sequence 
affected was a sequence from a control dog and did not have a statistical impact, so all sequences 
presented here were analyzed one way, to the 2nd-CYS. The following formula was used: IGHV identity 
(%) = 100 – (mutations/aligned IGHV region length × 100), with an insertion or deletion of multiple 
nucleotides counted as one mutation. Cases were classified as unmutated when the percent identity 
was >98% and mutated when percent identity was <98%, according to the convention used for human 
CLL.92,109 Mutated BCLL cases were further categorized into those with percent identity between 96%-
97.9% and those with <96% sequence homology.110,111 The CDR3 length was identified by determining 
the number of codons from the first codon following 2nd-CYS to the last codon preceding TRP-118.97 
Additionally, a subset of IGHV-D-J rearrangements were analyzed using the NCBI IgBLAST web-based 
program (http://www.ncbi.nlm.nih.gov/igblast/,112) and IMGT/V-QUEST 
(http://www.imgt.org/IMGT_vquest/vquest, version 3.4.8,108,113), to confirm that the same results were 
obtained by other analysis methods. Custom reference databases were used in IgBLAST by uploading the 
canine germline IGHV, IGHD and IGHJ gene libraries. 
Statistical analysis 
A chi-square test and Fisher exact tests were performed to determine the statistical significance 
of differences in IGHV gene repertoire and mutational status.  
Results 
Study population 
A total of 55 patients with BCLL were included in the study, including 29 females and 26 males. 
The median age at the time of sample collection was 10.5 years (range, 4.9-15.6 years; one unknown). 
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Initially, BCLL cases were selected at random, with no bias for breed. However, as it became apparent 
that Boxer dogs had a unique IGHV gene usage, additional Boxer dogs were sequenced. Therefore, of 
the 55 BCLL patients sequenced, 19 dogs (35%) were Boxers. Twenty-one breeds were represented in 
the non-Boxer group (Table 3). The peripheral B-cell count ranged from 7,300-816,600 cells/µL.  




Breeda Identity (%) Mutational 
statusb 
IGHV IGHJ CDR3 
lengthc 
1 SHI 91.7 Mutated IGHV3-75 IGHJ6 17 
2 CDT 88.9 Mutated IGHV3-47 IGHJ4 16 
3 MIX 92.4 Mutated IGHV3-47 IGHJ6 13 
4 COC 93.1 Mutated IGHV3-47 IGHJ4 22 
5 RAT 87.8 Mutated IGHV3-41 IGHJ4 11 
6 BDC 99.0 Unmutated IGHV3-41 IGHJ4 16 
7 BIC 99.0 Unmutated IGHV3-41 IGHJ4 18 
8 AIR 100.0 Unmutated IGHV3-41 IGHJ4 14 
9 MIX 89.2 Mutated IGHV3-38 IGHJ2 16 
10 CKP 89.9 Mutated IGHV3-38 IGHJ4 14 
11 SHI 91.3 Mutated IGHV3-38 IGHJ6 16 
12 MLT 93.1 Mutated IGHV3-38 IGHJ6 17 
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13 JRT 93.8 Mutated IGHV3-38 IGHJ4 14 
14 BIC 95.8 Mutated IGHV3-38 IGHJ4 12 
15 BIC 95.8 Mutated IGHV3-38 IGHJ4 17 
16 CRN 96.5 Borderline IGHV3-38 IGHJ4 13 
17 MIX 97.6 Borderline IGHV3-38 IGHJ2 12 
18 CSH 97.6 Borderline IGHV3-38 IGHJ4 23 
19 LAB 100.0 Unmutated IGHV3-38 IGHJ4 15 
20 WET 100.0 Unmutated IGHV3-38 IGHJ4 16 
21 CCR 94.8 Mutated IGHV3-35 IGHJ4 14 
22 MIX 91.0 Mutated IGHV3-19 IGHJ4 13 
23 SHI 91.0 Mutated IGHV3-19 IGHJ2 14 
24 CRN 94.1 Mutated IGHV3-19 IGHJ4 13 
25 SHI 94.8 Mutated IGHV3-19 IGHJ4 13 
26 MIX 94.8 Mutated IGHV3-19 IGHJ4 14 
27 PIT 95.5 Mutated IGHV3-19 IGHJ4 10 
28 MIX 100.0 Unmutated IGHV3-19 IGHJ4 14 
29 MIX 97.9 Borderline IGHV3-12 IGHJ2 15 
30 POM 98.6 Unmutated IGHV3-9 IGHJ4 17 
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31 MIX 99.0 Unmutated IGHV3-9 IGHJ6 12 
32 LBD 92.0 Mutated IGHV3-5 IGHJ4 16 
33 BOR 95.1 Mutated IGHV3-5 IGHJ4 13 
34 SHI 95.5 Mutated IGHV3-5 IGHJ2 14 
35 STS 98.6 Unmutated IGHV3-5 IGHJ2 27 
36 LAB 95.8 Mutated IGHV3-2 IGHJ4 15 
37 BOX 99.0 Unmutated IGHV3-67 IGHJ4 11 
38 BOX 99.7 Unmutated IGHV3-67 IGHJ4 10 
39 BOX 100.0 Unmutated IGHV3-67 IGHJ4 10 
40 BOX 96.9 Borderline IGHV3-41 IGHJ4 14 
41 BOX 97.9 Borderline IGHV3-41 IGHJ2 17 
42 BOX 98.3 Unmutated IGHV3-41 IGHJ4 17 
43 BOX 99.3 Unmutated IGHV3-41 IGHJ6 18 
44 BOX 99.7 Unmutated IGHV3-41 IGHJ4 11 
45 BOX 99.7 Unmutated IGHV3-41 IGHJ4 11 
46 BOX 99.7 Unmutated IGHV3-41 IGHJ6 22 
47 BOX 100.0 Unmutated IGHV3-41 IGHJ4 12 
48 BOX 100.0 Unmutated IGHV3-41 IGHJ4 13 
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49 BOX 100.0 Unmutated IGHV3-41 IGHJ4 16 
50 BOX 100.0 Unmutated IGHV3-41 IGHJ6 17 
51 BOX 97.9 Borderline IGHV3-38 IGHJ4 13 
52 BOX 100.0 Unmutated IGHV3-38 IGHJ4 10 
53 BOX 100.0 Unmutated IGHV3-38 IGHJ4 14 
54 BOX 96.5 Borderline IGHV3-19 IGHJ4 12 
55 BOX 99.3 Unmutated IGHV3-5 IGHJ4 10 
aBreed abbreviations: SHI, Shih-Tzu; CDT, Coton de Tulear; MIX, Mixed breed; COC, Cocker Spaniel; RAT, 
Rat Terrier; BDC, Bearded Collie; BIC, Bichon Frise; AIR, Airedale Terrier; CKP, Cockapoo; MLT, Maltese; 
JRT, Jack Russell Terrier; CRN, Cairn Terrier; CSH, Chihuahua, Shorthair; LAB, Labrador Retriever; WET, 
Soft Coated Wheaten Terrier; CCR, Chinese Crested; PIT, Pit Bull Terrier; POM, Pomeranian; LBD, 
Labradoodle; BOR, Border Collie; STS, Schnauzer; BOX, Boxer. bMutational status: mutated (<96% 
similarity); borderline (96-98% similarity); unmutated (>98% similarity). cHeavy chain complementary-
determining region 3 amino acid length. 
 
Eleven Boxer dogs with large B-cell lymphoma were sequenced, including 4 females and 7 
males. The median age at the time of sample collection was 8.5 years (range, 7.1-13.1 years).  
Six dogs without lymphoproliferative disease were sequenced, including 3 Boxer dogs and 3 
non-Boxer dogs. The Boxers ranged in age from 6.0-8.4 years and included one female and two males. 
The non-Boxers included one Labrador retriever, one mixed breed dog, and one Chihuahua. The non-
Boxers ranged in age from 9.0-13.0 years and included two females and one male. Five of 6 animals 
were deceased at the time of lymph node collection. One animal was alive at sample collection, 
diagnosed with mast cell tumor disease, and had 5 months follow up since sample collection. Two dogs 
died of heart failure and the remaining 4 dogs had non-lymphoid neoplasms. All 6 dogs had polyclonal 
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immunoglobulin and T-cell receptor rearrangements by PARR, providing additional support that the 
dogs did not have lymphoproliferative disease. 
Newly identified IGHV and IGHJ genes 
A combination of BLAST/BLAT searching and Dotplot analyses were employed to identify 7 new 
germline IGHV genes and 3 new germline IGHJ genes compared to those originally described by Bao et 
al.,94 bringing the totals to 87 IGHV and 6 IGHJ genes. All 7 newly identified IGHV genes belong to the 
predominant IGHV3 subgroup, and were named: IGHV3-76, IGHV3-71, IGHV3-47-1, IGHV3-21-1, IGHV3-
4, IGHV3-NL1, and IGHV3-NL2 (Supplemental table S1). Three of these 7 new IGHV genes were also 
annotated recently by Martin et al.98 Five of the new IGHV genes mapped to chromosome 8 and 2 
(designated NL) mapped to an unplaced genomic scaffold. Only IGHV3-76 and IGHV3-NL1 were 
considered functional. These 2 genes had open reading frames and conserved IMGT motifs, including 
the conserved amino acids: 23 (1st-CYS), 41 (CONSERVED-TRP), 89 (hydrophobic) and 104 (2nd-CYS). 
Two IGHV genes previously described94 were reordered to reflect the genomic location on chromosome 
8: IGHV3-32 (previously VH1-6) and IGHV3-78 (previously VH1-49P). The truncated sequence of VH1-42 
that was previously published94 was expanded and the more complete gene was renamed IGHV3-40. 
The 3 new IGHJ genes were clustered with the previously reported IGHJ genes on a 1.8 kb span 3’ to the 
IGHV region, and the IGHJ numbering system was revised from that which is already published94 to 
IGHJ1-IGHJ6, 5’ to 3’ (Figure 3). This new annotation of the IGHJ genes is consistent with that described 





Figure 3. Dog IGHJ locus. The organization of the 6 canine IGHJ genes is shown, with the genomic 
locations on chromosome 8 identified (CanFam3.1, NCBI Accession NC_006590.3). Gene segments are 
shown as light grey bars, recombination signal sequences as dark grey bars, and splice signal sequences 
as black triangles. The 3 new IGHJ genes are IGHJ1, IGHJ2 and IGHJ5. The 3 IGHJ genes previously 
described94 have been renamed from JH1, JH2 and JH3 to IGHJ3, IGHJ4 and IGHJ6, respectively, based on 
their genomic position. IGHC, immunoglobulin heavy constant genes. 
 
BCLL IGHV repertoire and mutational status 
IGHV-D-J rearrangements from 55 BCLL patients were examined (Table 3). Eleven IGHV genes 
were represented in the BCLL patient cohort. In non-Boxers, IGHV3-38 (33.3%) and IGHV3-19 (19.4%) 
were the most commonly used IGHV genes, followed by IGHV3-41 (11.1%) and IGHV3-5 (11.1%) (Figure 
4A). In Boxers with BCLL, IGHV3-41 (57.9%) was most commonly used, followed by IGHV3-38 (15.8%) 
and IGHV3-67 (15.8%) (Figure 4B). IGHV gene usage was significantly different between non-Boxers and 
Boxers for IGHV3-67 (p=0.037) and IGHV3-41 (p<0.001). 
Among non-Boxers with BCLL, 9/36 (25%) cases were classified as unmutated and 27/36 (75%) 
cases were mutated. Among Boxers with BCLL, 15/19 (79%) cases were unmutated, while 4/19 (21%) 
cases were mutated. The majority of mutated non-Boxer BCLL cases had a percent identity <96% (24/36 
(66.7%) cases), and few cases had a 96%-97.9% identity (3/36 (8.3%) cases). All 4 mutated Boxer BCLL 
cases had a percent identity between 96%-97.9%, with none of the cases having a percent identity 





Figure 4. Distribution of IGHV gene usage and 
mutational status in (A) non-Boxer dogs with 
BCLL (n=36), (B) Boxer dogs with BCLL (n=19), and 
(C) Boxer dogs with large B-cell lymphoma 
(n=11). IGHV gene usage is reported as the 
percentage of patients using an IGHV gene within 
that cohort. There were significant differences in 
the IGHV gene usage between non-Boxers and 
Boxers with BCLL for IGHV3-67 (p=0.037) and 
IGHV3-41 (p<0.001). There were significantly 
more unmutated cases in the Boxer BCLL cohort, 
compared to non-Boxers with BCLL (p<0.001) and 
Boxers with large B-cell lymphoma (p=0.026). 
 
 The IGHJ gene repertoire was not significantly different between non-Boxer and Boxer BCLL 
patients. Across the cohort of 55 patients, 3 IGHJ genes rearranged. IGHJ4 (72.7%) was the most 
frequently used IGHJ gene, followed by IGHJ6 (14.5%) and IGHJ2 (12.7%). The heavy chain CDR3 mean 
length was 14.6 AA (range, 10-27 AA) across all BCLL cases. There was not a significant difference in 
CDR3 length between breed groups or between mutated and unmutated cases.  
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These results indicate that Boxers with BCLL have preferential rearrangement of IGHV3-41 and 
that the majority of cases are unmutated, regardless of IGHV gene usage.  
Large B-cell lymphoma IGHV repertoire and mutational status 
To determine whether Boxers with other forms of lymphoproliferative disease have preferential 
rearrangement of IGHV3-41 or unmutated IGHV genes, IGHV-D-J rearrangements from 11 Boxers with 
large B-cell lymphoma were examined. IGHV3-41 (63.6%) was most commonly used, at a frequency 
similar to that seen in the Boxer BCLL cohort (Figure 4C). 4/11 (36.4%) cases were classified as 
unmutated, and 7/11 (63.6%) cases were mutated. Among mutated cases, one case had a percent 
identity between 96%-97.9%, and remaining mutated cases had <96% homology to germline. The IGHJ 
gene repertoire was similar to BCLL, with IGHJ4 (72.7%) most frequently used, followed by IGHJ6 (18.2%) 
and IGHJ2 (9.1%). The CDR3 mean length was 13.8 AA (range, 10-20 AA). These results indicate that 
Boxers with large B-cell lymphoma preferentially use IGHV3-41, as seen in Boxers with BCLL, but in the 
majority of large B-cell lymphoma cases the IGHV genes are mutated rather than unmutated. 
Normal canine IGHV repertoire and mutational status 
IGHV-D-J rearrangements from 6 control dogs without lymphoproliferative disease were 
examined, including 3 non-Boxers and 3 Boxers. The number of unique productive clones obtained for 
each animal ranged from 27 to 65 (Figure 5). Across the 6 dogs, which included 323 unique IGHV-D-J 
rearrangements, the most commonly used IGHV genes were IGHV3-19 (28.2%), IGHV3-47 (24.5%), and 
IGHV3-41 (24.1%), followed by IGHV3-38 (6.5%), IGHV3-5 (6.2%) and IGHV3-2 (5.0%). There were 
significant differences in IGHV gene usage between individual animals and between breeds. Boxers 
(Figure 5A-C) used IGHV3-41 (p<0.001) and IGHV3-47 (p<0.001) significantly more than non-Boxers, and 
non-Boxers (Figure 5D-F) used IGHV3-19 (p<0.001) and IGHV3-38 (p<0.001) significantly more than 
Boxers. There was no significant difference in mutational status between Boxers and non-Boxers. These 
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results indicate that Boxers with normal B cells preferentially use IGHV3-41 and IGHV3-47 compared to 
other breeds, and the majority of rearrangements are mutated. 
Discussion 
 
 In this study, we investigated IGHV gene usage and mutational status in canine patients with 
BCLL. Among non-Boxer patients with BCLL, we found that the majority of cases (75%) were mutated, 
using the homology cutoff value of 98% as established in human CLL. The ratio of mutated to unmutated 
cases was slightly higher than seen in the human population.14,114 Boxers were analyzed separately as 
they were preferentially sequenced over other breeds due to their skewed use of unmutated IGHV 
genes. Among Boxers with BCLL, 79% of cases were unmutated and all of the mutated cases had a 
percent identity between 96%-97.9%, demonstrating that none of the Boxer BCLL cases sequenced were 
highly mutated. These data suggest that the Boxer breed may be a useful model for unmutated CLL. 
However, the reference dog genome sequence was obtained by sequencing a Boxer;67 therefore, we 
were concerned that the high homology between the Boxer BCLL cases and reference genome may be 
due to breed bias. To address this question, we sequenced IGHV genes from additional Boxer dogs with 
large B-cell lymphoma and without lymphoproliferative disease and found that these dogs used 
predominantly mutated IGHV genes. The majority of IGHV genes from Boxers with large B-cell 
lymphoma (64%) were mutated. There was no significant difference in the number of unmutated IGHV 
gene rearrangements in normal Boxers compared to other breeds, suggesting use of unmutated IGHV 




Figure 5. Distribution of IGHV gene usage and mutational status in 3 Boxer dogs (A-C) and 3 non-Boxer 
dogs (D-F) without lymphoproliferative disease. IGHV gene segment usage is reported as the percentage 
of unique rearrangements using an IGHV gene within a single dog’s repertoire. There were significant 
differences in the IGHV gene usage between Boxers and non-Boxers for IGHV3-47, IGHV3-41, IGHV3-38, 
and IGHV3-19 (p<0.001 for all genes). There was no significant difference in the mutational status 
between Boxers and non-Boxers. The number of unique rearrangements examined for each case 
included: Boxer 1, n=27; Boxer 2, n=63; Boxer 3, n=65; non-Boxer 1 (Labrador retriever), n=48; non-





 We examined gene usage in BCLL patients as well as the normal IGHV gene repertoire in 6 
control dogs. IGHV3-38 and IGHV3-19 were most commonly used in non-Boxers with BCLL and in the 
normal gene repertoire of 2 of the 3 non-Boxer control dogs. One of the 3 control non-Boxers had a 
gene repertoire more similar to the Boxers. Bao et al.94 demonstrated a bias for IGHV3-38 and IGHV3-19 
amongst 3 healthy dogs, and IGHV3-38 was preferentially rearranged in canine cases with diffuse large 
B-cell lymphoma.101,102 Boxers with BCLL, large B-cell lymphoma, and without lymphoproliferative 
disease preferentially used IGHV3-41, indicating IGHV3-41 gene usage is high in Boxers, regardless of 
disease status. IGHV3-47 was commonly used in all 3 control Boxers without lymphoproliferative 
disease, but was not used in Boxers with BCLL or large B-cell lymphoma. IGHV3-67 was one of the more 
commonly used IGHV genes in Boxers with BCLL, but was not used in any of the non-Boxers with BCLL, 
Boxers with large B-cell lymphoma, or normal B-cell repertoires examined. This suggests IGHV3-67 may 
be preferentially used in Boxers with BCLL, but the number of cases is small and additional cases are 
needed to verify this finding. A limitation of this study is that the leader primer used for sequencing is 
specific to the IGHV3 subgroup, which likely had a small effect on the normal repertoire of control dogs. 
The IGHV3 subgroup is the dominant subgroup in multiple studies,94,99,100 accounting for 90% or more of 
rearranged genes in one study,99 and we were able to identify the clone in 92% of BCLL cases we 
attempted to sequence with an IGHV3-specific primer.  
This study contributes to our understanding of the canine immunoglobulin heavy chain variable 
region. Seven new IGHV genes and 3 new IGHJ genes were identified compared to the original 
annotation from Bao et al.94 Some of the additions may be attributed to different reference genome 
builds. Martin et al. recently described 3 of these new IGHV genes and the new IGHJ genes.98 Slight 
differences in our annotations may be due to different consensuses used to search for new IGHV genes. 
Additionally, all of the IGHV genes were assessed for functionality and annotated using the IMGT 
guidelines. All productive rearrangements used for analysis had the 4 previously described conserved AA 
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and the conserved Gly-X-Gly motif following codon 118. Eight of 389 sequences examined in this study 
had a residue other than the highly conserved PHE or TRP at codon 118, but were considered adequate 
for interpretation because the Gly-X-Gly was conserved.93  
A challenge of mutational analysis in dogs is the lack of knowledge about polymorphisms in 
IGHV genes across dog breeds and individuals. Ideally, canine BCLL sequences would be compared to 
reference genome sequences from the same breed, but those are not available at this time. 
Additionally, the homology cutoff of 98% which distinguishes clinically distinct subsets of human CLL 
patients13,14,115 may need to be adjusted to distinguish subsets of canine patients with different 
prognoses. The next phase of this study is to perform a large-scale outcome study in dogs with BCLL to 
correlate clinical outcome with mutational status. An additional challenge is the lack of antibodies 
available to differentiate BCLL from other canine B-cell neoplasms. The case criteria used in this study 
define an entity in dogs that most closely resembles CLL in people in its clinical presentation.62 However, 
this entity may represent a different small B-cell neoplasm with lymphocytosis, such as leukemic mantle 
cell lymphoma,3 or group of small B-cell neoplasms. We consider leukemic mantle cell lymphoma a less 
likely differential because this histologic subtype appears quite rare in dogs.77,78,116 Future steps include 
obtaining histopathology and gene expression profiling to correlate canine findings with that seen in 
human CLL. 
These results contribute to our understanding of the canine immunoglobulin genes and are the 
first to examine mutational status in a canine population with BCLL. This study identified Boxers with 
BCLL as having predominantly unmutated IGHV gene rearrangements and no highly mutated 
rearrangements. This suggests that this breed may be a valuable model to study CLL associated with 










 Canine B-cell chronic lymphocytic leukemia (BCLL) is generally considered an indolent disease, 
but previous studies demonstrate a wide range in survival times. We hypothesized that BCLL has a 
heterogeneous clinical course, similar to human chronic lymphocytic leukemia (CLL). Our objectives 
were to assess clinical progression and outcome in a large number of canine BCLL patients and evaluate 
the prognostic significance of clinical and flow cytometric factors. This retrospective study reviewed the 
medical records for 121 canine BCLL cases, defined as >5,000 lymphocytes/µL in the blood with a 
homogeneous expansion of small-sized CD21+ B cells (>60% of lymphocytes) by flow cytometry. Three 
breed groups were represented: small breed dogs (n=55) due to increased risk of BCLL; Boxers (n=33) 
due to preferential use of unmutated immunoglobulin genes; other breeds (n=33) to compare outcome 
to small breed cases. We retrieved signalment, laboratory data, physical exam and imaging findings, 
treatments and survival information. Cellular proliferation, determined by the percent of Ki67-
expressing CD21+ B cells by flow cytometry, was measured in 39/121 cases. The median overall survival 
time (MST) for all cases was 300 days (range, 1-1644 days). Boxers had significantly shorter survival 
(MST, 178 days) compared to non-Boxers (MST, 423 days; p=0.0003), and there was no significant 
survival difference between small breeds and other non-Boxer breeds. Cases with high Ki67 (>40% Ki67-
expressing B cells) had significantly shorter survival (MST, 173 days) than cases with <40% Ki67 (MST 
undetermined) (p=0.023), irrespective of breed. Cases with a high lymphocyte count (>60,000 
lymphocytes/µL) or clinical signs at presentation had significantly shorter survival. In summary, BCLL 





B-cell chronic lymphocytic leukemia is a malignancy of small-sized B cells, which are clonally 
expanded in the blood and/or bone marrow. BCLL is a common form of lymphoid leukemia in dogs. 
Among samples submitted for flow cytometric immunophenotyping, BCLL affected 8% of all canine 
submissions from any site with a suspicion of lymphoproliferative disease in one study, and 36% of 
blood submissions from 153 canine CLL cases in another study.62,117 Diagnostic criteria for canine BCLL 
are variable across studies, generally requiring >5,000-6,000 lymphocytes/µL in the peripheral blood and 
identification of a significant expansion of B cells by immunophenotyping.62,66,84,118,119 Some studies 
incorporate small mature cytomorphology or small cell size by flow cytometry in the inclusion criteria, 
and some exclude cases with moderate or severe lymphadenopathy or splenomegaly. BCLL generally 
affects older dogs, with a median age at diagnosis ranging from 10-11.9 years across studies.62,66,84 A 
previous study assessing the breed distribution and clinical presentation of canine BCLL in 491 dogs 
demonstrated that small breed dogs have an increased risk of BCLL and approximately half of patients 
have lymphadenopathy or splenomegaly and approximately one quarter have anemia.62 
 In people, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is a common 
neoplasm of clonally-expanded B cells in the blood, bone marrow, lymph nodes and spleen.52 A 
diagnosis of CLL requires >5,000 lymphocytes/µL in the blood and SLL requires lymphadenopathy and/or 
splenomegaly with <5,000 circulating B cells/µL, but these two entities are considered different 
manifestations of the same disease. This human neoplasm has a highly variable clinical course and a 
combination of genetic and clinical variables are used to assess prognosis.51,52,88 Canine BCLL is generally 
considered an indolent disease, but two studies assessing outcome demonstrate a wide range in survival 
times.84,85 One study evaluating 17 BCLL patients found a MST of 480 days and young age was associated 
with a poor prognosis.84 A second study evaluating outcome in 21 cases with small cell CD21+ B-cell 
lymphocytosis found that the majority of dogs had a prolonged clinical course (MST not reached), but 
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survival times ranged from 25 days to >1000 days.85 We hypothesize that canine BCLL may have a 
variable clinical course like human CLL. 
 The goal of this study was to assess overall survival and prognostic factors in a larger number of 
canine BCLL cases. For this study, we included cases with an expansion of small-sized B cells in the blood 
by flow cytometry. We did not exclude cases with lymphadenopathy or splenomegaly or cytopenias, as 
these criteria may exclude true BCLL cases with more progressive disease. While it’s possible some of 
the cases in this study have a different small B-cell neoplasm, we wanted to include all cases with a 
diagnosis of small cell B-cell lymphocytosis in the blood, as it is unknown whether cases with tissue 
infiltration are a different manifestation of BCLL versus an entirely different neoplasm. Additionally, we 
currently do not have markers in veterinary medicine to differentiate subtypes of small B-cell 
neoplasms, so all of these cases receive the same flow cytometry diagnosis. We evaluated clinical 
features and Ki67 expression for association with survival. Ki67 expression is a marker of proliferation 
and was shown to have prognostic value in canine high-grade B-cell lymphoma when measured by flow 
cytometry.120 We previously found that Boxers with BCLL preferentially rearrange unmutated 
immunoglobulin heavy variable region (IGHV) genes, which is a poor prognostic indicator in human CLL, 




 The Colorado State University-Clinical Immunology (CSU-CI) laboratory database was queried for 
canine BCLL cases with blood samples submitted for immunophenotyping by flow cytometry between 
October 2010 and October 2018. Inclusion criteria included: (1) >5,000 lymphocytes/µL on CBC; (2) 
>60% of lymphocytes in the blood sample expressed CD21 by flow cytometry; (3) no cells in the 
population expressed CD34; (4) CD21+ B cells were small-sized, defined by a ratio of the geometric 
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median of forward scatter of B cells:neutrophils ≤0.60. Cases were randomly selected and veterinarians 
were contacted for medical records. Additional Boxer cases were contacted to investigate breed-specific 
differences in outcome. English bulldogs were excluded from this study because we identified a 
condition of polyclonal B-cell expansion in this breed, described in chapter 4.  
For controls to evaluate CD21, CD25 and class II MHC expression on normal B cells, routine flow 
cytometry was performed on blood from 30 healthy dogs without lymphocytosis, which ranged in age 
from 1.9-8.9 years old, included 57% females, and represented a range of breeds. These dogs had 
lymphocyte subsets within normal limits by flow cytometry and polyclonal immunoglobulin 
rearrangements by PCR for antigen receptor rearrangements (PARR). Samples were processed and 
analyzed on the Coulter Gallios instrument with the same protocol used for clinical samples. 
 Between June 2017 and August 2019, the CSU-CI laboratory performed Ki67 staining by flow 
cytometry on a subset of randomly selected BCLL cases and nodal large B-cell lymphoma cases, as 
described below. Large B-cell lymphoma cases were defined by flow cytometry as lymph node samples 
with a homogeneous expansion of CD21+ B cells with a median forward scatter >500. In a separate 
study, the majority of cases with these flow cytometric features were diffuse large B-cell lymphoma, 
with smaller numbers diagnosed as nodal marginal zone lymphoma or Burkitt-like lymphoma.122  
Additionally, Ki67 staining was performed on 7 lymph node aspirates and 5 blood samples from 12 
control dogs with no evidence of lymphoproliferative disease. For all BCLL cases with Ki67 data obtained 
between September 2017 and October 2018, veterinarians were contacted for medical records and 
those cases with available data were included in the outcome study.  
Clinical variables 
 For all samples, the CSU-CI laboratory submission form and medical records were reviewed for 
signalment, physical exam findings, laboratory data, clinical signs, imaging findings and treatment and 
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survival data. Anemia was defined by a hematocrit below the lower limit of the reference interval for the 
laboratory performing the CBC. Thrombocytopenia was defined by a platelet count below the 
laboratory’s reference interval with no evidence of platelet clumping on blood smear review. 
Hyperglobulinemia was defined using the upper limit of the reference interval for globulins on available 
biochemistry panels. Lymph node, spleen, and liver abnormalities, including enlargement or masses, 
were identified by palpation, ultrasound examination or radiology.  
Flow cytometry 
 All cases had a blood sample submitted for flow cytometry at the CSU-CI laboratory. A small 
number of cases also had lymph node aspirates submitted for flow cytometry. Sample collection, 
storage, and staining were performed as previously described, using antibody panels listed in Table 4.65 
Samples submitted prior to May 11, 2012 were stained with antibody panel 1 and analyzed on a single 
laser Coulter XL (Beckman Coulter Inc., Brea, CA), samples submitted from May 11, 2012 to March 7, 
2017 were stained with antibody panel 2 and analyzed on a three laser Coulter Gallios (Beckman Coulter 
Inc., Brea, CA), and samples submitted after March 7, 2017 were stained with antibody panel 3 and 
analyzed on a three laser Coulter Gallios. Data were analyzed using Kaluza Analysis Software (Beckman 
Coulter Inc., Brea, CA). Expression of CD21, class II MHC, and CD25 on B cells was determined for all 
cases submitted after May 11, 2012. Expression of CD21 and class II MHC was determined by median 
fluorescence intensity. Because anti-CD25 is not in the same staining reaction as anti-CD21, the 
percentage of B cells expressing CD25 was determined by gating on lymphocytes in tube 2, excluding 
cells expressing CD3, CD4, CD5 and CD8, and calculating %CD25 on remaining cells. The B-cell:neutrophil 
size ratio was determined by dividing the median forward scatter of CD21+ B cells by CD4+ CD5- CD18+ 
neutrophils. There was no significant difference in neutrophil size between cases run on the Coulter XL 
and the Coulter Gallios instruments, so size data from all cases were used for statistical analysis. 
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Table 4. Antibody panels for canine flow cytometry immunophenotyping.  
Antibody 
tube 
Antibody specificity and fluorochrome 
Panel 1  
1 None 
2 Ma IgG1-FITC/CD45-PE 





8 Class II MHC-FITC/CD34-PE 
Panel 2 
1 M IgG1-FITC/M IgG1-PE/M IgG1-Alexa 647/M IgG1-Alexa 700/M IgG1-PE-Alexa-750/M 
IgG1-Pacific Blue 
2 CD3-FITC/CD25-PE/CD5-APC/CD8-Alexa 700/CD4-Pacific Blue 
3 Class II MHC-FITC/CD22-PE/CD21-Alexa 647 
4 Class II MHC-FITC/CD34-PE/CD5-APC/CD14-PE-Alexa 750 
5 Class II MHC-FITC/CD18-PE/CD5-APC/CD14-PE-Alexa 750/CD4-Pacific Blue 
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6 CD5-FITC/CD45-PE/CD21-Alexa 647 
Panel 3 
1 M IgG1-FITC/M IgG1-PE/M IgG1-Alexa 647/M IgG1-Alexa 700/M IgG1-PE-Alexa-750/M 
IgG1-Pacific Blue 
2 CD3-FITC/CD25-PE/CD5-APC/CD8-Alexa 700/CD4-Pacific Blue 
3 CD21-Alexa 647/Class II MHC-FITC/CD34-PE 
4 Class II MHC-FITC/CD18-PE/CD5-APC/CD14-Alexa 700/CD4-Pacific Blue 
5 CD5-FITC/CD45-PE/CD21-Alexa 647 
aM, mouse. Antibody clones and sources are provided in Chapter 1, Table 1. 
 
Clonality testing and immunoglobulin mutation status 
 B-cell clonality was determined by evaluating clonality of immunoglobulin receptor 
rearrangements. The CSU-CI laboratory PARR assay was performed as previously described.123 A small 
number of cases had PARR requested at the time of flow cytometry. For the remaining cases, PARR was 
performed retrospectively for all cases that had material still available at the time of data collection.   
 Cloning and sequencing were performed on a subset of cases with material available to 
determine IGHV mutation status, as previously described.121 The percent identity between the patient 
IGHV gene sequence and the reference germline IGHV gene sequence was calculated. Cases with a 





Ki67 expression by flow cytometry 
 Intracellular Ki67 was measured by flow cytometry on the same blood samples and lymph node 
aspirates used for diagnostic immunophenotyping. Red blood cells were lysed as described for routine 
immunophenotyping and the leukocyte pellet was washed in 1 mL 1x phosphate buffered saline (PBS), 
centrifuged and resuspended in 200 µL diluted Zombie Violet (1:1,000 in 1x PBS; Zombie Violet™ Fixable 
Viability Kit, BioLegend, San Diego, CA). Samples were incubated in the dark for 30 minutes at 25oC, 
washed with 1000 µL flow buffer (PBS-2%, FBS-0.1%, NaAZ), and centrifuged. The cell pellet was 
resuspended in 25 µL flow buffer and combined with 25 µL of surface antibody cocktail, incubated in the 
dark for 15 minutes at 25oC, and washed in 1 mL flow buffer. The surface antibody cocktail contains: CD5 
Percp-eFluor710 (YKIX322.3 clone, eBioscience), CD18 PE (YFC118.3 clone, Bio-Rad Serotec, Hercules, 
CA), and CD21 Alexa Fluor 647 (CA2.1D6 clone, Bio-Rad Serotec). Samples were fixed and permeabilized 
by resuspending the cell pellet in 1 mL of diluted permeabilization reagent and fixation reagent, 
prepared according the manufacturer recommendations (FoxP3 Staining kit, eBioscience, San Diego, 
CA), and incubated in the dark overnight at 4oC. To stain cells for nuclear antigens, samples were 
centrifuged, washed twice with 1 mL permeabilization buffer, and resuspended in 200 µL 
permeabilization buffer. 90 µL of the resuspended cell pellet was combined with 5 µL of blocking 
reagent and incubated in the dark for 30 minutes at 4oC. Without washing, 5 µL of intracellular Ki67 FITC 
antibody (SolA15 clone, eBioscience) or isotype-FITC were added, samples were incubated in the dark 
for 30 minutes at 4oC, washed twice with 1 mL permeabilization buffer, and resuspended in 220 µL flow 
buffer. Samples were analyzed on a three laser Coulter Gallios (Beckman Coulter Inc.) and analyzed 
using Kaluza Analysis software (Beckman Coulter Inc.). The isotype control was strictly used to 
determine the percent positive for Ki67 expression. Ki67 expression was measured for research 





Signalment, physical exam findings, hematologic data, and flow cytometry data were 
summarized for all BCLL cases. To evaluate breed specific differences, we grouped cases into 3 broad 
breed groups: (1) small dog breeds with increased risk of BCLL, as previously defined;62 (2) Boxer dogs; 
and (3) other breeds. To compare findings across breed groups, continuous variables were assessed 
using Kruskal Wallis or Mann Whitney tests and categorical variables were assessed using chi-square 
tests. Overall survival was calculated as days from the time of the flow cytometry diagnosis, since this 
date was available for all cases. Cases that were lost to follow-up or alive at the time of data collection 
were censored at the date of last contact. Continuous risk factors were divided into groups above and 
below the median for survival analysis, except for lymphocyte count. For lymphocyte count, cases were 
grouped above and below 60,000 lymphs/µL, as this cutoff was significant, but a cutoff at the median 
was not. Treatments were categorized as: (1) no treatment; (2) corticosteroid only; (3) corticosteroids 
and chlorambucil; or (4) maximum tolerated dose (MTD) injectable/oral chemotherapy. Individuals with 
missing/unknown data were excluded from analysis. Blood smear lymphocyte morphology obtained 
from the pathology report was categorized as: (1) intermediate to large-sized lymphocytes; or (2) small, 
small to intermediate, or intermediate-sized lymphocytes. Associations between patient data and 
survival were assessed using Kaplan-Meier log rank tests. For Ki67 expression analysis and survival 
analysis, the ‘other breeds’ group was further divided into small breeds and medium-large breeds. Small 
breeds were defined by an upper body weight range limit <15 kg, based on the American Kennel Club 
breed weight chart, and medium-large breeds had a lower body weight range limit >15 kg (AKC Material, 
URL: akc.org/expert-advice/nutrition/breed-weight-chart/). Statistical analysis was performed in 






 Medical records were obtained for 121 BCLL cases, representing 3 major breed groups: small 
breeds with increased risk of BCLL (n=55), Boxer dogs (n=33), and other breeds (n=33). Signalment, 
laboratory data and physical exam findings at the time of diagnosis are summarized in Table 5. The 
median age of all cases in the study was 10.4 years (interquartile range [IQR], 8.6-12.4 years; range, 2.3-
16.4 years). Fifty-five percent of all cases were male, including 57 castrated males, 7 intact males, and 2 
males with unknown castration data. Of the female cases, 53 were spayed and 2 were intact.  
Table 5. Signalment data, laboratory data, physical exam findings and treatment data for 121 BCLL 
patients in the outcome study. 
 Boxers (n=33) 































































Anemia 33 45% 55 45% 33 30% 88 40% 
Thrombocytopen
ia 
33 36% 55 18% 33 21% 88 19% 
Hyperglobulinem
ia 
32 19% 52 23% 30 13% 82 20% 


































































30 67% 41 59% 25 32% 66 48% 
Hepatic 
abnormalities 
30 30% 41 41% 26 23% 67 34% 
Clinical signs at 
presentation 






























a n, number of cases with available data 
 
Laboratory data: The median lymphocyte count for all cases on CBC was 39,675 lymphocytes/µL 
(IQR, 14,944-85,710/µL; range, 5,120-903,000/µL). Forty-one percent of cases were anemic and the 
anemia was generally mild to moderate (hematocrit median, 31.5%; IQR, 26-36%; range, 18-39%). 
Thirty-four of 50 anemic cases had a reticulocyte count performed and 50% had a regenerative anemia 
based on the reference interval of the laboratory, with reticulocyte counts ranging from 64,000-698,000 
reticulocytes/µL (median, 119,000/µL; IQR, 102,950-246,500/µL). Twenty-four percent of cases were 
thrombocytopenic, with a decreased platelet count and no evidence of clumping. Thrombocytopenia 
severity was variable, but mild to moderate in most cases (median, 113,000 platelets/µL; IQR, 91,500-
156,000/µL; range, 30,000-198,000/µL).  
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Blood smear review by a board-certified clinical pathologist was available for 107 cases. Ninety-
two percent of cases were described as small, small to intermediate, or intermediate in size, and of 
those, 93% were described as having mature chromatin patterns. Nine cases were described as having 
intermediate to large sized lymphocytes cytologically, but these cases were included in the study, as the 
cells were small-sized by flow cytometry, with a B-cell:neutrophil size ratio ranging from 0.44-0.60. Small 
numbers of cases had descriptions of atypical chromatin patterns, including smooth, fine, or stippled. 
Moderate numbers of cases were described as having rare cells with a faint nucleolus, but 2 cases were 
described as having consistent nucleoli. Bone marrow cytology reports were available for 11 cases, and 
3 samples were diagnosed with lymphocytic leukemia, 2 samples with lymphocytosis suspicious for CLL 
(40-45% small lymphocytes), 3 samples with mild lymphocytosis (7-16% small lymphocytes), 1 sample 
with few atypical lymphocytes consistent with possible lymphoid neoplasia, and 2 samples with 
lymphocytes considered within normal limits.   
At diagnosis, 19% (n=22) of cases were hyperglobulinemic. Serum protein electrophoresis was 
performed in 8 cases. Six of 8 cases had a monoclonal gammopathy (the 1 case with immunofixation 
labeled with anti-IgM), 1/8 cases had a biclonal gammopathy (immunofixation not performed), and 1/8 
cases had an IgM monoclonal gammopathy and a biclonal IgA gammopathy. Additional cases developed 
hyperglobulinemia after diagnosis, so that 25% of all cases had hyperglobulinemia during the course of 
disease. Thirteen cases had proteinuria on urinalysis, 3/13 had urine protein-creatinine ratio measured, 
which was elevated in all 3 cases, and none had urine protein electrophoresis performed.  
Physical exam findings: Peripheral lymphadenopathy was detected in 53% of cases at diagnosis, 
and an additional 11 cases developed lymphadenopathy during the study, resulting in 62% of cases 
having peripheral lymphadenopathy at some time point. Lymph node cytology was evaluated in 37 
cases, and 43% were diagnosed as lymphoma, 22% as possible/probable lymphoma, 24% as lymphoid 
hyperplasia/reactive lymphoid hyperplasia, and 11% as within normal limits. By histology (n=3), 1 case 
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was diagnosed with low grade small cell lymphoma, 1 with high grade small cell lymphoma (high mitotic 
rate), and 1 with probable small cell lymphoma. Fifty-four percent of cases had splenic abnormalities at 
diagnosis, an additional 5 cases developed splenic abnormalities after BCLL diagnosis (splenic 
abnormalities in 58% of total cases), and 2 cases had a previous splenectomy at the time of flow 
cytometry diagnosis. Splenic cytology was evaluated in 17 cases, and 29% were diagnosed as lymphoma, 
41% as possible lymphoma, and 29% as lymphoid hyperplasia. By histology (n=3), 2 cases were 
diagnosed with low to intermediate grade lymphoma of small to medium sized lymphocytes and 1 case 
was diagnosed with lymphoid hyperplasia. 
Forty-six percent of cases had thoracic or abdominal lymphadenopathy, and 33% of cases had 
hepatic abnormalities. Ten cases (8%) were presumed to have rectal involvement based on palpation, 
and half of these cases (4% of all cases) had rectal prolapse. Lymphoma was diagnosed in rectal tissue in 
3 cases by cytology (n=1) or histology (n=2). Five cases had peritoneal effusion and 2 cases had 
bicavitary effusion. Five cases had multiple dermal or subcutaneous nodules interpreted as 
lymphoproliferative disease by the clinician based on gross appearance, and 2 cases with cytology were 
diagnosed as lymphoma. Six cases had ocular changes presumed secondary to lymphoproliferative 
disease or hyperglobulinemia/hyperviscosity syndrome by the clinician. Five cases had neurologic signs 
that were suspected to be secondary to lymphoproliferative disease at some point during the disease 
course; however, only 1 case had advanced imaging and that patient had multifocal disease throughout 
the spinal cord presumed secondary to progression of lymphoproliferative disease. Seven cases had 
pulmonary infiltrates on thoracic radiographs that were interpreted as possible neoplastic infiltrate by 
the radiologist. 
Clinical signs: Sixty-two percent of patients were asymptomatic at diagnosis and leukocytosis +/- 
lymphadenopathy was an incidental finding. Thirty-eight percent of patients had clinical signs at 
presentation. Lethargy (n=21) and decreased appetite (n=20) were the most common clinical signs, with 
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weight loss (n=12), vomiting (n=9), diarrhea (n=9), and labored breathing (n=6) affecting smaller 
numbers of cases.  
Flow cytometry 
 By flow cytometry, CD21+ B cells accounted for 64%-99% of lymphocytes in the blood in BCLL 
cases. The B-cell:neutrophil size ratio ranged from 0.37-0.60 (median, 0.50) in BCLL cases (n=121), 
compared to 0.39-0.54 (median, 0.44) in healthy controls (n=30). The percentage of B cells expressing 
CD25 was variable across BCLL cases, ranging from 0.6% to 99% (median, 64%; n=99), compared to 
healthy controls (median, 11%; range, 2.0%-24%) which had significantly fewer CD25-expressing B cells 
(p<0.0001) (Figure 6A). Class II MHC expression on B cells was significantly lower in BCLL cases (median, 
158; range, 12-1168; n=99) compared to controls (median, 383; range, 256-511) (p<0.0001) (Figure 6B). 
CD21 expression was not significantly different between BCLL cases and control B cells, though BCLL 
cases had a wider range in CD21 expression (median, 48; range, 7-114; n=99) compared to controls 
(median, 46; range, 30-57) (p=0.212) (Figure 6C).  
 
Figure 6. B-cell CD25, class II MHC and CD21 expression in BCLL cases compared to control B cells and 
comparison of B-cell size in paired blood and lymph node samples from BCLL cases. (A-C) Expression of 
CD25 (A), class II MHC (B) and CD21 (C) by flow cytometry is plotted for individual cases. Lines depict the 
median and interquartile range for each group. BCLL cases had significantly higher CD25 expression and 
significantly lower class II MHC expression than B cells from healthy controls. (D) Median forward light 
scatter of B cells is plotted for paired blood and lymph node samples from BCLL patients. B cells in the 




 Flow cytometry and cytology were performed simultaneously on lymph node aspirates in 12 
cases. All lymph node samples had a marked expansion of small-sized B cells, consistent with a small B-
cell neoplasm. CD21+ B cells accounted for 88%-97% of all leukocytes in the sample and the median 
forward light scatter of B cells was <500 (median, 407; range, 323-497) in all cases. B cells in the lymph 
node were larger than the same patient’s B cells in the peripheral blood by flow cytometry in all cases 
(Figure 6D). Nine of the 12 cases had flow cytometry and cytology performed on a lymph node aspirate 
at the same time. Five cases were diagnosed as lymphoma of small to intermediate-sized lymphocytes 
(n=1), intermediate lymphocytes (n=1), or intermediate to large-sized lymphocytes (n=3). One case was 
diagnosed with probable lymphoma, 2 cases as lymphoid hyperplasia, and 1 case as normal lymphocyte 
distribution.  
Breed specific differences 
Signalment, laboratory data, physical exam findings, and flow cytometry data were compared 
between 3 breed groups: small breeds with increased risk of BCLL, Boxer dogs, and other breeds. Across 
all variables, there were no significant differences between small breeds and other breeds, except for 
sex (males over-represented in the other breeds group, p=0.015); therefore, small breed and other 
breed cases were combined into a non-Boxer group (n=88). Comparing Boxer and non-Boxer cases, 
Boxers were significantly younger (median, 9.3 years) than non-Boxers (median, 10.6 years) (p=0.010). 
Boxers had a significantly higher presenting lymphocyte count (median, 72,700/µL) compared to non-
Boxers (27,000/µL) (p<0.001) (Figure 7A). There was no difference in the frequency of anemia, 




Figure 7. Breed-specific differences in lymphocyte count, B-cell size and B-cell CD25 expression between 
Boxers and non-Boxers with BCLL. Presenting lymphocyte count (A), B-cell:neutrophil forward side 
scatter ratio (B) and B-cell CD25 expression (C) are plotted for non-Boxer and Boxer BCLL cases. Lines 
depict the median and interquartile range for each group. Boxers had significantly higher presenting 
lymphocyte counts and larger sized B cells than non-Boxers. There was a significantly larger proportion 
of Boxer cases with very high CD25 expression (≥98% CD25-expressing B cells) compared to non-Boxers. 
 
Comparing flow cytometry features across the 2 breed groups, Boxers had significantly larger B 
cells by flow cytometry compared to non-Boxers (p=0.037) (Figure 7B). Expression of CD21 and class II 
MHC on B cells was not significantly different between breed groups. The median percentage of CD25-
expressing B cells was not significantly different between breed groups, however there was a larger 
proportion of Boxer cases (20%) with very high CD25 expression (≥98% CD25-expressing B cells) 
compared to non-Boxers (4%) (p=0.042) (Figure 7C).  
Clonality and immunoglobulin mutation status 
Sixty-four cases had sample available for PARR analysis. The PARR assay was performed on a 
blood sample in 61/64 cases, a splenic aspirate in 2 cases, and a lymph node aspirate in 1 case.  63/64 
cases (98%) had clonal immunoglobulin rearrangements, supporting the diagnosis of B-cell neoplasia. 
The IGHV mutation status was determined in 14 cases, including 5 Boxers and 9 non-Boxers. Nine of 14 





 The percentage of CD21+ B cells expressing Ki67 (Ki67%) was determined by flow cytometry in 
controls (n=12), BCLL cases (n=202) and large B-cell lymphoma cases (n=101) collected between 2017-
2019. There was no significant difference in Ki67 expression between normal B cells in the control blood 
(n=5) and lymph node (n=7) samples, so these samples were combined for analysis. BCLL cases included 
small breeds with increased risk of BCLL (n=84), other small breeds (n=32), non-Boxer medium-large 
breeds (n=38) and Boxers (n=48). The median Ki67% in control B cells was 8.5%, and 11/12 control cases 
had low Ki67 expression, defined as <20% Ki67-expressing B cells (Figure 8).120 Among non-Boxer BCLL 
breed groups, median Ki67% ranged from 14-16%, and there were no significant differences between 
small breeds with increased BCLL risk, other small breeds, or non-Boxer medium-large breeds. Boxers 
with BCLL had significantly higher Ki67% (median, 42%) compared to non-Boxer BCLL cases (p<0.0001). 
Large B-cell lymphoma cases had significantly higher Ki67% (median, 64%) than all BCLL groups 
(p<0.0001), and 87% of large B-cell lymphoma cases had >40% Ki67-expressing B cells. We used a Ki67% 
cutoff of >40% to identify high Ki67 expression cases.120 The percentage of high Ki67 cases was 
significantly higher in Boxers with BCLL (58%) compared to non-Boxers with BCLL (27%) (p<0.0001), and 
the majority of non-Boxer BCLL cases (59%) had low ki67% (<20%).  
Clinical outcome and survival analysis 
 The median overall survival time from flow cytometry diagnosis for all 121 outcome cases 
examined was 300 days (range, 1-1644 days). Boxers had significantly shorter survival (MST, 178 days) 
compared to non-Boxers (MST, 423 days) (p<0.0001) (Figure 9A). There was no significant difference in 
survival between small breed dogs and non-Boxer medium-large breed dogs (p=0.46), so all non-Boxer 
cases were combined for further analysis. Among Boxers, 47% of cases received MTD chemotherapy, 




Figure 8. B-cell Ki67% expression measured by flow cytometry in control B cells, BCLL cases, and large B-
cell lymphoma cases. The percentage of CD21+ B cells expressing Ki67 is on the vertical axis. The 
majority of non-Boxer BCLL cases had <20% Ki67 and there was no significant difference in Ki67 
expression between small breeds with increased BCLL risk, other small breeds and non-Boxer medium-
large breeds. Boxers with BCLL had significantly higher Ki67%. The vast majority of large B-cell 
lymphoma cases had high Ki67 (>40%). Violin plots show the median (solid line) and quartiles (dashed 
lines) for each group. 
 
Among non-Boxers, 32% of cases received MTD chemotherapy, 48% received corticosteroids or 
corticosteroids + chlorambucil, and 20% were untreated. There was a trend toward more Boxers 
receiving MTD chemotherapy and more non-Boxers receiving no treatment, but neither finding was 
statistically significant (p=0.150 and p=0.164, respectively). The IGHV mutation status was not 



















































































Figure 9. Kaplan-Meier curves showing overall survival in cases with BCLL. (A) Boxers had significantly 
shorter survival than non-Boxers. (B) Cases with high Ki67 (>40%) had significantly shorter survival than 
cases with low-intermediate Ki67 (<40%). 
 
Ki67 data were available for 39 cases where survival data was also available, including 15 Boxers 
and 24 non-Boxers. High Ki67% (>40%) cases had significantly shorter survival (MST, 173 days; n=28) 
compared to cases with <40% Ki67 (MST, undefined; n=11) (p=0.026) (Figure 9B). The 3 cases with <40% 
Ki67 expression that died included a non-Boxer with heartworm disease and bicavitary effusion that 
died at home with no necropsy and the only 2 Boxers in the <40% Ki67 group, which were both 
managed aggressively with multi-agent MTD protocols. When Boxers were omitted from Ki67 survival 
analysis, the results did not change, indicating that non-Boxers with high Ki67% also have poorer 
prognosis. Low-intermediate Ki67 cases (<40% Ki67) were managed with corticosteroids +/- 
chlorambucil (36%) or no treatment (36%), except for the 2 Boxers in the group (18%, MTD 
chemotherapy) and 1 non-Boxer that received lomustine for a lung tumor but no treatment for BCLL. 
Among high Ki67 cases (>40% Ki67), 46% received MTD chemotherapy, 43% received corticosteroids +/- 
chlorambucil, and 11% were untreated. While a greater proportion of high Ki67 cases received MTD 
chemotherapy, this trend was not significant (p=0.30). 
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 Signalment, laboratory, physical exam and flow cytometry variables were assessed for 
association with survival in all cases, non-Boxer cases only, and Boxer cases only, and results are 
summarized in Table 6. Among all cases, high presenting lymphocyte count, presence of clinical signs at 
diagnosis, and high CD25 expression were associated with significantly shorter survival. Presence of 
hyperglobulinemia was associated with significantly longer survival. Among non-Boxers only, 
lymphocyte count, clinical signs and hyperglobulinemia were still similarly associated with survival, and 
low CD21 expression was associated with shorter survival. Among non-Boxers only, CD25 expression 
was no longer significantly associated with survival. Among Boxers only, presence of clinical signs and 
absence of splenomegaly or splenic masses were associated with significantly shorter survival. Across all 
cases, though the number was small, cases with lymphocytes described as intermediate to large in size 
on blood smear review had significantly shorter survival than cases described as small, small to 
intermediate, or intermediate in size. When intermediate sized cases were combined in the 
intermediate-large group, this finding was no longer significant. Six of the 9 intermediate-large sized 
cases were Boxers, and when these were omitted, lymphocyte size by morphology was no longer 
significant, though the number of cases was small. 
Table 6. Log rank test results evaluating factors for potential association with survival. 
  All cases (n=121) Non-Boxers (n=88) Boxers (n=33) 
Variable Cutoff n MST p n MST p n MST p 











































































































































































































CD25  ≥64% 50 202 0.024* 33 314 0.19 17 104 0.054 
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n, number of cases; MST, median survival time (days); LAD, lymphadenopathy; MTD, maximum 





This study found that BCLL, as defined by an expansion of small-sized CD21+ B cells in the blood 
by flow cytometry, has a variable clinical presentation and outcome. Cases demonstrated wide 
variability in overall survival times, and Ki67 expression was useful in identifying cases with a poor 
prognosis. Additionally, Boxers with BCLL had significantly shorter overall survival. 
 The overall survival time in this study for all 121 BCLL cases was 300 days (range, 1-1644 days), 
however, Boxers were intentionally over-represented in this population. When survival was assessed in 
non-Boxers, the MST of 423 days was similar to that previously reported in canine BCLL.84 A subset of 
patients in this study had more indolent disease and were frequently asymptomatic, managed with 
corticosteroids, corticosteroids + chlorambucil or no treatment, and had prolonged survival. However, a 
<64% 49 377 36 427 13 272 





























































subset had more aggressive disease and shorter overall survival. We aimed to find factors that would 
help identify these patients.  
B-cell Ki67 expression, as measured by flow cytometry, was variable in BCLL cases and 
associated with prognosis. The majority of non-Boxers had low-intermediate Ki67 expression (Ki67% 
<40%), but a subset of non-Boxers and the majority of Boxers had high Ki67 expression (Ki67% >40%). 
Cases with high Ki67 expression, indicating increased cellular proliferation, had significantly shorter 
overall survival. A previous study which evaluated the prognostic significance of Ki67 expression by flow 
cytometry in canine high-grade B-cell lymphoma also used Ki67% >40% to define high Ki67 cases.120 That 
group defined low Ki67% as <20%, and our study found that peripheral blood B cells in healthy control 
dogs and the majority of non-Boxer BCLL cases had Ki67% <20%. We did not have enough low-
intermediate Ki67 BCLL cases with outcome to determine whether low Ki67 cases (Ki67% <20%) and 
intermediate Ki67 cases (Ki67% 20-40%) have different prognoses, but rather, these cases were 
combined for analysis. Future studies could evaluate whether distinguishing low and intermediate Ki67 
expression is significant in BCLL prognosis. In human CLL, high Ki67 expression is associated with poorer 
outcome, whether measured in neoplastic peripheral lymphocytes, lymph node proliferation centers, or 
as circulating Ki67 levels in plasma.25,124,125 
We hypothesized that Boxers with BCLL have more aggressive disease, due to preferential use of 
unmutated IGHV genes in neoplastic B cells,121 which is associated with poor prognosis in human CLL.13,14 
In this study, Boxers had significantly higher presenting lymphocyte counts, higher Ki67 expression and 
shorter overall survival compared to non-Boxers. However, when we evaluated survival in a group of 
Boxers and non-Boxers with IGHV sequencing, mutation status was not predictive of outcome. It is 
possible that too few cases were examined to detect a difference in survival, or, IGHV mutation status 
may not drive tumor biology in canine BCLL at all or as much as other factors. Additionally, we looked to 
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see whether other medium-large breed dogs had poorer prognosis similar to Boxers, but these other 
breeds had similar Ki67 expression and survival as small breed dogs.  
We hypothesize that canine BCLL can have different manifestations, as seen with human CLL, 
and Ki67 expression is one marker useful in distinguishing them. In addition to shorter survival, a higher 
proportion of Boxers and high Ki67 cases were treated with MTD chemotherapy, suggesting clinicians 
independently interpreted these cases as having more advanced or aggressive disease. In another 
subset of BCLL cases, including those with low Ki67 expression, which had more indolent disease, no 
treatment or treatment with corticosteroids +/- chlorambucil appeared to be an appropriate therapy. It 
is possible that these different subsets actually have different small cell B-cell neoplasms, rather than 
different clinical manifestations of BCLL. Gene expression profiling and identification of driver mutations 
would be useful in determining whether these cases represent a spectrum of one disease or distinct 
diseases. Currently, we do not have antibodies available to differentiate these BCLL subsets by routine 
immunophenotyping. Among the B-cell antigens we detect in routine immunophenotyping, CD25 
tended to be expressed at a higher level in Boxers compared to non-Boxers, but there was significant 
overlap between groups. Gene expression profiling may differentiate BCLL subsets, but until then, Ki67 
expression appears useful in identifying more aggressive cases. 
 In addition to Ki67 expression and breed, we found that lymphocyte count, presence of clinical 
signs and hyperglobulinemia were associated with prognosis. A high presenting lymphocyte count 
(>60,000/µL) was associated with shorter survival in non-Boxer BCLL cases. Lymphocyte count was not 
prognostic in two prior studies of canine BCLL.84,85 It is possible that these studies did not detect a 
difference due to smaller sample sizes (n=17 and n=21, respectively), or because they assessed 
association with survival using a different cutoff (30,000/µL) or lymphocyte count as a continuous 
variable. In our study, lymphocyte count was not prognostic when using the median lymphocyte count 
of the study population as a cutoff (40,000/µL), but was prognostic when the cutoff was raised to 
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60,000/µL. BCLL patients presenting with clinical signs had significantly shorter survival, which is an 
important prognostic factor in other types of canine lymphoma.126,127 In human CLL, high lymphocyte 
count and clinical symptoms are associated with poorer prognosis by univariable analysis and help guide 
treatment decisions, but they are not factors used in the historic Rai or Binet staging systems nor more 
recent prognostic staging systems.47,48,51,52,128 Hyperglobulinemia affected 19% of canine BCLL patients at 
diagnosis and was associated with longer survival. Serum protein electrophoresis was performed on only 
a subset of hyperglobulinemic samples, but all those examined had paraprotein detected. Paraproteins 
in this study and a separate study from our laboratory (chapter 4) were identified with immunofixation 
as IgM or less frequently IgA. In human CLL, serum free light chains are the most commonly detected 
paraproteins and are associated with poor prognosis.129 IgM or IgG paraproteins are detected in a 
smaller proportion of cases and are also associated with poorer prognosis.130,131 It was surprising that 
canine BCLL patients with hyperglobulinemia had prolonged survival, however, only a small subset of 
cases had SPE performed so it is unknown whether the hyperglobulinemia was secondary to a reactive 
process or paraprotein. If cases with paraprotein have prolonged survival, perhaps those cases have 
different signals driving B-cell stimulation and expansion or neoplastic B cells are more differentiated, 
affecting the clinical course of disease. High CD25 expression was associated with shorter survival across 
all cases, but not when assessed in non-Boxers only. Increased CD25 expression was associated with 
more progressive disease and poor prognosis in some human CLL studies but not others, as well as poor 
prognosis in canine diffuse large B-cell lymphoma, but more work is needed to fully elucidate its 
prognostic significance in canine BCLL.122,132–134 Age was not prognostic in our study as it was in a prior 
study.84 The vast majority of cases in our study were middle-aged to older (only 7/121 (6%) were <6 
years old), so perhaps there were too few young cases to appreciate a difference in survival.  
 In this study, we included all cases with a flow cytometry diagnosis of BCLL, irrespective of tissue 
involvement. Human CLL commonly affects secondary lymphoid tissues and SLL, which is defined by 
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lymphadenopathy and/or splenomegaly, is considered the same neoplasm as CLL without a leukemic 
component.2 Therefore, we did not want to exclude canine BCLL cases with secondary lymphoid organ 
enlargement and found that lymphadenopathy and splenomegaly or splenic masses were common in 
this study population. Other less common sites included rectal tissue, with rectal prolapse affecting 4% 
of cases, and apparent dermal, subcutaneous and pulmonary tissues. All 12 cases with flow cytometry 
performed on a lymph node aspirate had a marked expansion of small-sized B cells, consistent with 
neoplasia. These cases had a wide range of cytology diagnoses, demonstrating the difficulty in 
diagnosing small cell neoplasms by cytology alone. In the peripheral blood, lymphocyte cell size was also 
variable across blood smear pathology reports. It was not unusual for cases to be described as having 
intermediate-sized lymphocytes; these cases had a small B-cell size by flow cytometry and had the same 
prognosis as cases described as small-sized. These findings suggest that BCLL tumors may have 
intermediate-sized lymphocytes described in lymph node cytology or blood smear evaluation and this 
morphology does not necessarily indicate a different tumor or prognosis. A small number of cases were 
described as having intermediate to large-sized lymphocytes in the blood and these cases did have a 
poorer prognosis, with an over-representation of Boxers. These cases may represent more aggressive 
BCLL disease or a different B-cell neoplasm, such as mantle cell lymphoma, marginal zone lymphoma, or 
follicular lymphoma, all of which may have a leukemic component in humans.2 Nuclear descriptions 
were variable or lacking in these cases, making it difficult to fully characterize the cells in this 
retrospective study. Future studies that objectively characterize lymphocyte morphology on fresh blood 
films would be needed to thoroughly evaluate the utility of morphologic features in prognosis. Human 
CLL may have admixed larger cells and up to 55% prolymphocytes, and cases with increased 
prolymphocytes have poorer prognosis.135 A previous study of canine CLL found that prolymphocytes 
were not prognostic, but only 1/17 BCLL cases had >10% prolymphocytes.84  
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 Limitations of this study include the retrospective study design, incomplete staging for some 
cases, variable treatment protocols and lack of necropsies. Treatments were variable and could have 
been influenced by owners’ willingness to pursue therapy, making it difficult to assess the efficacy of 
different treatment types. In many cases, death or euthanasia was attributed to BCLL progression, but 
was not confirmed by necropsy. In some cases, patients were euthanized due to declining clinical 
condition, but given the old age and co-morbidities in these patients, cause of death is not certain. 
Additionally, by including cases with extensive tissue involvement and/or atypical cellular morphology, 
we may have included cases with a different small cell B-cell neoplasm. However, we currently cannot 
differentiate subtypes of small cell B-cell neoplasms by immunophenotyping, and therefore wanted to 
include any cases that would have a diagnosis of BCLL by routine flow cytometry.  
 In conclusion, this study demonstrated that canine BCLL, as defined by flow cytometry, has a 
variable clinical course. High Ki67 expression and Boxer breed were associated with more aggressive 
disease. We hypothesize that BCLL is a heterogeneous tumor, as is seen with human CLL. Future work to 
evaluate differences in gene expression and underlying mutations between subsets with different 










B-cell chronic lymphocytic leukemia is a common tumor in dogs and humans, defined by an 
expansion of small mature-appearing B cells in the blood and/or bone marrow. These diseases share 
similar presentations and heterogeneous clinical courses, and we hypothesize that spontaneous canine 
BCLL may serve as a natural model to study human CLL. However, little is known about the pathways 
driving canine BCLL development and progression. Our objective was to examine the gene expression 
profile of canine BCLL by NanoString and RNA Sequencing (RNA Seq) technology, to identify key 
molecular pathways in canine BCLL and compare the transcriptomes of canine BCLL and human CLL. 
Additionally, we examined heterogeneity and breed-specific differences in gene expression among 
canine BCLL samples, targeting small breeds and Boxers. For the NanoString study, RNA was extracted 
from peripheral blood in BCLL cases (n=26), lymph node samples in large B-cell lymphoma cases (n=23), 
and sorted CD21+ B cells from healthy dog lymph nodes (n=8). Expression was determined for a set of 
327 genes hand-curated from the human CLL literature. For the RNA Seq study, RNA was extracted from 
12 dogs with BCLL and sorted B cells from 3 healthy dog lymph node samples. Gene set enrichment 
analysis was used to identify enriched pathways and biological functions in canine BCLL and test 
whether human CLL gene sets were differentially expressed between canine BCLL cases and control B 
cells. Gene expression analysis segregated BCLL cases from large B-cell lymphoma cases and control B 
cells. By both methods, canine BCLL gene expression profiles were significantly enriched for the human 
CLL gene sets. By RNA Seq, 1,671 genes were differentially expressed between canine BCLL samples and 
control B cells. Canine BCLL exhibited upregulation of cytokine signaling pathways, KRAS signaling, NF-κB 
signaling and B-cell receptor signaling pathways. Clustering of BCLL samples by NanoString and RNA Seq 
analyses identified two subgroups, termed BCLL subgroup 1 and 2. We identified 3,541 genes 
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differentially expressed between subgroups by RNA Seq; BCLL subgroup 2 had overexpression of cell 
cycle progression and proliferation genes, and BCLL subgroup 1 had overexpression of the TNFA 
signaling via NF-κB pathway and ribosome and spliceosome genes. BCLL subgroup 2 had significantly 
higher Ki67 expression and an over-representation of Boxer dogs, previously shown to be associated 
with poor prognosis. These results identified similarities in gene expression profiles between canine 
BCLL and human CLL and identified two molecular subgroups of BCLL for further study. 
Introduction 
 
B-cell chronic lymphocytic leukemia is a common tumor in dogs and humans. In dogs, 
hematologic malignancies are among the most common tumors diagnosed, and BCLL accounts for 
approximately 8% of canine samples submitted for immunophenotyping with a suspicion of 
lymphoproliferative disease.62,136 In humans, CLL is the most common adult leukemia in western 
countries and approximately 5.0 new cases per 100,000 men and women are diagnosed per year.1,88 The 
dog is increasingly recognized as a model to study naturally occurring cancers, including to identify 
underlying genetic predispositions, to investigate mechanisms of tumor development, and to test new 
therapies.57,58 Similarities between canine and human tumors have been identified for several tumor 
types, including osteosarcoma, hemangiosarcoma, and urinary bladder tumors.57,137–139 To determine 
the utility of the canine model for particular tumor types, studies have assessed similarities in clinical 
presentation, histology or immunophenotype of neoplastic cells, risk factors, somatic or genomic 
changes, and dysregulated pathways driving tumor development. 
Previous studies evaluating the clinical presentation and outcome of canine BCLL have identified 
similarities to human CLL. In both species, these neoplasms are defined by an expansion of small-sized B 
cells in the blood and bone marrow, with lymph nodes and spleen often affected.52,62 B cells generally 
have small mature-appearing cytomorphology, with smaller proportions of intermediate-sized 
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lymphocytes or prolymphocytes.52,140 Human CLL cells express B-cell surface antigens CD19, CD20 and 
CD23, as well as the T-cell antigen CD5.33 Canine BCLL cells express the B-cell surface antigen CD21, but 
not the CD5 antigen.62 Antibodies to CD19, CD20, and CD23 are not readily available for routine 
immunophenotyping in the dog. These tumors typically affect older patients, with a median age at 
diagnosis of 67-72 years in people and 10-12 years in dogs.52,62,66,84 Humans with a family history of CLL 
have an increased incidence of disease, and small breed dogs have increased risk of BCLL suggesting a 
genetic predisposition.62,141  
Human and canine CLL have diverse clinical presentations and outcomes, ranging from indolent 
disease to more aggressive disease requiring therapy (chapter 2).52 Early staging systems in human CLL 
were based on the extent of blood and/or bone marrow, lymph node, spleen and liver involvement and 
presence of anemia and/or thrombocytopenia.47,48 More recently, numerous additional prognostic 
factors have been evaluated and an international consortium developed the CLL International 
Prognostic Index (CLL-IPI), which incorporates clinical, biological and genetic variables.51 This prognostic 
score incorporates TP53 status, immunoglobulin heavy variable region (IGHV) mutation status, serum 
β2-microglobulin concentration, clinical stage, and age, and identifies four risk groups with significantly 
different overall survival. Canine BCLL also has a variable clinical outcome with a wide range in survival 
times.84,85 Some of the human prognostic factors have not been assessed or were not prognostic in 
canine BCLL, but age and IGHV mutation status potentially play a role. Age was prognostic in one 
study,84 but not another (chapter 2). We previously found that Boxers preferentially rearrange 
unmutated IGHV genes and have poor prognosis, however, IGHV mutation status was not prognostic in 
a small number of non-Boxers, so the prognostic utility of IGHV mutation status in canine BCLL needs 
further investigation.121 We demonstrated that Ki67 expression, a marker of proliferation, was 
prognostic in canine BCLL and Boxers had significantly higher Ki67 expression than small breed dogs 
(chapter 2).  
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Several studies have evaluated the gene expression profile of human CLL and examined 
differential gene expression between prognostically different patient subsets. Two earlier studies using 
microarrays found that CLL samples displayed a common gene expression profile distinct from other B-
cell neoplasms and only a small number of genes distinguished IGHV mutated and unmutated cases, 
suggesting that mutated and unmutated CLL are in fact the same disease.22,142 Human CLL appeared to 
have an antiapoptotic phenotype with upregulation of genes in signal transduction pathways, including 
B-cell receptor (BCR) signaling.22 Rosenwald et al. found overexpression of B-cell activation genes in CLL 
patients with unmutated IGHV, suggesting the aggressive disease course in these patients may be 
attributed to enhanced BCR signaling.142 Two studies performed with RNA Seq highlighted alternative 
splicing events in CLL, which can alter protein structure and phosphorylation targets and ultimately 
affect numerous signaling pathways.143,144 Gene expression studies have also sought to determine the 
cell of origin for CLL. An early study found that tumor cells were most similar to memory B cells,22 while 
a more recent study comparing CLL to additional normal B-cell subsets determined that CLL is derived 
from CD5+ B cells, which represent a distinct differentiation stage in humans.15 IGHV unmutated CLL was 
derived from mature CD5+CD27- B cells, while mutated CLL was derived from a previously unrecognized 
post-germinal center memory CD5+ subset expressing the memory B-cell marker CD27 and carrying 
somatically mutated IGHV genes.15  
The goal of this study was to evaluate the gene expression profile of canine BCLL, which has not 
previously been examined. Gene expression was evaluated by NanoString analysis and RNA Seq analysis. 
NanoString studies evaluate expression of a pre-defined set of genes, which limits the scope of the 
analysis, but allows for evaluation of a larger number of samples and may be performed on lower 
quantity and lower quality RNA samples.145 RNA Seq allows for global assessment of the transcriptome, 
but costs can limit the number of samples analyzed. Given the overlap in clinical presentation and 
disease progression between human and canine CLL, one aim of this study was to compare human CLL 
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and canine BCLL gene expression profiles. A second aim was to evaluate the heterogeneity among 
canine BCLL samples, and to determine whether BCLL cases with different Ki67 expression have distinct 
gene expression profiles. 
Methods 
Cases and controls 
 Cases included BCLL cases and large B-cell lymphoma cases that had immunophenotyping by 
flow cytometry performed at the Colorado State University-Clinical Immunology laboratory between 
July 2014 and August 2017. BCLL was defined by an expansion of small-sized CD21+ B cells in the 
peripheral blood, as previously described.62 BCLL samples from Boxers or small breeds with an increased 
risk of BCLL were randomly selected. Ten BCLL samples were used for NanoString and RNA Seq 
experiments, 16 were used for NanoString only, and 2 were used for RNA Seq only. BCLL cases with 
available DNA had IGHV mutation status determined, as previously described.121 Large B-cell lymphoma 
was defined by an expansion of CD21+ B cells with a median forward scatter >500 and high class II MHC 
expression (median fluorescence intensity, >100) in a lymph node aspirate. Cases with these flow 
cytometry features were previously shown to be predominantly of the diffuse large B-cell lymphoma 
(DLBCL) histologic subtype.122 Twenty-three large B-cell lymphoma samples were used for the 
NanoString experiment: 13 samples were randomly selected from Golden retrievers, as Golden retriever 
results were being used for a second study; 3 samples were randomly selected from Boxers; and, an 
additional 7 cases irrespective of breed were randomly selected. Study population patient information is 
summarized in Table 7. 
Table 7. Summary patient information for BCLL cases and large B-cell lymphoma cases analyzed in 
NanoString and RNA Sequencing experiments. 
 NanoString BCLL cases 
(n=26) 
NanoString large B-cell 
lymphoma cases 





Age (years), median 
(IQR; range) 
10.3 (8.3-11.3; 5.2-15.0) 8.2 (7.4-10.7; 2.8-14.5) 11.1 (8.8-13.2; 7.4-
15.0) 
Sex (%) 73% female 43% female 75% female 
Breed distribution (n)a BIC (1), BOST (1), BOX (11), 
CRN (1), COC (1), CSH (1), 
DACH (1), JRT (2), MLT (2), 
POM (1), SHI (3), TIBT (1) 
BASS (1), BOR (1), BOX 
(3), CCR (1), GLDR (13), 
LAB (1), MAST (1), 
NEWFIE (1), VSL (1) 
BOX (4), CRN (1), 
COC (1), DACH (1), 
JRT (1), MLT (2), 
POM (1), SHI (1) 
CBC lymphocytes/µL, 








11/20 (55%) 23/23 (100%) 4/10 (40%) 
Anemia, (% affected)b 7/26 (27%) 2/15 (13%) 3/12 (25%) 
Thrombocytopenia, (% 
affected)b 
6/26 (23%) 2/14 (14%) 1/12 (8%) 
IQR, interquartile range; n, number; NA, not applicable. a Breed abbreviation: BASS, Bassett hound; BIC, 
Bichon frise; BOR, Border collie; BOST, Boston terrier; BOX, Boxer; CCR, Chinese crested; COC, Cocker 
spaniel; CRN, Cairn terrier; CSH, Chihuahua shorthair; DACH, Dachshund; GLDR, Golden retriever; JRT, 
Jack Russell terrier; LAB, Labrador retriever; MAST, Mastiff; MLT, Maltese; NEWFIE, Newfoundland; 
POM, Pomeranian; SHI, Shih Tzu; TIBT, Tibetan terrier; VSL, Vizsla. b For lymphadenopathy, anemia, and 
thrombocytopenia, the number of affected cases/the number of cases with available data is provided; 
the percent affected among cases with available data is reported. 
 
Control B cells were obtained from peripheral lymph node biopsies from healthy dogs that were 
used for IACUC-approved continuing education surgery courses. These samples had no evidence of 
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lymphoproliferative disease by histology, flow cytometry or clonality testing by PCR for antigen receptor 
rearrangements.  
Cell sorting and RNA isolation 
 Peripheral blood samples were sorted to purify B cells in the majority (20/28) of BCLL cases; the 
remaining 8 BCLL cases that were not sorted had >80% B cells comprising the leukocyte population. In 
sorted samples, B cells were purified from leukocyte pellets by magnetic depletion of T cells and CD18-
expressing myeloid cells using the Miltenyi Biotec protocol (Miltenyi Biotec, San Diego, CA). The 
leukocyte cell pellet was re-suspended in 145 µL flow buffer (PBS-2%FBS-0.1%NaAZ) with the following 
antibodies (purchased from Bio-Rad, Hercules, CA): anti-CD21 (A647, CA2.1D6 clone), anti-CD4 (FITC, 
YKIX302.9 clone), anti-CD8 (PE, YCATE55.9 clone), and anti-CD18 (PE, YFC118.3 clone). Samples were 
incubated for 10 minutes in the dark at 4oC and washed with MACS buffer (phosphate-buffered saline 
[PBS]‐0.5% BSA‐2 mM ethylenediaminetetraacetic acid [EDTA] −1 mM). The cell pellet was resuspended 
in 50 µL MACS buffer, 20 µL PE beads (Miltenyi Biotec), and 20 µL FITC beads (Miltenyi Biotec), 
incubated for 10 minutes in the dark at 4oC, washed and resuspended in 500 µL MACS buffer, and 
loaded onto the prepared LD column in a MidiMACS separator. The column was rinsed twice with 1 mL 
MACS buffer and the sorted B cells that were not bound by beads were collected. The median purity, 
determined by flow cytometry, was 93% (interquartile range [IQR], 88-96%). All NanoString BCLL 
samples had purity >80% except for 3 cases (60%, 77%, 79%) and all RNA Seq BCLL samples had purity 
>80% except for 1 case (77%). The large B-cell lymphoma samples used for NanoString analysis were not 
sorted and contained ≥80% CD21+ B cells (median, 90.5% B cells; range, 80.0-97.6% B cells). 
 CD21+ B cells were purified from control healthy dog lymph nodes by fluorescence-activated cell 
sorting. Samples were stained with anti-CD21-PE (B cells, clone CA2.1D6), anti-CD5-APC (T cells, clone 
YKIX322.3), anti-CD4-Pacific Blue (CD4 T cells, clone YKIZ302.9) and anti-CD8-FITC (CD8 T cells, clone 
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YCATE 55.9) and sorted on a MoFlo cell sorter (Beckman Coulter, Brea, CA). Purity was determined by 
flow cytometry and sorted samples with >90% CD21+ B cells were used for RNA isolation.  
 RNA was isolated using the Purelink RNA mini kit (Life Technologies, Carlsbad, CA). Cell samples 
were suspended in prepared RNA lysis buffer and stored at -80oC until RNA isolation. RNA was isolated 
according to manufacturer instructions, RNA concentration was determined using a Nanodrop and/or 
Qubit fluorometer instrument (Thermo Fisher Scientific, Waltham, MA), and RNA integrity was assessed 
using an Agilent RNA ScreenTape assay (Agilent Technologies, Santa Clara, CA). NanoString sample 
concentrations ranged from 3.2-690 ng/µL and RNA integrity numbers (RINs) ranged from 3.3-8.8. RNA 
Seq sample concentrations ranged from 28-672 ng/µL and RINs ranged from 8.3-10. 
NanoString: Gene expression and statistical analysis 
 NanoString technology was used to measure the expression of a custom set of 327 genes. Genes 
were selected that define the human CLL gene expression signature, have prognostic significance in 
human CLL, and/or are differentially expressed between normal B-cell subsets.15,22,142,143,146–151 Six 
housekeeping genes were selected that demonstrated low variability between samples in a previous 
canine NanoString experiment: EEF1G, GUSB, HPRT1, POLR2A, RPL19, SDHA.152 Approximately 100 ng of 
sample RNA was hybridized to custom-built mRNA probes and analyzed with the nCounter Digital 
Analyzer system (NanoString Technologies, Seattle, WA) through the University of Arizona Genetics 
Core. 
NanoString quality control, normalization, and data analysis were performed using nCounter 
software (version 4.0, NanoString Technologies). Quality control metrics assessing imaging, binding 
density, positive control linearity and limit of detection were acceptable, and all data were used for 
analysis. A background threshold of 20 was used to correct for probes with very low counts. Standard 
two-step normalization was performed using a combination of positive control normalization (synthetic 
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control targets) and CodeSet content normalization (housekeeping genes). Three housekeeping genes 
were differentially expressed between BCLL cases and controls and were omitted (EEF1G, HPRT1, 
SDHA). Remaining housekeeping genes (GUSB, POLR2A, RPL19) had little variability and were used for 
normalization. Normalized data were used to calculate ratios between control B-cell, BCLL and large B-
cell lymphoma groups to assess differential expression. Ratios were subsequently converted to log2 fold-
changes. The Benjamini-Yekutieli False Discovery Rate (FDR) method was used to compare groups and 
an FDR adjusted p value <0.05 was considered significant. 
 NanoString experiment heat maps were generated by unsupervised hierarchical clustering 
(Pearson correlation, average linkage) in Morpheus (https://software.broadinstitute.org/morpheus) 
using normalized log2 gene counts. Very low expressing genes (≤20 counts in >80% of cases) were 
omitted and the resulting 312 genes were included in the heat maps. To compare expression of 
individual genes between groups, normality was assessed using a Shapiro Wilk test and a t test or Mann 
Whitney test was performed using normalized log2 gene counts (GraphPad Prism, version 8.1, La Jolla, 
CA). A p value <0.05 was considered significant. Gene Set Enrichment Analysis (GSEA) software (version 
4.0.3, https://www.gsea-msigdb.org/gsea/index.jsp) was used to determine whether a defined gene set 
was differentially expressed between BCLL cases and controls.153,154 Three gene sets were hand-curated 
using the human CLL literature: (1) genes overexpressed in CLL vs. control B cells; (2) genes 
underexpressed in CLL vs. control B cells; (3) genes overexpressed in CLL vs. DLBCL.15,22,142,143,146–148 
Enriched gene sets were identified using 1000 permutations of the phenotype labels. Among the GSEA 
statistics, the normalized enrichment score (NES) reflects the degree to which the tested gene set was 
overrepresented in the phenotype of interest. The statistical significance of the enrichment score is 
estimated by the nominal p value. The false discovery rate (FDR) estimates the probability of a false 




RNA Sequencing: Gene expression and statistical analysis 
 Sample libraries were prepared and sequenced at Novogene Corporation Inc. (Sacramento, CA). 
For library construction, mRNA was enriched using oligo(dT) beads and fragmented, and cDNA was 
synthesized using random hexamers and reverse transcriptase, followed by second-strand synthesis 
using an Illumina buffer containing dNTPs, RNase H and Escherichia coli polymerase I. The cDNA library 
was subjected to purification, end repair, addition of a single A base, ligation of sequencing adapters, 
size selection and PCR enrichment. Libraries were sequenced on an Illumina HiSeq. Data quality control 
information for each sample is provided in Supplemental table S2. Sequencing reads were aligned to the 
CanFam3.1 reference genome using TopHat2 and mapping result details are provided in Supplemental 
table S3.155 GTF files providing genes features were obtained from the Ensembl website (release 82; 
http://www.ensembl.org/info/data/ftp/index.html).156  
Sequencing data were uploaded to the Galaxy web platform (https://usegalaxy.org/) for further 
analysis.157 Read counts per gene were generated using HTSeq-count.158 Read count data normalization 
and differential gene expression analysis were performed with DESeq2.159  A Benjamini-Hochberg 
adjusted p value <0.05 was considered significant to identify differentially expressed genes. Pairwise 
comparisons were made between controls and all BCLL samples or BCLL subgroups. Similarity among 
transcriptional profiles was visualized by unsupervised hierarchical clustering (Morpheus software) and 
principal component analysis (DESeq2). Unsupervised hierarchical clustering and heat maps were 
generated in Morpheus using either fragments per kilobase million (FPKM) values for filtered genes or 
rlog normalized counts of differentially expressed genes. For FPKM data, we omitted genes with low 
expression or low variability by excluding genes where FPKM equaled 0 in >20% of samples or the 
standard deviation across samples was <10. The FPKM values for the remaining 4,622 genes was log 
transformed. Differentially expressed gene lists generated by DESeq2 were analyzed by GSEA software 
to identify altered pathways and biological functions. GSEA was performed using curated gene sets from 
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the Molecular Signature Database and gene sets from the Staudt laboratory 
(https://lymphochip.nih.gov/signaturedb/index.html).153 Venn diagrams were created to visualize 
overlap in differentially expressed gene lists (http://genevenn.sourceforge.net/). We used GSEA to 
assess whether the canine BCLL gene expression profile was significantly enriched for human B-cell 
leukemia/lymphoma gene sets. Sets of genes that are overexpressed or underexpressed in tumor 
samples compared to controls were compiled for CLL, mantle cell lymphoma, splenic marginal zone 
lymphoma, and follicular lymphoma.143,160–162 To compare expression of individual genes between 
groups, normality was assessed using a Shapiro Wilk test, and a t test or Mann Whitney test was 
performed using rlog normalized counts (GraphPad Prism). The normalized log transformed counts of 
individual genes were compared between NanoString and RNA Seq methods using a Pearson correlation 
(GraphPad Prism). 
Results 
NanoString and RNA Seq identify genes differentially expressed in BCLL and control B cells 
 Hierarchical clustering of gene expression data clearly separated the controls and BCLL samples 
in the NanoString and RNA Seq experiments (Figure 10). Large B-cell lymphoma samples were also 
clearly separate from controls and BCLL samples in the NanoString study (Figure 10A). The gene 
expression profile of normal B cells from healthy control dog lymph nodes was relatively homogeneous, 
while BCLL samples demonstrated more heterogeneity. Clustering identified 2 main subgroups of BCLL 
cases (Figure 10). By RNA Seq, 2 BCLL samples formed their own clade, but their gene expression profiles 
were most similar to BCLL subgroup 2 visually and by principal component analysis, so these cases were 
grouped for further analysis. The 10 BCLL samples that were included in the NanoString and RNA Seq 
studies were clustered into the same BCLL subgroup by either method. There was no distinct separation 
of Boxers and small breeds with BCLL by either method, however 9/11 (82%) and 3/4 (75%) Boxers 
clustered in the BCLL 2 subgroup by NanoString and RNA Seq, respectively. Small breed dogs were 
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intermixed between BCLL subgroups. Of BCLL cases where IGHV mutation was determined, 4/4 (100%) 
BCLL subgroup 1 cases had mutated IGHV genes, and 5/12 (42%) BCLL subgroup 2 cases had mutated 
IGHV genes.  
 
Figure 10. Hierarchical clustering analysis of BCLL cases, large B-cell lymphoma cases and control B cells. 
(A) Hierarchical clustering was performed using 312 genes in the NanoString experiment. The BCLL 
cases, large B-cell lymphoma cases, and normal B cells from healthy control lymph nodes separated 
clearly. The BCLL cases formed 2 main subgroups, and the majority of Boxer cases were in BCLL 
subgroup 2. (B) Hierarchical clustering was performed using FPKM values of 4,622 filtered genes in the 
RNA Seq experiment. Normal B cells from healthy controls formed a relatively homogeneous clade. The 
BCLL cases were more heterogeneous and formed 2 main subgroups. The 2 cases to the far right were 
grouped with BCLL subgroup 2 for further analysis. 
 
 In the NanoString dataset, we quantified the number of genes significantly differentially 
expressed in pairwise comparisons between normal B cells from control dog lymph nodes, BCLL cases 
(either all together or as BCLL subgroups 1 or 2), and large B-cell lymphoma cases (nSolver analysis, FDR 
<0.05) (Table 8). 175/327 (54%) genes in the NanoString experiment were differentially expressed 
between all BCLL samples and control B cells. 59 genes were differentially expressed between BCLL 
76 
 
subgroups 1 and 2. Using the RNA Seq dataset, we quantified the number of differentially expressed 
annotated genes in all BCLL samples vs. control B cells, BCLL subgroup 1 vs. control B cells, BCLL 
subgroup 2 vs. control B cells, and BCLL subgroup 1 vs. BCLL subgroup 2 (Table 9). 1,671 genes were 
differentially expressed between all BCLL samples and control B cells (p-adj <0.05). The top 500 
transcriptional elements overexpressed or underexpressed in BCLL as determined by fold change are 
listed in Supplemental table S4. The vast majority (98%) of these elements are protein coding genes; 
non-coding RNAs may be underrepresented due to polyadenylated RNA enrichment methods, which can 
miss small non-coding RNAs like miRNAs, and a less well annotated canine non-coding RNA database 
compared to human. 1,086 genes that were differentially expressed between control B cells and BCLL 
samples were found in BCLL subgroup 1 vs. control and BCLL subgroup 2 vs. control comparisons, 
indicating that BCLL subgroups have a set of differentially expressed genes in common (Figure 11). 
Additionally, a large set of differentially expressed genes were identified in the BCLL subgroup 1. 
Table 8. Number of genes differentially overexpressed or underexpressed (nSolver, FDR <0.05) between 
normal B cells from healthy controls, BCLL subgroups and large B-cell lymphoma cases by NanoString 
analysis. 








All BCLL samples vs. control 
B cells 
175 78 97 
Large B-cell lymphoma vs. 
control B cells 
201 59 142 
Large B-cell lymphoma vs. 
all BCLL samples 
205 56 149 
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BCLL subgroup 1 vs. control 
B cells 
145 56 89 
BCLL subgroup 2 vs. control 
B cells 
146 64 82 
BCLL subgroup 1 vs. BCLL 
subgroup 2 
59 28 31 
 
Table 9. Number of genes differentially overexpressed or underexpressed (DESeq2, p-adj <0.05) 
between normal B cells from healthy controls and BCLL subgroups by RNA Seq analysis. 








All BCLL samples vs. 
control B cells 
1671 1110 561 
BCLL subgroup 1 vs. 
control B cells 
4784 2670 2114 
BCLL subgroup 2 vs. 
control B cells 
1775 1150 625 
BCLL subgroup 1 vs. BCLL 
subgroup 2 





Figure 11. Venn diagram showing overlap in differentially expressed genes between BCLL subgroups by 
RNA Seq analysis. The number of significantly overexpressed (A) and underexpressed (B) genes in BCLL 
samples vs. control B cells are presented (DESeq2, p-adj <0.05). Gene lists were compared between BCLL 
subgroup 1 samples vs. control B cells and BCLL subgroup 2 samples vs. control B cells. A set of 1,086 
differentially expressed genes were common among the gene lists, including 662 genes overexpressed in 
BCLL and 424 underexpressed in BCLL. 
 
To validate the expression data, a few genes of interest were selected and the log transformed 
normalized counts were compared between the NanoString and RNA Seq analyses for the 10 BCLL 
samples that were included in both experiments (Table 10; Figure 12). There was high correlation 
between NanoString and RNA Seq expression for the genes evaluated. 
Table 10. Pearson correlation of log transformed normalized counts between RNA Seq and NanoString 
methods for select genes of interest.  
Gene Pearson's r   95% confidence interval p value 
CD9 0.9795 0.9129 to0.9953 <0.0001 
MKI67 0.9843 0.9329 to 0.9964 <0.0001 
BCL2 0.9901 0.9572 to 0.9977 <0.0001 




Figure 12. Comparison of CD9 expression between NanoString and RNA Seq experiments. Log 
transformed normalized CD9 counts from NanoString analysis or RNA Seq DESeq2 analysis are compared 
for 10 BCLL cases that were included in both experiments. (A) There was high correlation of CD9 
expression between NanoString and RNA Seq methods (Pearson’s r, 0.9795). (B) NanoString counts were 
relatively higher than RNA Seq counts, but increases were generally proportional across BCLL cases. (C) 
BCLL cases had significantly higher CD9 expression than control B cells in both experiments. Data points 
are shown for 10 BCLL cases included in both studies; the control samples were different in the 
NanoString and RNA Seq experiments. 
 
Functional pathway analysis in canine BCLL 
 We used GSEA to predict biological functions and pathways underlying canine BCLL. 
Differentially expressed genes identified by RNA Seq between all BCLL samples and control B cells were 
analyzed. All enriched gene sets in the hallmarks gene set database (FDR <0.25) are listed in Table 11.163 
Genes involved in inflammatory responses, cytokine signaling pathways, KRAS signaling, and TNFA 
signaling via NF-κB were overexpressed in BCLL. Genes in cell cycle progression were underexpressed in 
BCLL compared to control lymph node B cells. This finding may suggest BCLL cells have a more quiescent 
phenotype as seen in human CLL, or this result may be attributed to a difference in tissue source, as 
BCLL samples were from blood and control B cells were collected from lymph nodes. Additionally, a BCR 
signaling gene set curated from the Staudt laboratory (published164–166 and unpublished data, 
https://lymphochip.nih.gov/signaturedb/index.html) was enriched in the BCLL samples compared to 
controls (normalized enrichment score, 1.90; p=0.008; FDR=0.106). 
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Table 11. Summary of hallmark gene sets enriched between canine BCLL vs. control B cells. 
Gene set Enriched phenotype NES NOM p-val FDR q-val 
Inflammatory response BCLL 3.05 <0.0001 <0.0001 
KRAS signaling up BCLL 2.86 <0.0001 <0.0001 
IL2 STAT5 signaling BCLL 2.74 <0.0001 <0.0001 
Coagulation BCLL 2.73 <0.0001 <0.0001 
Epithelial mesenchymal transition BCLL 2.42 <0.0001 0.0013 
Complement BCLL 2.32 0.0038 0.0032 
TNFA signaling via NFKB BCLL 2.24 <0.0001 0.0041 
P53 pathway BCLL 1.89 0.0214 0.0323 
Apoptosis BCLL 1.76 0.0261 0.0558 
Hypoxia BCLL 1.70 0.0303 0.0594 
IL6 JAK STAT3 signaling BCLL 1.71 0.0290 0.0613 
Heme metabolism BCLL 1.66 0.0241 0.0673 
Interferon gamma response BCLL 1.55 0.0659 0.0842 
Cholesterol homeostasis BCLL 1.59 0.0382 0.0859 
Allograft rejection BCLL 1.57 0.0447 0.0884 
Glycolysis BCLL 1.55 0.0500 0.0894 
Xenobiotic metabolism BCLL 1.29 0.1598 0.2359 
PI3K AKT MTOR signaling BCLL 1.27 0.1887 0.2442 
E2F targets Control B cells -3.29 <0.0001 <0.0001 
G2M checkpoint Control B cells -2.88 <0.0001 <0.0001 
Oxidative phosphorylation Control B cells -1.91 0.0059 0.0206 
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Mitotic spindle Control B cells -1.95 0.0040 0.0215 
NES, normalized enrichment score; NOM p-val, nominal p value; FDR q-val, false discovery rate. 
 
 We assessed whether the canine BCLL gene expression profile was enriched for human CLL gene 
sets by GSEA. Using the NanoString dataset, we tested whether the manually curated human CLL gene 
sets (CLL vs. normal B cells and CLL vs. DLBCL) were differentially expressed in canine BCLL samples vs. 
control B cells and BCLL samples vs. large B-cell lymphoma samples (Figure 13). The set of genes 
overexpressed in human CLL compared to normal B cells was significantly enriched in canine BCLL 
samples compared to control B cells (Figure 13B). Genes underexpressed in human CLL compared to 
normal B cells were not significantly enriched in the canine NanoString data. The set of genes 
overexpressed in human CLL compared to DLBCL was significantly enriched in canine BCLL samples 
compared to large B-cell lymphoma samples, though this gene set was relatively small. 
 
Figure 13. Comparison of human CLL gene sets and canine BCLL differentially expressed gene lists 
generated by NanoString analysis. (A) Results from GSEA testing whether sets of differentially expressed 
genes between human CLL vs. normal B cells and human CLL vs. DLBCL were enriched in canine BCLL 
samples, when compared to control B cells or large B-cell lymphoma samples, respectively. The 
normalized enrichment score (NES) reflects the degree to which the human gene set was 
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overrepresented in the canine phenotype of interest. A false discovery rate (FDR) <0.25 was considered 
significant. (B) GSEA enrichment score plot comparing the NanoString differentially expressed genes 
between canine BCLL and control B cells with the compiled list of genes overexpressed in human CLL vs. 
normal B cells. Differentially expressed genes in canine BCLL vs. control B cells are ranked with genes 
overexpressed in BCLL on the left. Vertical black lines represent genes in the human gene set that 
appear in the ranked list of genes from the canine NanoString analysis. An accumulation of lines on the 
left indicates that genes overexpressed in human CLL are overexpressed in canine BCLL.  
 
We performed GSEA on the RNA Seq dataset to look for enrichment of human gene sets from 
CLL and other B-cell neoplasms that may have a leukemic component. Among CLL, mantle cell 
lymphoma, splenic marginal zone lymphoma, and follicular lymphoma gene sets, only the human CLL 
gene set was significantly differentially expressed in canine BCLL samples compared to controls. Genes 
overexpressed in human CLL vs. normal blood CD19+ B cells (Liao et al. data set143) were overexpressed 
in canine BCLL (NES, 5.44; FDR, <0.001) (Figure 14A), but genes downregulated in human CLL were not 
significantly underexpressed in canine BCLL. We tested BCLL subgroup 1 vs. control B cells and BCLL 
subgroup 2 vs. control B cells gene lists as well, to determine whether both BCLL subgroups were 
independently enriched for the human CLL gene set. Genes overexpressed in human CLL were 
overexpressed in both BCLL subgroup 1 (Figure 14B) and BCLL subgroup 2 (Figure 14C).  
 
Figure 14. Enrichment of the human CLL gene set in canine BCLL subgroup gene expression profiles 
generated by RNA Seq. Enrichment plots from GSEA show significant enrichment of the human CLL gene 
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set in all BCLL samples vs. control B cells (A), BCLL subgroup 1 samples vs. control B cells (B), and BCLL 
subgroup 2 samples vs. control B cells (C). The human CLL gene set contains genes overexpressed in CLL 
tumor cells compared to normal blood CD19+ B cells.143 Ranked gene lists from canine samples were 
obtained from differential gene expression analysis in DESeq2. 
 
 In summary, these results identified similarities in gene expression profiles between canine BCLL 
and human CLL by two different methods. And, both of the BCLL subgroups were independently 
enriched for the human CLL gene set, suggesting these BCLL molecular subtypes each share genes and 
pathways overexpressed in human CLL. 
Comparison of BCLL subgroup transcriptomes 
 We compared the gene expression profiles of the two BCLL subgroups detected by hierarchical 
clustering in the NanoString and RNA Seq experiments. 3,541 annotated genes were differentially 
expressed between BCLL subgroups by RNA Seq (Figure 15A). Gene set enrichment analysis of genes 
differentially expressed in BCLL subgroup 2 vs. BCLL subgroup 1 found that BCLL subgroup 2 was 
significantly enriched for proliferation gene sets (Figure 15B), E2F targets, and glycolysis genes 
(Supplemental table S5). Top gene sets enriched in BCLL subgroup 1 included TNFA signaling via NF-κB 
(Figure 15C), unfolded protein response, and ribosome and spliceosome genes (Supplemental table S5). 
Given the increased expression of cell cycle progression genes in BCLL subgroup 2 samples, we 
hypothesized that these samples would have increased Ki67 expression. We compared normalized log 
transformed MKI67 counts for control B cells and BCLL samples and found that BCLL subgroup 2 samples 
had significantly higher MKI67 expression than BCLL subgroup 1 samples by RNA Seq (p=0.0051; Figure 
15D) and NanoString (p=0.0001; Figure 15E) analyses.  
 We independently compared BCLL subgroup 1 samples and BCLL subgroup 2 samples to control 
B cells from healthy dog lymph nodes. A total of 4,784 annotated genes were differentially expressed 
between BCLL subgroup 1 samples and control B cells by DESeq2 analysis. A total of 1,775 annotated 
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genes were differentially expressed between BCLL subgroup 2 samples compared to control B cells. 
There was overlap in the gene sets enriched in the BCLL subgroups compared to control B cells. Genes 
 
 
Figure 15. Transcriptome comparison between BCLL subgroups. Two major BCLL subgroups were 
identified by hierarchical clustering based on gene expression in the NanoString and RNA Seq 
experiments. (A) Unsupervised hierarchical clustering of BCLL samples using annotated genes 
differentially expressed in BCLL subgroup 2 vs. BCLL subgroup 1 by RNA Seq analysis (DESeq2, p-adj 
<0.05). A total of 3,541 genes were differentially expressed between BCLL subgroups. (B-C) GSEA 
enrichment plots comparing the ranked list of differentially expressed genes in BCLL subgroup 2 vs. BCLL 
subgroup 1. Vertical lines represent genes in the gene set that appear in the ranked list of differentially 
expressed BCLL genes. An accumulation of genes on the far left or far right indicate enrichment in the 
BCLL subgroup 2 or subgroup 1 phenotype, respectively. BCLL subgroup 2 samples were enriched for cell 
cycle progression gene sets, including mitotic spindle assembly (B). BCLL subgroup 1 samples were 
enriched for genes regulated by NF-κB in response to TNF (C). (D-E) RNA Seq normalized rlog MKI67 
counts (D) and NanoString normalized log2 MKI67 counts (E) for control B cells, BCLL samples and large 
B-cell lymphoma samples. BCLL subgroup 2 samples had significantly higher MKI67 expression than 




overexpressed in BCLL subgroup 1 and 2 groups compared to control B cells were independently 
enriched in TNFA signaling by NF-κB, BCR signaling, inflammatory responses and cytokine signaling gene 
sets (Supplemental tables S6-S8). BCLL subgroup 1 samples were also enriched for NF-κB targets, TGFB 
signaling, ribosome and spliceosome KEGG gene sets, and splicing-related gene sets in the reactome 
database (Supplemental tables S6 and S7). Additionally, BCLL subgroup 2 samples had decreased 
expression of genes involved in DNA repair and TP53 activity compared to control B cells (Supplemental 
table S8). 
Markers to distinguish BCLL subgroups 
 After identifying BCLL subgroups based on their transcriptome, we wanted to determine 
whether there was a targeted list of genes that could distinguish the subgroups in a larger number of 
cases. Of the 1,145 genes differentially expressed by >1.5 fold-change between RNA Seq BCLL subgroup 
1 and BCLL subgroup 2 cases (n=12), 49 genes were represented in the NanoString probe set 
(Supplemental table S9). Expression of these 49 genes was examined in the larger set of BCLL cases 
(n=26) in the NanoString dataset (Figure 16). When these 49 genes were used to perform unsupervised 
hierarchical clustering of the NanoString BCLL cases, 23/26 cases were classified into their original BCLL 
subgroup. Three cases that were originally classified as BCLL subgroup 1 clustered with BCLL subgroup 2 
cases using the refined gene list; these 3 cases are indicated with an asterisk in Figure 16A and an open 
blue circle in Figure 16B. Genes overexpressed in BCLL subgroup 1 included genes involved in cellular 
responses to TNF, apoptosis regulation and BCR, TLR and NF-κB signaling. Genes overexpressed in BCLL 
subgroup 2 included genes involved in cell cycle progression and proliferation, as well as the anti-
apoptotic gene BCL2. A few of the genes differentially expressed between BCLL subgroups by RNA Seq 
and NanoString analysis, in addition to Ki67, include BCL2, CD72, RELA, IL10RA and BCL3 (Figure 16B). 
IL2RA (CD25) tended to have higher expression in BCLL subgroup 2 samples by NanoString analysis, but 
gene expression was not significantly different. By flow cytometry, a larger number of subgroup 2 cases 
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(63%) had high CD25 expression (>80% CD25+ B cells) compared to subgroup 1 cases (30%), but this 
trend was not significant. These comparisons identify a number of genes that could be tested in 
prospective studies for their ability to distinguish BCLL subgroups and predict prognosis. 
 
 
Figure 16. Expression of 49 genes differentially expressed between BCLL subgroups. Genes that were 
differentially expressed between RNA Seq BCLL subgroups (DESeq2 p-adj <0.05, fold change >1.5) and 
measured in the NanoString experiment were selected. (A) Heat map using normalized log2 counts 
measured by NanoString technology in 26 BCLL cases. Unsupervised hierarchical clustering placed 3 
cases originally classified as BCLL subgroup 1 into the BCLL subgroup 2 (asterisks). (B) Expression of 
select genes by NanoString in control B cells from healthy dog lymph nodes and BCLL subgroup cases, as 
originally classified in Figure 10A. The 3 BCLL subgroup 1 cases classified in subgroup 2 with the refined 
gene list are depicted as an open blue circle. BCLL subgroup 1 cases had significantly lower expression of 
BCL2 and CD72 (p <0.0001, p=0.0023, respectively) and significantly higher expression of RELA, IL10RA 
and BCL3 (p <0.0001, for each gene) compared to BCLL subgroup 2 cases. There was a trend for BCLL 
subgroup 2 cases to have higher IL2RA expression, but there was significant overlap between BCLL 






 This study evaluates the gene expression profile of canine BCLL and identifies genes 
differentially expressed between BCLL and normal B cells, compares canine BCLL and human CLL gene 
expression profiles, and identifies subgroups of BCLL cases based on differences in gene expression. This 
work utilized RNA Seq technology to evaluate the transcriptome globally and NanoString technology to 
measure expression of select genes in a larger number of cases. 
 There was clear separation of BCLL cases and control lymph node B cells from healthy dogs by 
RNA Seq and NanoString analysis. Additionally in the NanoString study, BCLL cases were compared to 
large B-cell lymphoma cases defined by flow cytometry. A previous study showed that the vast majority 
of large B-cell lymphoma cases with these flow cytometry features were DLBCL subtype by histology, 
which is the most common lymphoma subtype in the dog.76,77,122,167 The set of genes measured in the 
NanoString study, which encompassed genes that define different normal B-cell subsets and/or are 
differentially expressed in human CLL, clearly separated BCLL and large B-cell lymphoma cases. A total of 
1,671 genes were differentially expressed (p-adj <0.05) between all BCLL cases and control B cells by 
RNA Seq, and 856 genes were differentially expressed by >2 fold change. Some genes overexpressed in 
BCLL samples may be attributed to the blood tissue source compared to the lymph node source for 
control B cells; for example, apparent overexpression of platelet activation and coagulation cascade 
genes may be attributed to RNA released from platelets or platelet particles in the blood. Inflammatory 
response, cytokine signaling, KRAS signaling, NF-κB signaling, BCR signaling and JAK/STAT signaling were 
among the pathways enriched in BCLL. Cytokine-cytokine receptor signaling, NF-κB signaling, BCR 
signaling, and JAK/STAT signaling are among the mechanisms important for human CLL.168 KRAS 
mutations, which are common in certain carcinomas, have been recognized more recently in CLL where 
they affect the Ras-MAPK pathway and are associated with shorter treatment free survival.169  
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 We compared the canine BCLL gene expression profile to human CLL by NanoString analysis and 
RNA Seq analysis. For the NanoString comparison, we compiled a list of genes overexpressed or 
underexpressed in human CLL compared to normal B cells across several studies. We found significant 
enrichment of the human CLL upregulated gene set in the list of genes overexpressed in canine BCLL vs. 
control B cells. The list of genes underexpressed in canine BCLL was not significantly enriched for the 
human CLL downregulated gene set. For the RNA Seq comparison, we compared differentially expressed 
genes between canine BCLL and control lymph node B cells to differentially expressed genes identified 
by RNA Seq in a human CLL study by Liao et al.143 Additionally we compared the canine BCLL 
transcriptome to other human B-cell tumor gene signatures, including mantle cell lymphoma, splenic 
marginal zone lymphoma and follicular lymphoma, but only the CLL gene set was significantly enriched 
in the canine BCLL phenotype. Similar to the NanoString study, RNA Seq found similarity between genes 
overexpressed in human CLL and canine BCLL, but the set of genes downregulated in human CLL was not 
significant in canine BCLL. A major limitation of these comparisons is the source of control B cells used 
for differential expression analysis. Our study used pooled CD21+ B cells from lymph nodes from healthy 
young dogs. These lymph nodes had prominent germinal centers by histology. We lack the antibodies in 
veterinary medicine to sort specific B-cell subsets so the control B-cell population in this study contained 
a mixture of B cells at different stages of differentiation. In contrast, many of the human CLL 
transcriptome studies use peripheral blood CD19+ B cells or sorted specific B-cell subsets as controls. In 
the future, normal canine blood B cells would be a useful control population for transcriptome 
comparisons. Additionally, as our ability to identify and sort specific canine B-cell subsets improves, it 
would be useful to compare canine BCLL to normal B-cell subsets to try and discern the cell of origin. 
 Gene expression analysis identified 2 major subgroups of BCLL cases, referred to as BCLL 
subgroup 1 and 2. BCLL subgroup 2 contained the majority of Boxer cases and had significantly higher 
MKI67 expression compared to subgroup 1, as determined by gene expression in the NanoString and 
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RNA Seq studies. The Boxer breed and high Ki67 expression were associated with poorer prognosis in 
our BCLL outcome study, suggesting BCLL subgroup 2 may represent more aggressive BCLL. Because the 
BCLL cases grouped together by hierarchical clustering and over one thousand differentially expressed 
genes were shared between BCLL subgroups when compared to control B cells, we hypothesize that 
BCLL subgroup 1 and 2 are manifestations of one tumor, rather than distinct neoplasms. When BCLL 
subgroups were independently compared to control B cells, there was overlap in the enriched pathways, 
including NF-κB signaling, KRAS signaling, and cytokine-JAK/STAT signaling, suggesting similar 
mechanisms may drive these tumors. Additionally, each BCLL subgroup was independently enriched for 
the human CLL gene set. However, there were a large number of genes differentially expressed between 
these subgroups as well. Compared to control B cells, BCLL subgroup 1 had upregulation of genes 
involved in TGFB signaling, PI3K AKT MTOR signaling, and misfolded protein responses, as well as 
ribosome and spliceosome genes. Among the genes differentially expressed between BCLL subgroups, 
BCLL subgroup 1 overexpressed genes included: RELA, involved in NF-κB heterodimer formation and 
survival of human CLL cells,170 IL10RA, which has anti-inflammatory functions and is overexpressed in 
human CLL, mantle cell lymphoma, and Waldenström's macroglobulinemia,171,172 and BCL3, which 
promotes NF-κB signaling and cell survival and is overexpressed in B-cell neoplasms including CLL.173  
Top genes overexpressed in BCLL subgroup 2 compared to subgroup 1 were primarily cell cycle and 
proliferation genes (e.g. CDK1, CCNB2, CCND3, BUB1, MKI67), including genes involved in B-cell 
proliferation, such as CD40 and TLR9. BCLL subgroup 2 had fewer genes differentially expressed when 
compared to control lymph node B cells, suggesting this subgroup was more similar to the lymph node 
B-cell population, which likely contained many proliferating and reactive B cells. Additional genes 
overexpressed in BCLL subgroup 2 compared to subgroup 1 included the anti-apoptotic gene BCL2, 
which is upregulated in human CLL, and CD72, which regulates BCR signaling. IL2RA (CD25) was 
significantly overexpressed in BCLL subgroup 2 cases compared to subgroup 1 by RNA Seq. In a larger 
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number of cases in the NanoString study, high IL2RA-expressing cases by gene expression or flow 
cytometry were more likely to be subgroup 2 cases, though there was overlap between subgroups. This 
marker may help distinguish subgroup cases when combined with other markers, and IL2RA (CD25) was 
increased in Boxers with BCLL and a poor prognostic indicator in our canine BCLL outcome study. The 
IGHV mutation status did not correlate with BCLL subgroup in this study, but few samples were 
examined. All BCLL subgroup 1 cases examined rearranged mutated IGHV genes, but subgroup 2 
contained a mixture of mutated and unmutated IGHV cases. Previous human CLL studies have 
demonstrated large overlap between mutated and unmutated IGHV CLL transcriptomes, and an RNA 
Seq study by Ferreira et al. identified two distinct CLL subgroups independent of IGHV mutation status 
with significantly different clinical outcomes.22,142,144 Our study suggests that there are distinct canine 
BCLL subgroups, and based on the prognostic significance of Ki67 expression, we hypothesize that these 
subgroups have different clinical outcomes. The next step is to perform a larger prospective study to 
correlate transcriptome profiles and outcome. This would allow us to determine the clinical significance 
of distinguishing BCLL subgroups. If these subgroups have different outcomes or therapeutic indications, 
designing a small panel of differentially expressed genes between subgroups, which could be measured 
by NanoString technology, would be useful for diagnostic purposes.  
 In summary, we identified a large number of genes and pathways differentially expressed 
between canine BCLL and control B cells for further study. To better determine the function of these 
pathways in the development and progression of BCLL, evaluating protein abundance and 
phosphorylation of these pathways and/or studying the effects of pathway inhibitors on BCLL cells is 
needed. Additional analyses to perform with this RNA seq dataset include identifying variants and fusion 
genes and assessing alterative splicing and transcriptional elements beyond protein-coding genes. 
Splicing alterations play an important role in human CLL, with recurrent mutations described in the 
splicing factor SF3B1 and splicing abnormalities identified in previous CLL RNA Seq studies.143,144,174 
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Future work is also aimed at characterizing the mutations and chromosomal abnormalities underlying 
canine BCLL and comparing them to human CLL. Investigation of the pathways dysregulated in canine 
BCLL, the cell of origin, the role of alternative splicing, and the genetic mutations will help further 











English bulldogs disproportionally develop an expansion of small B cells, which has been 
interpreted as B-cell chronic lymphocytic leukemia (BCLL). However, clonality testing in these cases has 
often not been supportive of neoplasia. We hypothesized that English bulldogs have a syndrome of non-
neoplastic B-cell expansion. We characterized this syndrome by assessing B-cell clonality, clinical 
presentation, flow cytometric features and immunoglobulin gammopathy patterns. We evaluated 84 
English bulldogs with small-sized CD21+ B-cell lymphocytosis in the blood as determined by flow 
cytometry. Flow cytometry features were compared to normal B cells and BCLL cases. PCR for antigen 
receptor rearrangements using multiple immunoglobulin primers was performed to assess B-cell 
clonality. A subset of cases with gammopathy were examined by protein electrophoresis, 
immunofixation and immunoglobulin subclass ELISA quantification. Seventy percent of cases had 
polyclonal or restricted polyclonal immunoglobulin gene rearrangements, suggesting nonmalignant B-
cell expansion. The median age of all dogs in the study was 6.8 years and 74% were male. The median 
lymphocyte count was 22,400/µL and B cells expressed low class II MHC and CD25. Splenomegaly or 
splenic masses were detected in 57% of cases and lymphadenopathy was uncommon. Seventy-one 
percent of cases had hyperglobulinemia and the vast majority had IgA +/- IgM polyclonal or restricted 
polyclonal gammopathy patterns. Polyclonal B-cell lymphocytosis in English bulldogs (PBLEB) is 
characterized by low B-cell class II MHC and CD25 expression, splenomegaly and hyperglobulinemia 








Lymphocytosis may be caused be a reactive or neoplastic process. In dogs, reactive expansions 
of nonneoplastic lymphocytes in the blood appear uncommon and are associated with only a small 
number of conditions, including Ehrlichia canis infection, hypoadrenocorticism and thymoma.175–179 
Neoplastic lymphocytosis is comprised of clonally expanded lymphocytes and is a more common cause 
of persistent lymphocytosis in adult dogs.180 Clonality testing by PCR for antigen receptor 
rearrangements (PARR) can help differentiate a monoclonal population of neoplastic lymphocytes that 
have an identically-sized antigen receptor rearrangement from a polyclonal population of reactive 
lymphocytes which contains diverse antigen receptor rearrangments.9,75 Reactive or inflammatory 
processes may also cause increased production of polyclonal immunoglobulin proteins.181,182 
Monoclonal immunoglobulin production is typically due to an immunoglobulin-secreting B-cell or 
plasma cell neoplasm, though rarely certain infectious or inflammatory conditions are associated with 
monoclonal gammopathy in dogs.181,183 
B-cell chronic lymphocytic leukemia is a common hematopoietic neoplasm in dogs, defined by a 
clonal expansion of small-sized B cells in the blood or bone marrow.62,84 Our laboratory identifies BCLL 
based on inclusion criteria of >5,000 lymphocytes/µL on CBC with small-sized CD21+ B cells accounting 
for >60% of the lymphocyte population by flow cytometry. We previously reported that small breed 
dogs had increased odds of developing BCLL.62 English bulldogs also had increased odds of developing 
BCLL, as defined in this study, but this breed had a unique presentation: they were significantly younger 
at diagnosis compared to mixed breed dogs, had increased frequency of hyperglobulinemia, and their 
expanded B cells had decreased CD25 and class II MHC expression by flow cytometry. This unique 
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presentation raised the question of whether English bulldogs have a different form of BCLL, or a 
different B-cell disease entirely. 
 Since detecting this unique presentation in English bulldogs, our laboratory anecdotally found 
that English bulldogs with B-cell lymphocytosis frequently had polyclonal immunoglobulin gene 
rearrangements by PARR. These PARR findings suggested that the B-cell expansions in these dogs may 
be nonneoplastic, and that English bulldogs have a B-cell lymphocytosis syndrome separate from BCLL. 
The goal of this study was to identify English bulldogs with B-cell lymphocytosis, to evaluate clonality 
using PARR and protein electrophoresis/immunofixation (PE/IF) modalities, and to analyze the clinical 
features of the cases. Here we describe a syndrome of polyclonal B-cell expansion in English bulldogs 
characterized by substantial increases in IgA +/- IgM, with normal to diminished IgG. 
Methods 
Case selection 
 The Colorado State University-Clinical Immunology (CSU-CI) laboratory database was queried for 
English bulldog cases with blood submitted for immunophenotyping by flow cytometry between 
9/17/2010 and 8/31/2019. Inclusion criteria included an expansion of small-sized CD21+ B cells 
exceeding the upper limit of the reference interval (724 CD21+ cells/µL) for canine blood samples at our 
institution. Small size was defined by a size ratio of CD21+ cell mean forward scatter:neutrophil mean 
forward scatter <0.60.  
 CSU-CI laboratory database query was also used to identify several control groups, including: 1) 
Blood from 30 clinically healthy non-English bulldogs without lymphocytosis or evidence of 
lymphoproliferative disease by flow cytometry and PARR, which were a range of breeds, included 57% 
females and ranged in age from 1.9-8.9 years old; 2) blood from 49 clinically healthy control English 
bulldogs with no suspicion of lymphoproliferative disease and a normal CD21+ B-cell count (<724/µL by 
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flow cytometry), which included 41% females and ranged in age from 1.0-12.0 years old (median, 3.9 
years old); 3) 53 small breed BCLL cases from BCLL-predisposed breeds62 with blood submitted for flow 
cytometry between 1/1/2015-10/1/2019 and clonal immunoglobulin (IG) rearrangements by PARR; and 
4) PARR results from 25 small breed BCLL patients with a flow cytometry diagnosis and routine PARR 
performed on submitted blood. 
Serum immunoglobulins were evaluated in 30 English bulldog cases, 6 control English bulldogs 
with no evidence of CD21+ lymphocytosis by flow cytometry, 15 non-bulldog BCLL cases with 
hyperglobulinemia, and 4 control non-bulldogs with polyclonal gammopathy and no lymphocytosis.  
Clinical variables 
Signalment, physical exam findings, and laboratory data were provided on the CSU-CI laboratory 
submission form. Hematology data were collected from the CBC performed at the time of flow 
cytometry submission. Anemia, thrombocytopenia and neutropenia were identified using the CBC 
laboratory’s reference interval for hematocrit, platelet count and neutrophil count, respectively. 
Hyperglobulinemia was identified if indicated by the veterinarian on the submission form, or if globulins 
were elevated on a biochemistry panel or by protein electrophoresis. Physical exam findings, including 
lymphadenopathy, splenic abnormalities and hepatic abnormalities, were identified by palpation, 
ultrasound, radiographs or a combination of these tests. When available, blood films, bone marrow 
cytology reports and spleen histology samples were reviewed. Histology samples had 
immunohistochemistry performed for Pax5 expression (monoclonal mouse anti-human Pax5, DAK-Pax5 
clone; Dako North America Inc., Carpinteria, CA), CD3 expression (monoclonal mouse anti-human CD3, 
LN10 clone; Leica Biosystems Newcastle Ltd., Newcastle Upon Tyne, UK) and MUM1 expression 
(monoclonal mouse anti-human MUM1, MUM1p clone; Dako North America Inc.). For cases with 




 Flow cytometry was performed on blood samples at the CSU-CI laboratory. Samples were 
collected, stored, and stained as previously described,65 using antibody panels listed in Chapter 2. 
Expression of CD25, class II MHC, and CD21 on B cells were determined in English bulldog cases, healthy 
control dogs and small breed BCLL cases. Because anti-CD25 is not in the same staining reaction as anti-
CD21, the percentage of B cells expressing CD25 was determined by gating on lymphocytes in tube 2, 
excluding cells expressing CD3, CD4, CD5 and CD8, and calculating %CD25 on remaining cells. Class II 
MHC and CD21 expression were determined by median fluorescence intensity. Six English bulldog cases 
sampled prior to May 2012 did not have CD25 or class II MHC data available. 
PCR for antigen receptor rearrangements 
The CSU-CI routine PARR assay was performed as previously described.75,123 This assay detects B-
cell clonality by targeting both complete and incomplete IG gene rearrangements in the IG heavy chain 
(IGH) locus. Complete IGH-VDJ rearrangements consist of a V (variable), D (diversity) and J (joining) 
gene, while incomplete IGH-DJ rearrangements consist of a D and J gene.  
An expanded PARR assay was developed to detect additional complete IGH-VDJ and incomplete 
IGH-DJ rearrangements not detected with routine PARR, as well as IG light chain rearrangements. 
Primers were designed and tested as described in the Appendix (Supplemental material for Chapter 4). 
The expanded assay for complete IGH-VDJ rearrangements targets IGH variable (IGHV) subgroup genes 
not detected by our routine PARR assay. Additionally, IGH-VDJ primers in the expanded assay target a 
different region of the IGHV gene, to increase detection of IGHV genes that did not amplify with routine 
PARR due to polymorphisms or somatic hypermutation in the primer binding region. Light chain primers 
target kappa deleting element (Kde) and IG lambda (IGL) rearrangements. The routine and expanded 
PARR assays were performed on all English bulldog cases with available sample.  
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PARR results were interpreted as clonal, polyclonal or restricted polyclonal using the rubric 
provided in Table 12. These criteria were internally validated and apply only to these primers and cycling 
conditions when analyzed by fragment analysis methods, and therefore, are not applicable for other 
assays and laboratories. Cases with 1 or 2 peaks reaching objective criteria for clonality were classified 
as clonal, as lymphocytes may rearrange one or both alleles of the IG locus resulting in up to 2 clonal 
peaks.6 Representative tracings for the electrophoretic patterns are provided in Figure 17. DNA quantity 
and quality were determined to be sufficient based on PARR results, as previously described.184 PARR 
results were independently interpreted by the authors (E Rout, A Avery), blinded to the signalment and 
flow cytometry data. 
Table 12. Immunoglobulin PCR for antigen receptor rearrangements (PARR) assay diagnostic criteria. 
Interpretation Capillary electrophoretic pattern 
IGH-VDJ, Kde or IGL rearrangements 
Clonal 1 or 2 tall narrow peak(s) >5000 in amplitude and >3x the height of the base 
peaks forming the polyclonal background 
Polyclonal Multiple peaks forming a Gaussian distribution 
Restricted polyclonal No peaks reach clonal criteria, but ≥1 peak is >2000 in amplitude and >2x the 
height of the base peaks forming the polyclonal background 
IGH-DJ rearrangements 
Clonal Tall narrow peak >8000 in amplitude and >3x the height of the base peaks 
forming the polyclonal background 
Polyclonal Multiple peaks forming a Gaussian distribution 
IGH-VDJ, complete immunoglobulin heavy (IGH) chain variable (V)-diversity (D)-joining (J) gene 
rearrangement; IGH-DJ, incomplete immunoglobulin heavy chain diversity (D)-joining (J) gene 





Figure 17. PCR for antigen receptor rearrangements (PARR) results for English bulldogs with B-cell 
lymphocytosis. GeneMarker tracings for complete immunoglobulin heavy (IGH) chain variable (V)-
diversity (D)-joining (J) (IGH-VDJ) rearrangements are presented for 4 polyclonal cases (A), 4 restricted 
polyclonal cases (B), and 4 clonal cases (C). The size of the PARR amplicons is plotted on the horizontal 
axis and the abundance of amplicons is on the vertical axis. (A) Polyclonal cases have multiple peaks 
forming a Gaussian distribution. (B) Restricted polyclonal cases have 1-5 peaks >2000 in amplitude and 
2x the height of the polyclonal peaks forming the base. (C) Clonal cases have a peak >5000 in amplitude 
and >3x the base height. 
 
Serum immunoglobulins  
 Agarose gel PE and IF were performed at the CSU-Veterinary Diagnostic Laboratory to evaluate 
immunoglobulins, as previously described.123,185 PE and IF were performed on serum or plasma samples 
from a subset of English bulldog cases (n=30), control English bulldogs (n=6), and non-bulldog BCLL cases 
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(n=10). Five additional BCLL cases had PE without IF. The hemolysis and lipemia indices were determined 
for all samples (Cobas c501 Roche Diagnostics, Indianapolis, IN), as these factors may alter 
electrophoretogram morphology.181,186 Total globulin concentration was calculated as the sum of all 
globulin fractions by PE to avoid over-estimation of albumin in cases with a marked gammopathy.187 
Hyperglobulinemia was identified by PE if the total globulins exceeded our internal upper reference limit 
3.5 g/dL. PE/IF results were blindly and independently interpreted by the authors (E Rout, P Avery, AR 
Moore) using the rubric in Table 13. Representative results for the electrophoretic patterns are provided 
in Figure 18. Immunofixation results were interpreted to determine whether immunoglobulins were 
predominantly of IgGFC, IgA or IgM subclass.188 An IgA or IgM predominance was considered atypical, as 
normal dogs have predominantly IgGFC labeling with no to faint IgA and IgM.181    
Table 13. Protein electrophoresis and immunofixation diagnostic criteria. 
Interpretation Electrophoretic pattern 
Protein electrophoresis  
Normal No protein increases or atypical restricted bands present for the sample type 
Monoclonal Single atypical restricted peak with no more than minimal polyclonal 
increases 
Biclonal Pair of closely associated peaks with no more than minimal surrounding 
polyclonal increases 
Restricted polyclonal ≥1 atypical restricted band(s) on gel amid moderate polyclonal increases, 
irrespective of height of any peak 
Polyclonal Only diffuse/broad bands present 
Immunofixation 
Normal Moderate IgGFC polyclonal labeling with no to faint polyclonal IgA and IgM 
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Monoclonal Single restricted band of one IGH class with no more than minimal IgGFC 
polyclonal increase 




≥1 restricted bands of IgA and/or IgM amid moderate IgA and/or IgM 
polyclonal labeling and decreased IgGFC 
IgA/IgM polyclonal Increased immunoglobulin labeling without restricted bands in IgA and/or 
IgM with decreased IgGFC 
IgGFC polyclonal Increased immunoglobulin labeling without restricted bands with 
predominantly IgGFC labeling and no to faint IgA and IgM 
IGH, immunoglobulin heavy chain. 
 
 
Figure 18. Protein electrophoresis (PE) and immunofixation (IF) results in control dogs and English 
bulldogs with B-cell lymphocytosis. An agarose gel protein electrophoresis gel and tracing (top) and 
immunofixation gel (bottom) are provided. Immunofixation gels are labeled with anti-whole serum 
(WS), anti-canine IgGFC heavy chain (G), anti-canine IgA heavy chain (A), anti-canine IgM heavy chain (M) 
and anti-canine light chain (L) antibodies. (A) Serum PE and IF results from a healthy control English 
bulldog with no CD21+ B-cell lymphocytosis reveals polyclonal immunoglobulin proteins that 
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predominantly label with anti-IgGFC. (B) Serum PE and IF results from a non-bulldog with polyclonal 
gammopathy. Immunoglobulin proteins form a broad smear and predominantly label with anti-IgGFC. (C) 
Serum PE and IF results from an English bulldog B-cell lymphocytosis case diagnosed with polyclonal 
gammopathy, characterized by broad peaks in beta and gamma regions on PE, with no evidence of 
restricted bands by PE or IF. There is heavy labeling with anti-IgA by IF relative to IgGFC, which is atypical 
as compared to the control (A), and a lack of a hypergammaglobulinemia, which is atypical for an IgG-
centric polyclonal gammopathy. (D) Serum PE and IF results from an English bulldog B-cell lymphocytosis 
case diagnosed with restricted polyclonal gammopathy, characterized by multiple restricted peaks 
within a polyclonal background. By IF, the majority of protein labels with anti-IgA. (E) Plasma PE and IF 
results from an English bulldog B-cell lymphocytosis case with a clonal immunoglobulin gene 
rearrangement by PARR. There is a tall narrow peak in the beta 2 region on PE which labels with anti-
IgM by IF, consistent with an IgM monoclonal gammopathy. 
 
 Quantification of IgA, IgM and IgGFC proteins was performed using commercially available ELISA 
kits, as previously described.185 Immunoglobulin proteins were measured in serum and plasma samples 
from a subset of English bulldog cases (n=12), 4 clinically healthy English bulldogs and 3 clinically healthy 
non-bulldogs. 
Statistical analysis 
 For all English bulldog cases, signalment, physical exam findings, hematologic data and flow 
cytometry data were summarized, and descriptive statistics were calculated. For continuous variables, 
normality was assessed visually and using a Shapiro Wilk test. To compare continuous variables between 
English bulldog cases, healthy controls and BCLL cases, a Kruskal-Wallis test was calculated. Dunn’s test 
for multiple comparisons was subsequently used for pairwise comparisons. Immunoglobulin 
quantification was compared between controls and English bulldog cases with a Mann-Whitney test. For 
comparisons between clonal and non-clonal English bulldog cases, a Mann-Whitney test was calculated. 
A Fishers exact test was used to compare categorical variables across groups. Cases with missing or 
unknown data on the submission form were censored for that data. Statistical analysis was performed in 





Between 9/17/2010 and 8/31/2019, 84 of 195 English bulldogs with blood submitted to the 
CSU-CI laboratory for immunophenotyping by flow cytometry had an expansion of small-sized CD21+ B 
lymphocytes. Signalment and laboratory data from these cases are summarized in Table 14. The median 
age at diagnosis was 6.8 years and there was a male predominance. The lymphocyte count was 
moderately elevated in most cases, but a small number of cases had >50,000 lymphocytes/µL (median, 
22,400 lymphs/µL; interquartile range (IQR), 12,000-41,100 lymphs/µL; range, 2,000-384,400 
lymphs/µL). Anemia was present in 26/84 cases (31%) and mild to moderate in most cases (median 
hematocrit, 30%; IQR, 27-34%; range, 21-38%). The anemia was non-regenerative in 14/17 cases with 
reticulocyte counts available, as defined by the laboratory’s reticulocyte reference interval. 
Thrombocytopenia was uncommon, affecting 8/84 cases (10%), and mild to moderate in most affected 
cases (median, 114,000 platelets/µL; IQR, 89,500-152,000/µL; range, 38,000-198,000/µL). 
Hyperglobulinemia affected 65% of patients with globulin data at diagnosis. An additional 7 cases had 
hyperglobulinemia detected after initial diagnosis, resulting in 71% of cases having hyperglobulinemia at 
some point during the course of their syndrome. Splenomegaly or splenic masses or both were also 
common, but lymphadenopathy was rare. 
Table 14. Summary signalment data, laboratory data and physical exam findings for 84 English bulldogs 
with B-cell lymphocytosis at the time of diagnosis. 
 Number of cases 
with available data 
Number affected (%) or median 
(IQR; range) 
Signalment  
Male 84 74% 




Lymph count, median (IQR; range), x103/µL 84 22.4 (12.0-41.1; 2.0-384.4) 
Anemia 84 31% 
Thrombocytopenia 84 10% 
Neutropenia 84 2% 
Hyperglobulinemia 69 65% 
Physical exam  
Splenomegaly/splenic mass 46 57% 
Peripheral lymphadenopathy 61 11% 
Visceral lymphadenopathy 38 13% 
Hepatomegaly/hepatic mass 42 14% 
For variables besides age and lymphocyte count, the percentage of cases affected among those with 
available data are presented. For age and lymphocyte count, the median, interquartile range (IQR) and 
range of values are presented. 
 
Of 44 cases where lymphocyte morphology was evaluated by a clinical pathologist, 35/44 were 
described as small or small to intermediate in size, 4 were described as intermediate-sized, and 5 cases 
were described as intermediate to large-sized. All cases met the flow cytometric small size inclusion 
criteria. Chromatin was described as mature, clumped or condensed in all cases evaluated, except in one 
where it was described as fine. Six cases were described as having few nucleoli. Ten cases with blood 
smears available at the CSU-Veterinary Diagnostic Laboratory were reviewed by the authors (E Rout, P 
Avery). Lymphocytes were predominantly smaller than a neutrophil with a small round nucleus, 
condensed chromatin and scant basophilic cytoplasm (Figure 19A). Rare cells were intermediate-sized 
with slightly expanded pale blue cytoplasm. When cases were blindly pooled with blood films from 10 
Shih Tzu dogs with BCLL, the English bulldog cases could not be differentiated cytologically. Two English 
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bulldog cases had bone marrow aspirates performed. Megakaryocytes and erythroid and myeloid series 
were considered within normal limits and small mature lymphocytes accounted for 20% and 43% of 
nucleated cells. 
Six cases had cytologic evaluation and 4 cases had histologic evaluation of the spleen. None of 
these samples were definitively diagnosed with lymphoma. Six cytology samples were diagnosed with 
lymphoid hyperplasia and 3 of those had a second diagnosis of possible lymphoma. One sample was 
minimally cellular, but remaining cases were described as moderately to highly cellular with a 
heterogeneous lymphoid population, consisting of predominantly small lymphocytes with condensed 
chromatin, with few large lymphocytes and plasma cells. Cytology report comments often indicated that 
the heterogeneity and predominance of small well-differentiated lymphocytes was consistent with 
lymphoid hyperplasia, but given the clinical history, a small cell lymphoma or BCLL infiltration into the 
spleen could not be ruled out. Histologically, there was expansion of the spleen with lymphoid 
hyperplasia of variable severity. Lymphoid hyperplasia ranged from mild expansion around periarteriolar 
sheaths to more marked nodular lymphoid hyperplasia. Nodular lymphoid hyperplasia formed small, 
non-coalescing follicular structures to occasionally larger rarely coalescing follicles (Figure 19B). Follicles 
were composed of predominantly B cells (Figure 19D) with scattered small T cells often radiating around 
follicles and scattered plasma cells within sinusoids. The B cells occupying the follicular structures were 
heterogeneous, composed of small and intermediate-sized lymphocytes with condensed chromatin or 
occasional marginal zone appearance with a prominent central nucleolus (Figure 19C).  
Flow cytometry 
Among English bulldog cases, the median CD21+ B-cell count was 20,606 cells/µL (IQR, 10,461-




Figure 19. Blood smear and histopathology and immunohistochemistry of spleen from English bulldog 
cases with polyclonal B-cell lymphocytosis. (A) Peripheral blood film from an English bulldog with B-cell 
lymphocytosis and polyclonal immunoglobulin gene rearrangements. Lymphocytes are small with 
condensed chromatin and scant basophilic cytoplasm (Wright Giemsa, 60x objective). (B-D) 
Histopathology of spleen from a different English bulldog with B-cell lymphocytosis and polyclonal 
immunoglobulin gene rearrangements. There is lymphoid hyperplasia characterized by nodules of 
multifocal to rarely coalescing lymphoid follicular structures (B, H&E, 2x objective). The follicular 
structures are composed of primarily small lymphocytes with condensed chromatin with fewer 
intermediate-sized lymphocytes and scattered lymphocytes with marginal zone appearance with a single 
central prominent nucleolus (C, H&E, 40x objective). Lymphocytes within the follicles are predominated 
by B cells with strong nuclear immunoreactivity for PAX5 (D, PAX5, Fast Red chromogen, 4x objective). 
 
99% of the lymphocyte population in the blood by flow cytometry. English bulldog cases were 
characterized by low expression of CD25 and class II MHC. Sixty-eight percent of cases had only 0-2% of 
B cells expressing CD25, and English bulldog cases had significantly lower CD25 expression than B cells 
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from clinically healthy non-bulldogs (p=0.001), clinically healthy English bulldog controls (p<0.001) and 
small breed BCLL cases (p<0.001) (Figure 20). B-cell class II MHC expression was also significantly lower 
in English bulldog cases compared to non-bulldog controls (p<0.001), English bulldog controls (p<0.001) 
and small breed BCLL cases (p<0.001). English bulldog cases had significantly higher B-cell CD21 
expression than non-bulldog controls (p<0.001), English bulldog controls (p<0.001) and small breed BCLL 
cases (p<0.001). Comparing non-bulldog and English bulldog controls, English bulldog controls had 
significantly lower CD25 and CD21 expression (p=0.0024 and p=0.015, respectively). 
 
Figure 20. B-cell expression of CD25, class II MHC, and CD21 in English bulldog B-cell lymphocytosis 
cases compared to clinically healthy non-bulldog controls, English bulldog controls with normal B-cell 
counts, and small breed BCLL cases. Expression of CD25 (left), class II MHC (center) and CD21 (right) by 
flow cytometry is plotted for individual cases. Lines depict the median and interquartile range for each 
group. English bulldog cases had significantly lower expression of CD25 and class II MHC and significantly 
higher expression of CD21 compared to peripheral blood B cells from healthy non-bulldog and English 
bulldog controls and small breed BCLL cases. 
 
Clonality 
 Eighty-three of 84 English bulldog cases had sample material available for routine PARR analysis. 
Eighty-one cases had PARR performed on the same blood sample that was submitted for flow 
cytometry. Two cases had tissue samples (spleen and bone marrow, respectively) submitted for PARR 
within one month of the blood flow cytometry analysis; PARR results from those sources were used for 
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analysis. Thirty-nine percent of cases had polyclonal IG rearrangements, 37% of cases had restricted 
polyclonal IG rearrangements, and 24% had clonal IG rearrangements by routine PARR. Representative 
PARR tracings for polyclonal, restricted polyclonal, and clonal cases are presented in Figure 17. Of the 25 
cases which met inclusion criteria for small breed BCLL during an 18-month period, 100% of BCLL cases 
had clonal IG rearrangements by routine PARR analysis, with either complete IGH-VDJ primers alone 
(76%), incomplete IGH-DJ primers alone (12%), or both (12%).    
 Eighty-five percent of English bulldog cases (n=71) had sample available for PARR with expanded 
IG primers. Clonal results were detected with the expanded primer set in 5 cases that had been 
polyclonal by routine PARR. These 5 cases had polyclonal complete IGH-VDJ rearrangements by routine 
PARR, but clonal complete IGH-VDJ rearrangements with the expanded primers. When results from 
routine PARR and expanded PARR were combined, 37% of English bulldogs were polyclonal, 33% of 
cases had restricted polyclonal IG rearrangements, and 30% were clonal (Table 15). 
Table 15. Summary clonality results for immunoglobulin gene rearrangements and immunoglobulin 
proteins in English bulldog cases with B-cell lymphocytosis. 




PE cases with 
clonal PARR result 
Immunoglobulin gene rearrangements a  
Polyclonal 31 37% NA 
Restricted polyclonal 27 33% NA 
Clonal 25 30% NA 
Immunoglobulin proteins b 
IgGFC polyclonal  1 3% 1/1 
IgA polyclonal  7 23% 1/7 
IgA + IgM polyclonal 1 3% 0/1 
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IgA restricted polyclonal 3 10% 0/3 
IgA + IgM restricted polyclonal 12 40% 0/12 
IgA monoclonal 2 7% 2/2 
IgM monoclonal 4 13% 4/4 
a Clonality of immunoglobulin gene rearrangements was determined by PCR for antigen receptor 
rearrangements (PARR) in 83 unique cases. NA, not applicable. b Clonality of immunoglobulin proteins 
was determined by protein electrophoresis (PE) and immunofixation in 30 unique cases. The number of 
cases with a clonal IG rearrangement by PARR is presented in the far-right column. All cases with 
monoclonal protein had clonal IG gene rearrangements. 22/24 cases with polyclonal or restricted 
polyclonal proteins had polyclonal or restricted polyclonal IG gene rearrangements. 
 
Immunoglobulin protein analysis 
 Peripheral globulins were evaluated in 30 English bulldog cases with PE/IF. Total globulin 
concentrations ranged from 3.3-10.7 g/dL (median, 6.1 g/dL; IQR, 4.3-8.7 g/dL; reference interval, 2.2-
3.5 g/dL). Eighty percent of cases had hypoalbuminemia. Among hypoalbuminemic patients, the median 
albumin concentration was 2.1 g/dL (IQR, 1.8-2.5 g/dL; range, 1.4-2.7 g/dL; reference interval, 2.8-3.7 
g/dL). Many English bulldog samples had an atypical banding pattern, which did not fit a classic 
polyclonal or monoclonal pattern, so a rubric was developed to interpret these samples (Table 13) and 
representative results are presented in Figure 18. Six cases had an IgA or IgM monoclonal gammopathy, 
and all 6 cases had clonal IG rearrangements by PARR (Table 15). Remaining cases were classified as 
polyclonal (n=7) or restricted polyclonal (n=17) by PE alone. By IF, 1 case was classified as polyclonal 
with IgGFC predominance; this case had a clonal IG rearrangement by PARR and mild hyperglobulinemia 
(3.95 g/dL). Eight cases had polyclonal gammopathy with increased IgA +/- IgM. Fifteen cases had 
restricted polyclonal gammopathy with increased IgA +/- IgM. All cases had an appropriate light chain 
pattern for all IG heavy chains present. Of 23 cases with IgA/IgM polyclonal or restricted polyclonal 
gammopathy, globulins were frequently increased in the beta region on PE and gamma globulins were 
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often within the reference interval. 2/23 (9%) cases had hypogammaglobulinemia and 15/23 (65%) 
cases had normogammaglobulinemia. In summary, 77% of cases were classified as polyclonal or 
restricted polyclonal with increased IgA +/- IgM. One of the patients with IgA/IgM polyclonal or 
restricted polyclonal IG protein had a clonal IG rearrangement by PARR, and the remaining cases had 
polyclonal or restricted polyclonal IG rearrangements. 
 English bulldog PE/IF results were compared to control English bulldogs without CD21+ B-cell 
lymphocytosis (n=6) and non-bulldog BCLL cases (n=15). Three of the control English bulldogs had 
normal PE/IF, and the other 3 dogs had mild hyperglobulinemia with mild polyclonal gammopathy on 
PE, labeling with predominantly IgGFC heavy chain antibody. Two of these patients had increased acute 
phase proteins, suggesting underlying inflammation in these control dogs. Of 5 BCLL cases with PE only, 
4 cases had a monoclonal protein in the beta 1-beta 2 region, and the fifth case had a suspicious band in 
the beta 2 region that could not be confirmed as M-protein without IF. Of 10 BCLL cases with PE and IF, 
6 cases had monoclonal IgM gammopathy, 1 case had monoclonal IgA gammopathy, 1 case had biclonal 
IgA gammopathy, and 2 cases had polyclonal gammopathy with IgGFC predominance. 
 Serum IgA, IgM and IgGFC proteins were quantified by ELISA in a subset of English bulldog cases 
(n=12) to confirm the increases in IgA and IgM seen on IF (Figure 21). IgA, IgM and IgGFC proteins were 
also measured in 3 non-bulldog healthy dogs and 4 healthy English bulldogs without CD21+ B-cell 
lymphocytosis. There were no significant differences in measurements between non-bulldog and 
bulldog control samples, so control values were combined. English bulldog cases with B-cell 
lymphocytosis had significantly higher quantities of IgA (p<0.001) and IgM (p=0.012), and significantly 
less IgGFC than controls (p=0.004). All 12 English bulldog cases had IgA values above the range seen in 
control cases, although one case with marked IgM gammopathy had only a mild increase in IgA. Four 
cases had marked increases in IgM. All English bulldog cases had IgGFC quantities below the mean 
concentration seen in controls and 9 cases (75%) had IgGFC quantities below the minimum value seen in 
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controls, which correlates with the normogammaglobulinemia and hypogammaglobulinemia seen on 
PE/IF. The pattern of relative IG concentration by ELISA subjectively matched the pattern observed by IF, 
confirming that English bulldog cases had increased IgA and decreased IgGFC concentrations, and a 
subset had increased IgM. 
 
Figure 21. IgA, IgM and IgGFC protein quantification by ELISA in English bulldog cases with B-cell 
lymphocytosis. Each English bulldog case is colored consistently across the three graphs. Data points 
plotted at 10 g/dL were above the limits of quantification for the assay. Dotted lines represent the mean 
(black line) and range (grey lines) of values for 7 control dogs. English bulldog cases had significantly 
greater quantities of serum IgA (p<0.001), and a subset of cases had increased IgM, compared to control 
dogs. English bulldogs had significantly less IgGFC than controls (p=0.004). 
 
Clonal versus non-clonal English bulldog cases 
 We investigated clinical and immunophenotypic differences between clonal cases (n=25) and 
non-clonal cases (n=58). The non-clonal group included cases with polyclonal or restricted polyclonal IG 
rearrangements by PARR. Clonal cases were significantly older than non-clonal cases (p=0.002) (Figure 
22A). There were significantly more males in the non-clonal group (81%) compared to clonal cases (56%) 
(p=0.029) (Figure 22B). The CD21+ B-cell count was not significantly different between clonal cases 
(median, 21,700/µL; IQR, 10,900-73,500/µL; range, 1,200-378,800/µL) and non-clonal cases (median, 
19,700/µL; IQR, 9,800-38,300/µL; range, 1,400-285,000/µL) (p=0.380). Class II MHC expression was not 
significantly different between groups (p=0.118), but clonal cases had significantly lower expression of 
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CD21 (p=0.040, not shown) and significantly higher expression of CD25 (p=0.003) (Figure 22C). The 
majority of non-clonal cases (76%) had <2% CD25-expressing B cells, while 48% of clonal cases had <2% 
CD25-expressing B cells. There were no significant differences in anemia, thrombocytopenia or 
splenomegaly/splenic mass between groups. The presence of hyperglobulinemia was not significantly 
different between clonal and non-clonal cases, although the type of gammopathy was different: in the 8 
clonal cases with PE/IF, 6/8 cases had monoclonal IgA or IgM protein, and none of the non-clonal PARR 
cases had monoclonal PE/IF results. Peripheral lymphadenopathy was more common in clonal cases 
(32%) than non-clonal cases (2%) (p=0.003). Of the 6 clonal cases with peripheral lymphadenopathy, 5/6 
were female, 5/6 were >6.8 years old, and 5/6 had high CD25 expression, in contrast to the young male 
signalment and low CD25 expression frequently seen in non-clonal cases. 
 
Figure 22. Signalment and B-cell CD25 expression in non-clonal and clonal English bulldog cases with B-
cell lymphocytosis. (A) The age at diagnosis for non-clonal cases with polyclonal or restricted polyclonal 
immunoglobulin PARR results and clonal cases with clonal immunoglobulin PARR results. Clonal cases 
(median, 8.2 years old) were significantly older than non-clonal cases (median, 6.3 years old) (p=0.002). 
(B) The percentage of males and females within non-clonal and clonal groups is presented. There were 
significantly more males in the non-clonal group (p=0.029). (C) The percentage of B cells expressing 
CD25 by flow cytometry in non-clonal and clonal cases. Non-clonal cases had significantly lower CD25 






Sequential sample analysis 
Sequential PARR samples >1 month apart were available for 18 cases with polyclonal or 
restricted polyclonal IG rearrangements on initial presentation. Most cases had 1 sequential sample, but 
6 cases had 2-5 sequential samples available for analysis. The time between initial diagnosis and the 
most recent sample varied from 2.6-64.5 months. The PARR results did not change over time for 13/18 
cases. Cases with restricted polyclonal IG rearrangements had identically-sized peaks over time (Figure 
23). In one case, which was followed for 64.5 months, the restricted peaks became more pronounced 
over time, resulting in several tall narrow peaks with minimal polyclonal background (Figure 23C). Of the 
5 cases where PARR results changed over time, 2 restricted polyclonal cases became polyclonal (both 
were receiving oral chemotherapy and prednisone), one polyclonal case became restricted polyclonal, 
and 2 restricted polyclonal cases progressed to having clonal IG rearrangements. In both cases, a 
restricted peak initially identified increased in amplitude over time and reached clonal criteria in the 
sequential sample.  
 
Figure 23. Sequential PCR for antigen receptor rearrangements (PARR) results using immunoglobulin 
primers for 3 English bulldog cases with B-cell lymphocytosis. For each case, immunoglobulin PARR 
results at initial presentation (top) and sequential PARR results (bottom) 3.4-64.5 months after diagnosis 
are presented. The size of the PCR amplicons is indicated along the horizontal axis. Restricted peaks 
persist over time and are identical in size to those present at initial presentation. The PARR tracings 
maintain a similar pattern over time in 2 cases (A, B), and become more restricted in a patient that has 
been monitored over 5 years (C). 
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A number of monitored cases have been clinically stable over time with no treatment, while 
others were managed with steroids alone or steroids and oral chemotherapy. In general, treated cases 
had reductions in the B-cell count, improvement of splenomegaly, and reductions in globulins, though 
atypical PE/IF patterns and IgA increases often persisted. Treatment protocols were variable in these 




 Our study identified a syndrome in English bulldogs characterized by an expansion of non-clonal 
B cells in the blood, with polyclonal or restricted polyclonal IG rearrangements by PARR. This syndrome, 
termed polyclonal B-cell lymphocytosis in English bulldogs (PBLEB), frequently affects young males and 
is commonly associated with splenomegaly or splenic masses and hyperglobulinemia. The 
hyperglobulinemia is characterized by a polyclonal or restricted polyclonal pattern, with increased IgA 
+/- IgM. 
 Forty-three percent of English bulldogs with blood submitted to the CSU-CI laboratory for flow 
cytometry over a nearly nine-year period had a B-cell expansion. These patients generally have 
moderate lymphocytosis (median, 22,400 lymphocytes/µL). An expansion of a single lymphocyte subset 
of this magnitude typically corresponds with lymphoid neoplasia in dogs, which is consistent with the 
fact that 100% of the small breed dogs with B-cell lymphocytosis in this study had clonal IG 
rearrangements. However, the majority (70%) of English bulldogs with B-cell lymphocytosis did not have 
clonal IG rearrangements by PARR, suggesting a nonneoplastic process.  
To help rule out a false negative PARR result, an expanded PARR assay was developed. The 
routine PARR assay has high sensitivity among traditional BCLL cases, but its sensitivity in detecting 
neoplasms with extensive somatic hypermutation is not known. We were concerned that the bulldogs 
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may have a neoplasm with somatic hypermutation, which affected PARR sensitivity. We developed an 
expanded PARR assay, which assessed clonality in additional IG loci, to test whether this assay would 
detect clonality in bulldog cases. Detection of incomplete IGH-DJ and IG light chain rearrangements 
increases sensitivity in detecting B-cell and plasma cell neoplasms in humans, cats and dogs, as 
compared to complete IGH-VDJ rearrangements alone.6,184,189,190 Incomplete IGH-DJ and Kde 
rearrangements are less prone to somatic hypermutation, and analysis of the IG kappa locus was shown 
to be useful in detecting clonality in canine tumors with somatic hypermutation, such as 
plasmacytomas.6,189 The expanded PARR assay targeting additional IGH-VDJ and IGH-DJ gene 
rearrangements and IG light chain rearrangements identified an additional 5 cases as clonal, but the 
majority of non-clonal cases remained non-clonal with the expanded PARR assay. False negative PARR 
results in the English bulldogs due to nonfunctional IG rearrangements, such as a J region deletion, are 
unlikely since patients have large quantities of immunoglobulin protein in the serum, suggesting gene 
rearrangements are functional.9 While it is still possible that the expanded B cells in these English 
bulldogs are rearranging an unusual or highly variable IGHV gene not detected with these assays, the 
PARR testing with this extensive pool of primers suggests that most of these English bulldogs have a 
nonneoplastic or preneoplastic syndrome.  
  One third of the bulldog cases had an unusual restricted polyclonal IG PARR pattern defined by 
IG peaks which did not meet objective criteria for clonality, within a polyclonal background. 
Approximately 50% of cases had an unusual restricted polyclonal PE/IF pattern, where restricted bands 
of IG protein were present among a polyclonal background. These patterns suggest restricted IG 
diversity in the B-cell population, possibly attributed to proliferation of a restricted, but not necessarily 
neoplastic pool of B cells. The nature of this restricted pool was remarkably consistent over time. 
Identically-sized IG rearrangements were detected in subsequent samples, suggesting persistence of 
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expanded B-cell populations. The unusual restricted IG protein pattern seen on PE/IF also supports the 
hypothesis that there are restricted pools of IG-secreting B cells. 
There are rare human disorders of nonmalignant polyclonal B cells, which may be associated 
with splenomegaly and hyperglobulinemia. Persistent polyclonal B-cell lymphocytosis (PPBL) is a benign 
disease characterized by expanded polyclonal B cells in the blood and increases in polyclonal serum 
IgM.191 Patients are generally asymptomatic and a subset of cases have splenomegaly. Rare cases have 
massive splenomegaly, which may require splenectomy and mimic splenic lymphoma histologically.192–
194 Familial cases suggest a genetic predisposition and many cases have an isochromosome (3q) 
abnormality and chromosomal instability.191,195 Most patients remain polyclonal and clinically stable, but 
there are rare reports of patients progressing to a clonal B-cell malignancy.196 PPBL is hypothesized to 
result from hyperproliferation of B cells with a marginal zone-like phenotype and altered CD40 
signaling.192,197,198 Ras-associated autoimmune lymphoproliferative disorder (RALD) is a rare 
nonmalignant human syndrome caused by mutations in RAS genes and characterized by persistent 
monocytosis, polyclonal B-cell lymphocytosis, massive splenomegaly, lymphadenopathy, 
hypergammaglobulinemia, and autoimmunity.199 This syndrome is diagnosed at a young age and 
generally has an indolent clinical course, though rare cases may undergo malignant transformation. 
Sequencing in one patient demonstrated a restricted B-cell receptor repertoire, with expansions of 
many different B-cell clones.200 There are features of human PPBL and RALD that are not consistent with 
the canine PBLEB syndrome described here, including binucleate lymphocyte morphology and female 
predisposition in PPBL, and monocytosis, lymphadenopathy, hypergammaglobulinemia and IgG 
gammopathy in RALD. However, these human syndromes do highlight the possibility for an underlying 
mutation or chromosomal abnormality to cause altered lymphocyte homeostasis, resulting in polyclonal 
B-cell expansions, splenomegaly and gammopathy. 
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We hypothesize that this syndrome begins as a nonneoplastic condition, with a potential for 
malignant transformation over time. In PBLEB cases with sequential samples, we documented 
progression from polyclonal IG rearrangements to restricted polyclonal IG rearrangements in one case, 
and from restricted polyclonal IG rearrangements to clonal IG rearrangements in 2 cases. Additionally, 
clonal cases were significantly older than polyclonal cases. A subset of those clonal English bulldogs had 
features consistent with PBLEB, including splenomegaly without lymphadenopathy, hyperglobulinemia 
and low class II MHC and CD25 expression on B cells, raising the possibility that some PBLEB cases may 
undergo malignant transformation over time. In human medicine, monoclonal gammopathy of 
undetermined significance is considered a premalignant disease that may undergo malignant 
transformation and progress to Waldenstrom macroglobulinemia or a plasma cell neoplasm.201 
Additionally, a subset of apparently healthy asymptomatic people with monoclonal B-cell lymphocytosis 
will progress to chronic lymphocytic leukemia.202 We hypothesize that bulldogs with PBLEB also have a 
spectrum of disease, and some bulldogs will maintain nonneoplastic polyclonal B-cell expansions while 
others progress to malignancy. Therefore, these bulldogs may require monitoring over time to identify 
progression.  
A separate subset of clonal English bulldog cases had a different clinical and flow cytometry 
presentation than the PBLEB cases. These cases had a female predominance, lymphadenopathy and 
higher class II MHC and CD25 expression. We hypothesize these bulldogs have a different B-cell disease, 
such as conventional BCLL as seen in other breeds. It is unclear if these cases have a different clinical 
course, but this information would be useful. Though these cases and the PBLEB cases that progress may 
both meet the clinical definition of BCLL, we hypothesize that these are different entities with different 
underlying predisposition and different events leading to B-cell neoplasia. 
A larger outcome study is underway to investigate the progression of the PBLEB syndrome, 
variables associated with clonality, and indications for and response to treatment in English bulldogs. 
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Limited data suggest that a subset of bulldogs maintain stable lymphocyte counts and globulin levels 
without a need for therapeutic intervention, but a subset of cases (including polyclonal cases) require 
treatment to control marked hyperglobulinemia and its sequela and massive splenomegaly.  
Hyperglobulinemia and splenomegaly were common features in PBLEB cases. Globulins were 
often moderately to markedly increased. All cases tested had increased IgA, a subset of patients had 
concurrent increases in IgM, and IgGFC was typically normal to decreased. In T cell-dependent IgA class 
switching pathways, cytokines in combination with CD40L may promote B-cell proliferation and IgA class 
switching.203 In T cell-independent pathways, soluble factors such as BAFF and APRIL induce IgA class 
switching.203 Several mechanisms may explain the constellation of findings in these dogs. PBLEB cases 
may have either increased factors which stimulate IgA class switching, or a decrease in inhibitors of class 
switch recombination. For example, APRIL is hypothesized to cause hyper-production of IgA in human 
IgA nephropathy and BAFF overexpression in mice resulted in a hyper-IgA syndrome with B-cell 
hyperplasia.204,205 Alternatively, certain B-cell subsets, including splenic marginal zone B cells in mice, 
class switch to IgA more effectively than other subsets, and perhaps the expanded B cells in PBLEB are 
primed to readily/robustly switch to IgA when exposed to stimuli.203,206 Many PBLEB cases had 
splenomegaly/splenic masses without lymphadenopathy. A subset of cases had massive splenomegaly 
and a few patients were treated with splenectomy due to patient discomfort. Histology was only 
available in a small number of cases, but splenic samples were expanded by enlarged lymphoid follicles 
consisting of heterogeneous B cells. The expanded B cells in this syndrome may originate in the spleen, 
there may be stimulatory molecules in the spleen promoting proliferation and survival at this site, 
and/or the expanded B cells express receptors promoting homing to the spleen rather than lymph node. 
A limitation of this study is that only 2 cases had bone marrow aspirates performed. In these cases, 
small, mature appearing lymphocytes comprised 20% and 43% of the bone marrow nucleated cells 
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suggesting that this compartment may be involved. Additional cases would be necessary to confirm this 
suspicion. 
There appears to be a genetic predisposition in English bulldogs for this syndrome. English 
bulldog controls with normal B-cell counts had significantly lower CD25-expressing B cells than non-
bulldog controls of various breeds. Because we do not have this data for a population of other purebred 
dogs, we do not know if this finding is specific to English bulldogs, nor if it is related to the syndrome 
being described. Future directions are aimed at performing genome sequencing to identify underlying 
mutations. We have documented a few cases of this syndrome in other breeds. These non-bulldog cases 
were identified because of their clinical presentation, including splenomegaly and hyperglobulinemia, 
and flow cytometric B-cell features, including low class II MHC and CD25 expression. Polyclonal IG gene 
rearrangements by PARR and polyclonal IgA gammopathies by PE/IF supported a diagnosis of this 
syndrome in these non-English Bulldog cases. Future work is aimed at determining the prevalence of this 
syndrome in other breeds.     
In summary, we have identified a syndrome found in English bulldogs characterized by 
polyclonal B-cell expansion. This syndrome frequently affects young males and is often associated with 
IgA +/- IgM gammopathy and splenomegaly. We hypothesize that this syndrome represents a 
nonneoplastic or preneoplastic syndrome with an, as yet incompletely defined, subset of patients 







 Canine neoplasms provide an opportunity to study genetic risk, investigate tumor pathogenesis 
and test novel therapies, which may translate to human medicine. B-cell chronic lymphocytic leukemia 
(BCLL) is a common neoplasm in dogs, though little was known about the clinical progression of this 
disease or the underlying mechanisms. Our goal was to further characterize this canine cancer, to 
improve the diagnosis and management of canine patients and evaluate BCLL as a model for human 
chronic lymphocytic leukemia (CLL). 
 Our collective results demonstrate that canine BCLL is a heterogeneous disease, as seen in 
human CLL. BCLL cases had a heterogeneous clinical outcome and gene expression profile. One subset of 
cases was defined by high tumor cell proliferation. These cases had increased expression of proliferation 
gene sets by gene expression profiling and significantly higher Ki67 expression compared to other BCLL 
cases. In the outcome study, cases with high Ki67 expression by flow cytometry had poorer outcomes. 
Though we didn’t have outcome data on the cases in the gene expression study, we hypothesize that 
the proliferative cases, which were defined as BCLL subset 2, had more aggressive disease based on the 
prognostic significance of Ki67. Boxer dogs were overrepresented in the proliferative BCLL subset by 
gene expression profiling. In the outcome study, Boxers had significantly higher Ki67 expression and 
shorter survival than non-Boxers. We determined that Boxers with BCLL preferentially rearrange 
unmutated immunoglobulin heavy variable region (IGHV) genes. Unmutated IGHV CLL in people is 
associated with increased tumor cell proliferation and shorter survival times, similar to what we found in 
Boxers.13,14,165 These results suggest that unmutated IGHV genes may play a role in the pathogenesis and 
clinical manifestation of BCLL, similar to human CLL. Importantly however, when we tested non-Boxers, 
we found that cases with poor prognosis +/- increased proliferation included a mixture of unmutated 
and mutated IGHV cases. Therefore, the role of IGHV mutation in canine BCLL needs further 
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investigation. Future directions are aimed at evaluating IGHV mutation status in a larger number of non-
Boxers with outcome and Ki67 expression data.    
This heterogeneity raised the question of whether these canine patient subsets had distinct 
neoplasms, or different manifestations of BCLL. This is a question that has been raised with several 
human lymphoma subtypes with a high degree of molecular and genetic heterogeneity, but early 
classification schemes concluded the most practical approach was to define entities that can easily be 
recognized with available morphologic, immunologic and genetic techniques, even if an entity 
encompasses distinctive clinical presentations.207 Human CLL demonstrates striking clinical 
heterogeneity, but cases had a similar gene expression profile irrespective of IGHV mutation status, 
suggesting a common pathogenesis.142 Human mantle cell lymphoma has two molecular subtypes that 
have different clinical behaviors, cells of origin and gene expression profiles, but they are characterized 
by the same translocation t(11;14) leading to CCND1 overexpression, and are thus considered two 
distinct subtypes of one disease.208 Human diffuse large B-cell lymphoma (DLBCL) has a highly variable 
clinical course and was thought to include more than one disease entity, but subgroups could not be 
identified by morphology.12,207 Gene expression profiling revealed that DLBCL encompasses two distinct 
diseases with largely non-overlapping transcriptomes and different cellular origins and activation states, 
but these diseases are morphologically indistinguishable and still fall within the DLBCL category.12 
Because we cannot differentiate canine BCLL subtypes by morphology or current immunophenotyping 
panels, we continue to classify these cases under the BCLL category. However, it is important to 
distinguish between subtypes for clinicians and clients, as these dogs have very different outcomes, with 
some dogs surviving weeks to months despite aggressive therapy, and others surviving years with no 
therapy. Future work is aimed at identifying antibodies or a panel of genes that could distinguish 
clinically relevant subgroups. For example, in human DLBCL, a gene expression signature that identifies a 
clinically and biologically distinct subgroup was translated into a NanoString assay.209 A NanoString assay 
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detecting a panel of genes that are differentially expressed between distinct canine BCLL subgroups 
could be applied routinely to BCLL samples, allowing for further classification and better prognostic 
information. Future directions also aim to examine the cell of origin and genetic mutations for canine 
BCLL subtypes.  
We investigated molecular and clinical similarities between canine BCLL and human CLL to 
evaluate the utility of canine BCLL as a translational model. These diseases share similarities in disease 
distribution and clinical presentation, including an expansion of small mature-appearing B cells in the 
blood, bone marrow and secondary lymphoid tissues, variable concurrent anemia and 
thrombocytopenia, older age at diagnosis, and inherited susceptibility/breed predisposition. Both 
diseases have marked clinical heterogeneity, with some patients having short survival despite aggressive 
therapy, and other patients having normal lifespans in which they may not need treatment and die of 
causes unrelated to BCLL/CLL. The canine BCLL gene expression profile was significantly enriched for 
human CLL gene sets by RNA Seq and NanoString analyses. Importantly, the gene expression profile of 
canine BCLL was not enriched for gene sets from other human B-cell neoplasms tested, including mantle 
cell lymphoma, follicular lymphoma and splenic marginal zone lymphoma. These results suggest that of 
the human B-cell neoplasms with a leukemic component, canine BCLL is most similar to human CLL. 
Numerous pathways are important for human CLL cell survival and proliferation, and we found that 
some of these pathways, including B-cell receptor signaling and NF-κB signaling, are altered in canine 
BCLL. Future work is aimed at evaluating these pathways functionally, to examine phosphorylation of 
signaling molecules and study effects of B-cell receptor activation and pathway inhibitors. We also aim 
to characterize the spectrum of genomic aberrations and somatic mutations in canine BCLL, to 
determine whether dogs have similar mutations to any of the human CLL subsets, which demonstrate a 
range of genomic aberrations and driver mutations. Other important aspects of human CLL biology that 
need to be evaluated in canine BCLL include the cell of origin, the epigenetic signature, 
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microenvironment interactions, microRNA dysregulation, splicing alterations and subclonal 
heterogeneity. As we explore these areas in the dog, we hope to learn more about this common canine 
neoplasm and uncover similarities to human CLL. 
Breed predilections in canine BCLL may provide an opportunity to identify disease-risk alleles 
through genome-wide association studies (GWAS). The GWAS approach scans the genome with 
microarrays of single nucleotide polymorphisms (SNPs) to identify loci associated with a disease.210 
Because of linkage disequilibrium in the genome, alleles in different DNA segments (referred to as 
haplotype blocks) are associated with one another. A GWAS can identify SNPs in the region of the 
disease allele, and these discovered loci can then be finely mapped to identify disease-susceptibility 
variants. In humans, large sample sizes of cases and controls and large numbers of SNPs are needed to 
identify loci contributing to disease risk. Due to inbreeding and the resulting lack of genetic 
heterogeneity within pure dog breeds, canine GWAS are simpler and require fewer samples.67,211 Dogs of 
a particular breed have larger haplotype blocks compared to humans, so fewer SNPs are needed to 
cover an inherited haplotype block.67 Additionally, portions of haplotypes are shared across breeds, so 
genetic risk factors may be shared across breeds; for example, genetic risk factors for BCLL may be 
shared across small dog breeds.67 A GWAS in small dog breeds with increased risk of developing BCLL 
may identify inherited risk loci associated with BCLL, which could potentially be of comparative value to 
human CLL. Additionally, a GWAS in Boxers, comparing BCLL cases and controls, may identify risk loci 
associated with more aggressive BCLL. We hypothesize that some of these loci identified in Boxers may 
be different than those identified in small breeds, and these results could perhaps inform studies of 
humans with aggressive unmutated IGHV CLL.  
Finally, we discovered a novel syndrome in English bulldogs, defined by an expansion of 
polyclonal B cells in the blood. These cases have hyperglobulinemia, characterized by large amounts of 
polyclonal IgA +/- IgM, and normal to decreased amounts of IgG. Cases frequently have marked 
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splenomegaly, characterized by large expansions of polyclonal B cells. Future directions are aimed at 
examining the gene expression profile of these cases, to understand the signaling pathways driving non-
malignant proliferation of B cells, IgA class switching and increased globulin secretion. The marked 
splenomegaly suggests that this syndrome may arise in the spleen, and future work is aimed at 
identifying the cell of origin. The predilection for this syndrome in young English bulldogs suggests a 
genetic predisposition in this breed, and we plan to pursue genomic sequencing to look for underlying 
mutations. We found that the diversity of immunoglobulin gene rearrangements in these cases becomes 
more restricted over time, and a subset of cases progress to a clonal malignancy. Future directions to 
monitor changes in gene expression and mutations over time would potentially identify mechanisms 
responsible for transformation from a pre-malignant reactive condition to a malignancy. 
Overall, this work has helped improve our understanding of small-cell B-cell lymphocytosis 
diseases in dogs. As we continue to study the genetic risk, pathogenesis and outcomes of these diseases, 
we hope to improve care for our veterinary patients and contribute to the field of comparative 
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3 VH1-03 F 74242927 yes ATGCAAAT ATG GT/AG CACAGTG ACACAAACC 
   
IGHV3-
80*01 
4 VH1-04 F 74224404 yes ATGCAAAT ATG GT/AG CACAGTG ACACAAACC 
































9 VH1-08 F 74144648 yes ATGCAAAG ATG GT/AG CACAGTG ATAGAAACC 




























14 VH1-12 F 74080028 yes ATGCAAAT ATG GT/AG CACAGTG ACACAAACT 
   
IGHV3-
69*01 
15 VH1-13 F 74068281 yes ATGCAAAT ATG GT/AG CACAGTG ACACAAACC 









17 VH1-15 F 74052503 yes ATGCAAAT ATG GT/AG CACAGTG ACACAAACC 









































23 VH1-21 F 73981005 yes ATGCAAAT ATG GT/TG CACATTG ACACAAACC 

















26 VH1-24 F 73956330 yes ATGCAAAT ATG GT/AG CACAGTG ACAGAAACC 

























30 VH1-28 F 73886557 yes ATGCAAAT ATG GT/AG CACAATG ACACAAACC 



























34 VH1-32 F 73838094 yes ATGCAAAT ATG GT/AG CACAGTG ACACAAACC 
























38 VH1-35 F 73751519 yes ATGCAAAT ATG GT/AG CACAGTG ACACAAACC 
   
IGHV3-
46*01 
39 VH1-36 F 73744495 yes ATGCAAAT ATG GT/AG CACAGTC ACACAAACC 

































44 VH1-41 F 73686189 yes ATGCAAAT ATG GT/AG CACAGTG ACACAAACC 









46 VH1-43 F 73655490 yes ATGCAAAT ATG GT/AG CACAGTG ACACAAACC 
   
IGHV3-
38*01 
47 VH1-44 F 73639568 yes ATGCAAAT ATG GT/AG CACAGTG ACACAAACC 
   
IGHV3-
37*01 
48 VH1-45 F 73620033 yes ATGCAAAT ATG GT/AG CACAGTC ACACAAACC 











50 VH1-47 F 73595945 yes ATGCAAAT ATG GT/AG CACAGTG ACACAAAAC 
   
IGHV3-
33*01 
52 VH1-48 F 73580014 yes ATGCAAAT ATG GT/AA CACAGTG ACACAAACC 
   
IGHV3-
32*01 
53 VH1-06 F 73576558 yes ATGCAAAT ATG GT/AG TACAGTG ACACAAAAT 









55 VH2-51 F 73558100 yes ATGCAAAT ATG GT/AG CACAGTG TCAGAAACC 



































61 VH1-57 F 73478222 yes ATGCAAAT ATG GT/AG CACAGTG ACACTCACT 
   
IGHV3-
23*01 
62 VH1-58 F 73466463 yes ATGCAAAT ATG GT/AG CACAGTG ACACAAACC 




























67 VH1-62 F 73387704 yes ATGCAAAT ATG GT/AG CACAGTG ACACAAACC 
   
IGHV3-
18*01 
68 VH1-63 F 73365401 yes ATGCAAAT ATG GT/AG CACAGTG ACACAAAAC 











70 VH1-65 F 73306390 yes ATGCAAAG ATG GT/AG CACAGTG ACACAAACC 















73 VH1-68 F 73267073 yes ATGCAAAT ATG GT/AG CACAGTG ACACAAACC 















76 VH1-71 F 73195153 yes ATGCAAAT ATG GT/AG CACCGTG ACACAAACC 
   
IGHV3-
9*01 
77 VH1-72 F 73185283 yes ATGCAAAT ATG GT/AG CACAGTG ACACAAACC 





78 VH1-73 F 73159977 yes ATGCAAAT ATG GT/AG CACAATG ACACAAACC 
   
IGHV3-
7*01 
79 VH1-74 F 73153457 yes ATGCAAAT ATG GT/AG CACAGTG ACACAAACC 
   
IGHV3-
6*01 
80 VH1-75 F 73137027 yes ATGCAAAT ATG GT/AG CACAGTG ACACAAACC 











82 VH1-77 F 73109226 yes ATGCAAAT ATG GT/AC CACCGTG ACACAAACC 
   
IGHV3-
4*01 





84 VH1-78 F 73056536 yes ATGCAAAT ATG GT/AG CACAGTG ACACAAACT 
   
IGHV3-
2*01 
85 VH1-79 F 73038393 yes ATGCAAAT ATG GT/AG CACAGTA ACACAAACC 
   
IGHV4-
1*01 
86 VH3-80 F 73028843 yes ATGCAAAT ATG GT/AG CACAGTG ACACAAACC 










0 n/a P n/a no ATACAAAG ATG AT/AG CGCAGGG ACGCAAACC 
 
• • 
aThe IMGT name is provided for the canine IGHV genes (http://www.imgt.org, release 201715-4 (13 April 2017)).  
bThe previous IGHV gene name from Bao et al. is listed.  
cIGHV genes are designated as functional (F) or pseudogenes (P). The IMGT name is bolded for functional canine IGHV genes. 
dThe genomic location on chromosome 8 is identified for the start of the initiation codon, INIT-CODON (CanFam3.1, NCBI Accession 
NC_006590.3). Pseudogenes without an INIT-CODON are indicated with an asterisk, and the genomic location provided is the start of the V-
HEPTAMER of the V-RS (recombination sequence). 
The sequence for the following gene elements is provided: OCTAMER, INIT-CODON, ACCEPTOR-SPLICE AND DONOR-SPLICE sites, V-HEPTAMER 
and V-NONAMER. ‘n/a’ indicates that the gene element was not found. 
ePseudogenes that are slightly altered are identified with an ‘•.’ These are pseudogenes in the reference Boxer genome, but appear to have the 
potential to be functional if there were minor changes/polymorphisms in the sequence.  
fPseudogenes that are highly altered are identified, indicating these genes have major alterations and do not appear to have the potential to be 
functional. 
gGenes indicated with an ‘•’ are newly identified IGHV genes, that were not previously reported in Bao et al.  
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Control 1 77688718 73920248 11.1G 0.01 97.13 92.85 48.99 
Control 2 75881332 72363692 10.9G 0.01 97.17 92.9 49.13 
Control 3 54559714 52504426 7.9G 0.02 95.55 89.42 49.2 
BCLL case 1 47531362 45433774 6.8G 0.02 96.52 91.49 49.5 
BCLL case 2 40192404 39153634 5.9G 0.02 97.25 92.98 51.49 
BCLL case 3 70326624 67326806 10.1G 0.02 97.23 92.85 49.23 
BCLL case 4 49317490 47975092 7.2G 0.02 97.06 92.63 48.33 
BCLL case 5 41326238 40378024 6.1G 0.02 97.12 92.78 48.64 
BCLL case 6 51314044 49057702 7.4G 0.02 96.62 91.69 48.74 
BCLL case 7 49739918 47767896 7.2G 0.02 96.8 92.07 48.53 
BCLL case 8 50493844 48534680 7.3G 0.02 96.83 92.1 48.7 
BCLL case 9 56455156 54476998 8.2G 0.02 97.14 92.67 47.89 
BCLL case 10 49226940 47987090 7.2G 0.02 96.97 92.38 49.53 
BCLL case 11 45011286 44037678 6.6G 0.02 97.16 92.78 49.74 
BCLL case 12 49111508 47957864 7.2G 0.02 96.68 91.86 49.4 
Raw Reads: the original sequencing reads counts; Clean Reads: number of reads after filtering; Clean 
Bases: clean reads number multiplied by read length; Error Rate: average sequencing error rate, which is 
calculated by Qphred=-10log10(e); Q20: percentage of bases whose correct base recognition rates are 
greater than 99% in total bases; Q30: percentage of bases whose correct base recognition rates are 





Supplemental table S3. RNA Seq mapping results for control B-cell and BCLL samples. 
Sample Total reads Total mapped Multiple mapped Uniquely mapped 
Control 1 73920248 62806568 (84.97%) 1472084 (1.99%) 61334484 (82.97%) 
Control 2 72363692 62132754 (85.86%) 1303151 (1.8%) 60829603 (84.06%) 
Control 3 52504426 42942469 (81.79%) 910145 (1.73%) 42032324 (80.05%) 
BCLL case 1 45433774 38195608 (84.07%) 1008821 (2.22%) 37186787 (81.85%) 
BCLL case 2 39153634 32661154 (83.42%) 1008805 (2.58%) 31652349 (80.84%) 
BCLL case 3 67326806 58276073 (86.56%) 1609866 (2.39%) 56666207 (84.17%) 
BCLL case 4 47975092 40848955 (85.15%) 1009378 (2.1%) 39839577 (83.04%) 
BCLL case 5 40378024 34464840 (85.36%) 816139 (2.02%) 33648701 (83.33%) 
BCLL case 6 49057702 42233186 (86.09%) 936891 (1.91%) 41296295 (84.18%) 
BCLL case 7 47767896 41728332 (87.36%) 945811 (1.98%) 40782521 (85.38%) 
BCLL case 8 48534680 42204240 (86.96%) 1130919 (2.33%) 41073321 (84.63%) 
BCLL case 9 54476998 47781244 (87.71%) 1008555 (1.85%) 46772689 (85.86%) 
BCLL case 10 47987090 41420202 (86.32%) 938795 (1.96%) 40481407 (84.36%) 
BCLL case 11 44037678 37948814 (86.17%) 822888 (1.87%) 37125926 (84.3%) 
BCLL case 12 47957864 40562951 (84.58%) 991397 (2.07%) 39571554 (82.51%) 
Total reads: total number of filtered reads; Total mapped: total number of reads mapped to the 
reference genome; Multiple mapped: number of reads that mapped to multiple sites in the reference 








Supplemental table S4. The top 250 genes overexpressed in all BCLL samples vs. control B cells (above) 
and the top 250 genes underexpressed in all BCLL samples vs. control B cells (below). Differentially 
expressed genes were identified RNA Seq DESeq2 analysis, p-adj <0.05. FC (fold change): log2(FC) BCLL 









Supplemental table S5. Summary of hallmark gene sets enriched between canine BCLL subgroup 1 and 
BCLL subgroup 2. Gene set enrichment analysis results using significantly differentially expressed genes 
in BCLL subgroup 2 vs. BCLL subgroup 1 (RNA Seq, DESeq2, p-adj <0.05). All gene sets with a false 
discovery rate <0.25 are listed. 
Gene set Enriched phenotype NES NOM p-val FDR q-val 
E2F targets BCLL subgroup 2 3.15 <0.0001 <0.0001 
Mitotic spindle BCLL subgroup 2 2.11 <0.0001 0.0152 
G2M checkpoint BCLL subgroup 2 2.03 0.0042 0.0179 
Glycolysis BCLL subgroup 2 1.68 0.0305 0.1128 
Spermatogenesis BCLL subgroup 2 1.54 0.0535 0.1744 
IL2 STAT5 signaling BCLL subgroup 2 1.47 0.0963 0.2011 
TNFA signaling via NFKB BCLL subgroup 1 -4.80 <0.0001 <0.0001 
Epithelial mesenchymal transition BCLL subgroup 1 -3.25 <0.0001 <0.0001 
Inflammatory response BCLL subgroup 1 -2.53 <0.0001 <0.0001 
Unfolded protein response BCLL subgroup 1 -2.37 <0.0001 0.0018 
Hypoxia BCLL subgroup 1 -2.11 0.0020 0.0111 
Myogenesis BCLL subgroup 1 -2.05 0.0021 0.0141 
KRAS signaling down BCLL subgroup 1 -1.94 0.0100 0.0265 
MYC targets BCLL subgroup 1 -1.80 0.0123 0.0481 
Oxidative phosphorylation BCLL subgroup 1 -1.80 0.0102 0.0526 
UV response up BCLL subgroup 1 -1.60 0.0471 0.1091 
KRAS signaling up BCLL subgroup 1 -1.61 0.0452 0.1118 
Coagulation BCLL subgroup 1 -1.57 0.0463 0.1199 
Apoptosis BCLL subgroup 1 -1.47 0.0692 0.1670 
DNA repair BCLL subgroup 1 -1.38 0.1106 0.2260 
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Estrogen response early BCLL subgroup 1 -1.36 0.1285 0.2307 
NES, normalized enrichment score, NOM p-val, nominal p value; FDR q-val, false discovery rate. 
 
Supplemental table S6. Summary of gene sets enriched between canine BCLL subgroup 1 and control B 
cells from healthy dog lymph nodes. Gene set enrichment analysis results using significantly 
differentially expressed genes in BCLL subgroup 1 vs. control B cells (RNA Seq, DESeq2, p-adj <0.05). All 
gene sets with a false discovery rate <0.25 are listed. 
 Gene set Enriched phenotype NES NOM p-val FDR q-val 
Hallmarks gene sets163 
TNFA signaling via NFKB BCLL subgroup 1 5.06 <0.0001 <0.0001 
Inflammatory response BCLL subgroup 1 4.10 <0.0001 <0.0001 
Epithelial mesenchymal transition BCLL subgroup 1 3.65 <0.0001 <0.0001 
Coagulation BCLL subgroup 1 3.64 <0.0001 <0.0001 
KRAS signaling up BCLL subgroup 1 3.10 <0.0001 <0.0001 
Complement BCLL subgroup 1 2.84 <0.0001 <0.0001 
IL2 STAT5 signaling BCLL subgroup 1 2.83 <0.0001 <0.0001 
Apoptosis BCLL subgroup 1 2.63 <0.0001 <0.0001 
Hypoxia BCLL subgroup 1 2.39 <0.0001 0.0015 
Estrogen response early BCLL subgroup 1 2.19 0.0020 0.0059 
KRAS signaling down BCLL subgroup 1 2.06 0.0063 0.0127 
IL6 JAK STAT3 signaling BCLL subgroup 1 2.01 0.0039 0.0151 
UV response up BCLL subgroup 1 1.97 0.0039 0.0171 
Myogenesis BCLL subgroup 1 1.83 0.0193 0.0354 
Allograft rejection BCLL subgroup 1 1.66 0.0240 0.0663 
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Unfolded protein response BCLL subgroup 1 1.67 0.0444 0.0695 
PI3K AKT MTOR signaling BCLL subgroup 1 1.58 0.0501 0.0926 
TGFB signaling BCLL subgroup 1 1.54 0.0745 0.1080 
UV response down BCLL subgroup 1 1.50 0.0684 0.1255 
Protein secretion BCLL subgroup 1 1.47 0.0660 0.1369 
p53 pathway BCLL subgroup 1 1.44 0.0837 0.1457 
Estrogen response late BCLL subgroup 1 1.36 0.1319 0.1874 
Heme metabolism BCLL subgroup 1 1.36 0.1250 0.1950 
Cholesterol homeostasis BCLL subgroup 1 1.29 0.1728 0.2372 
Adipogenesis BCLL subgroup 1 1.27 0.1889 0.2381 
E2F targets Control B cells -4.67 <0.0001 <0.0001 
G2M checkpoint Control B cells -3.50 <0.0001 <0.0001 
MYC targets Control B cells -2.31 <0.0001 0.0013 
Mitotic spindle Control B cells -1.80 0.0155 0.0303 
Oxidative phosphorylation Control B cells -1.66 0.0416 0.0523 
Staudt laboratory gene sets (https://lymphochip.nih.gov/signaturedb/index.html) 
Quiescence BCLL subgroup 1 2.06 0.0076 0.0272 
BCR signaling up BCLL subgroup 1 2.12 0.0060 0.0326 
TGFB up BCLL subgroup 1 1.75 0.0277 0.0928 
IL4 up BCLL subgroup 1 1.66 0.0437 0.1025 
IL6 up BCLL subgroup 1 1.57 0.0487 0.1082 
KRAS up BCLL subgroup 1 1.60 0.0282 0.1108 
NFKB targets BCLL subgroup 1 1.52 0.0719 0.1193 
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MYD88 up BCLL subgroup 1 1.48 0.0629 0.1225 
BCLL BCR signaling up BCLL subgroup 1 1.45 0.0870 0.1267 
KLF2 up BCLL subgroup 1 1.30 0.1654 0.2079 
JAK2 up Control B cells -2.63 <0.0001 <0.0001 
MYC up Control B cells -2.13 0.0019 0.0199 
E2F up Control B cells -2.01 0.0038 0.0305 
MTOR down Control B cells -1.85 0.0173 0.0569 
IRF4 down Control B cells -1.77 0.0204 0.0679 
KEGG (Kyoto Encyclopedia of Genes and Genomes) gene sets 
Complement and coagulation 
cascades 
BCLL subgroup 1 3.40 0.0000 0.0000 
Huntingtons disease BCLL subgroup 1 2.75 0.0000 0.0000 
Ribosome BCLL subgroup 1 2.67 0.0000 0.0004 
Spliceosome BCLL subgroup 1 2.52 0.0000 0.0031 
Cell adhesion molecules cams BCLL subgroup 1 2.46 0.0020 0.0033 
Cytokine-cytokine receptor 
interaction 
BCLL subgroup 1 2.48 0.0000 0.0035 
Neuroactive ligand receptor 
interaction 
BCLL subgroup 1 2.43 0.0000 0.0039 
Parkinsons disease BCLL subgroup 1 2.36 0.0000 0.0045 
Hematopoietic cell lineage BCLL subgroup 1 2.19 0.0020 0.0133 
Oxidative phosphorylation BCLL subgroup 1 2.05 0.0039 0.0267 
Adipocytokine signaling pathway BCLL subgroup 1 1.98 0.0135 0.0381 
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Alzheimers disease BCLL subgroup 1 1.96 0.0078 0.0388 
NOD like receptor signaling 
pathway 
BCLL subgroup 1 1.92 0.0082 0.0407 
ECM receptor interaction BCLL subgroup 1 1.73 0.0165 0.0997 
MAPK signaling pathway BCLL subgroup 1 1.74 0.0246 0.1012 
Gap junction BCLL subgroup 1 1.69 0.0235 0.1091 
Focal adhesion BCLL subgroup 1 1.64 0.0407 0.1354 
T cell receptor signaling pathway BCLL subgroup 1 1.60 0.0356 0.1532 
Prostate cancer BCLL subgroup 1 1.57 0.0552 0.1682 
Calcium signaling pathway BCLL subgroup 1 1.51 0.0736 0.2048 
Insulin signaling pathway BCLL subgroup 1 1.47 0.0799 0.2429 
Cell cycle Control B cells -2.14 0.0000 0.0296 
DNA replication Control B cells -2.04 0.0000 0.0419 
Pyrimidine metabolism Control B cells -2.14 0.0000 0.0592 
Oocyte meiosis Control B cells -1.91 0.0079 0.0706 
Peroxisome Control B cells -1.74 0.0259 0.0831 
Valine leucine and isoleucine 
degradation 
Control B cells -1.77 0.0163 0.0837 
Progesterone mediated oocyte 
maturation 
Control B cells -1.72 0.0297 0.0846 
Purine metabolism Control B cells -1.78 0.0194 0.0915 
Ubiquitin mediated proteolysis Control B cells -1.80 0.0081 0.1009 
P53 signaling pathway Control B cells -1.50 0.0668 0.2106 
NES, normalized enrichment score, NOM p-val, nominal p value; FDR q-val, false discovery rate. 
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Supplemental table S7. Summary of reactome gene sets enriched between canine BCLL subgroup 1 and 
control B cells from healthy dog lymph nodes. Gene set enrichment analysis results using significantly 
differentially expressed genes in BCLL subgroup 1 vs. control B cells (RNA Seq, DESeq2, p-adj <0.05). A 
total of 255 gene sets had a false discovery rate <0.25. Select gene sets with an FDR <0.1 are listed.  






Metabolism of RNA BCLL subgroup 1 3.83 <0.0001 <0.0001 
Cellular reponses to external stimuli BCLL subgroup 1 3.72 <0.0001 <0.0001 
GPCR ligand binding BCLL subgroup 1 3.44 <0.0001 <0.0001 
Processing of capped intron containing pre 
mRNA 
BCLL subgroup 1 3.24 <0.0001 <0.0001 
Eukaryotic translation elongation BCLL subgroup 1 3.23 <0.0001 <0.0001 
Signaling by GPCR BCLL subgroup 1 3.23 <0.0001 <0.0001 
Extracellular matrix organization BCLL subgroup 1 3.06 <0.0001 <0.0001 
mRNA splicing BCLL subgroup 1 3.00 <0.0001 <0.0001 
Post translational protein modification BCLL subgroup 1 2.84 <0.0001 <0.0001 
IL1 family signaling BCLL subgroup 1 2.45 <0.0001 0.0022 
Innate immune system BCLL subgroup 1 2.44 <0.0001 0.0022 
Autophagy BCLL subgroup 1 2.45 <0.0001 0.0022 
FCERI mediated NFKB activation BCLL subgroup 1 2.29 0.0022 0.0053 
Cell cell communication BCLL subgroup 1 2.01 <0.0001 0.0216 
Chromatin modifying enzymes BCLL subgroup 1 2.00 0.0020 0.0219 
Signaling by interleukins BCLL subgroup 1 1.97 0.0117 0.0241 
Cellular response to hypoxia BCLL subgroup 1 1.95 0.0060 0.0267 
IL4 and IL13 signaling BCLL subgroup 1 1.92 0.0096 0.0305 
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Signaling by WNT BCLL subgroup 1 1.91 0.0082 0.0317 
Transport of mature transcript to cytoplasm BCLL subgroup 1 1.87 0.0100 0.0379 
Downstream signaling events of B-cell receptor BCLL subgroup 1 1.86 0.0101 0.0387 
Integrin cell surface interactions BCLL subgroup 1 1.86 0.0136 0.0404 
Signaling by FGFR2 BCLL subgroup 1 1.82 0.0226 0.0476 
Signaling by ERBB2 BCLL subgroup 1 1.79 0.0099 0.0517 
PTEN regulation BCLL subgroup 1 1.79 0.0157 0.0520 
Signaling by NOTCH4 BCLL subgroup 1 1.75 0.0211 0.0608 
Cytokine signaling in immune system BCLL subgroup 1 1.75 0.0171 0.0622 
Regulation of PTEN stability and activity BCLL subgroup 1 1.71 0.0151 0.0739 
Death receptor signaling BCLL subgroup 1 1.69 0.0287 0.0767 
Antigen processing cross presentation BCLL subgroup 1 1.68 0.0259 0.0808 
MAPK6 MAPK4 signaling  BCLL subgroup 1 1.62 0.0339 0.0975 
Cell cycle Control B cells -3.56 <0.0001 <0.0001 
DNA repair Control B cells -3.09 <0.0001 <0.0001 
Cell cycle checkpoints Control B cells -2.88 <0.0001 1.07E-04 
Cell cycle mitotic Control B cells -2.93 <0.0001 1.28E-04 
Homology directed repair Control B cells -3.00 <0.0001 1.60E-04 
DNA double strand break repair Control B cells -3.01 <0.0001 2.13E-04 
Chromosome maintenance Control B cells -2.70 <0.0001 6.66E-04 
G2 M checkpoints Control B cells -2.41 <0.0001 0.0038 
DNA replication Control B cells -2.22 <0.0001 0.0107 
S phase Control B cells -2.19 0.0019 0.0108 
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Mitotic G1 phase and G1 S transition Control B cells -2.20 <0.0001 0.0109 
Processing of DNA double strand break ends Control B cells -2.14 <0.0001 0.0129 
M phase Control B cells -2.14 0.0020 0.0132 
Base excision repair Control B cells -2.02 0.0084 0.0214 
Telomere maintenance Control B cells -1.94 0.0077 0.0279 
Transcriptional regulation by TP53 Control B cells -1.94 0.0041 0.0284 
Regulation of TP53 activity Control B cells -1.63 0.0377 0.0978 
 
Supplemental table S8. Summary of gene sets enriched between canine BCLL subgroup 2 and control B 
cells from healthy dog lymph nodes. Gene set enrichment analysis results using significantly 
differentially expressed genes in BCLL subgroup 2 vs. control B cells (RNA Seq, DESeq2, p-adj <0.05). All 
gene sets with a false discovery rate <0.25 are listed. 
Gene set Enriched phenotype NES NOM p-val FDR q-val 
Hallmarks gene sets163 
Coagulation BCLL subgroup 2 3.18 <0.0001 <0.0001 
KRAS signaling up BCLL subgroup 2 2.93 <0.0001 <0.0001 
Complement BCLL subgroup 2 2.90 <0.0001 <0.0001 
Epithelial mesenchymal transition BCLL subgroup 2 2.81 <0.0001 0.0004 
Inflammatory response BCLL subgroup 2 2.45 <0.0001 0.0019 
IL2 STAT5 signaling BCLL subgroup 2 2.40 0.0019 0.0021 
Apoptosis BCLL subgroup 2 2.15 0.0040 0.0079 
TNFA signaling via NFKB BCLL subgroup 2 2.11 <0.0001 0.0088 
IL6 JAK STAT3 signaling BCLL subgroup 2 2.00 0.0040 0.0156 
Xenobiotic metabolism BCLL subgroup 2 1.89 0.0082 0.0259 
Hypoxia BCLL subgroup 2 1.84 0.0060 0.0341 
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Cholesterol homeostasis BCLL subgroup 2 1.79 0.0227 0.0428 
Interferon gamma response BCLL subgroup 2 1.72 0.0213 0.0513 
Estrogen response early BCLL subgroup 2 1.42 0.1098 0.1884 
Heme metabolism BCLL subgroup 2 1.32 0.1495 0.2121 
Allograft rejection BCLL subgroup 2 1.38 0.1051 0.2134 
Glycolysis BCLL subgroup 2 1.34 0.1199 0.2169 
Estrogen response late BCLL subgroup 2 1.35 0.1452 0.2204 
Apical junction BCLL subgroup 2 1.32 0.1549 0.2235 
MTORC1 signaling BCLL subgroup 2 1.28 0.1747 0.2350 
E2F targets Control B cells -2.79 <0.0001 0.0003 
Oxidative phosphorylation Control B cells -1.79 0.0081 0.0358 
G2M checkpoint Control B cells -1.85 0.0203 0.0361 
KRAS signaling down Control B cells -1.56 0.0469 0.0807 
Staudt laboratory gene sets (https://lymphochip.nih.gov/signaturedb/index.html) 
Quiescence BCLL subgroup 2 2.51 <0.0001 0.0027 
IRF3 targets BCLL subgroup 2 1.35 0.1295 0.2542 
JAK2 up Control B cells -2.07 0.0020 0.0333 
MTOR down Control B cells -1.94 0.0077 0.0463 
MYC up Control B cells -1.74 0.0280 0.1004 
MTOR up Control B cells -1.63 0.0507 0.1215 
JAK targets Control B cells -1.54 0.0562 0.1428 
KEGG (Kyoto Encyclopedia of Genes and Genomes) gene sets 
Hematopoietic cell lineage BCLL subgroup 2 2.54 <0.0001 <0.0001 
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Regulation of actin cytoskeleton BCLL subgroup 2 2.16 0.0021 0.0126 
Cell adhesion molecules CAMS BCLL subgroup 2 2.08 0.0041 0.0170 
Complement and coagulation 
cascades 
BCLL subgroup 2 1.90 0.0059 0.0341 
Cytokine-cytokine receptor 
interaction 
BCLL subgroup 2 1.96 0.0060 0.0346 
Pathways in cancer BCLL subgroup 2 1.92 0.0020 0.0354 
Lysosome BCLL subgroup 2 1.71 0.0241 0.0905 
ECM receptor interaction BCLL subgroup 2 1.68 0.0279 0.0917 
Chemokine signaling pathway BCLL subgroup 2 1.66 0.0401 0.0920 
Focal adhesion BCLL subgroup 2 1.59 0.0573 0.1191 
Neuroactive ligand receptor 
interaction 
BCLL subgroup 2 1.45 0.0758 0.2113 
Ubiquitin mediated proteolysis Control B cells -2.28 0.0020 0.0068 
Cell cycle Control B cells -1.55 0.0581 0.2454 
Reactome gene set 
Neutrophil degranulation BCLL subgroup 2 3.89 <0.0001 <0.0001 
Innate immune system BCLL subgroup 2 3.48 <0.0001 <0.0001 
Hemostasis BCLL subgroup 2 3.30 <0.0001 <0.0001 
Extracellular matrix organization BCLL subgroup 2 2.92 <0.0001 <0.0001 
Cell surface interactions at the 
vascular wall 
BCLL subgroup 2 2.67 <0.0001 0.0005 
Leishmania infection BCLL subgroup 2 2.57 <0.0001 0.0013 
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Platelet activation signaling and 
aggregation 
BCLL subgroup 2 2.46 <0.0001 0.0024 
GPCR ligand binding BCLL subgroup 2 2.43 <0.0001 0.0026 
Regulation of insulin like growth 
factor IGF transport and uptake 
by insulin like growth factor 
binding proteins IGFBPS 
BCLL subgroup 2 2.44 <0.0001 0.0027 
Degradation of the extracellular 
matrix 
BCLL subgroup 2 2.34 0.0020 0.0044 
Signaling by GPCR BCLL subgroup 2 2.23 <0.0001 0.0091 
Disease BCLL subgroup 2 2.20 0.0020 0.0100 
G alpha I signaling events BCLL subgroup 2 2.07 0.0040 0.0219 
Cell-cell communication BCLL subgroup 2 1.98 0.0080 0.0285 
Response to elevated platelet 
cytosolic Ca 
BCLL subgroup 2 2.00 0.0061 0.0301 
Class A 1 rhodopsin like receptors BCLL subgroup 2 1.99 0.0078 0.0301 
Metabolism of lipids BCLL subgroup 2 1.93 0.0041 0.0353 
Transport to the Golgi and 
subsequent modification 
BCLL subgroup 2 1.83 0.0040 0.0559 
Vesicle mediated transport BCLL subgroup 2 1.82 0.0147 0.0581 
Signaling by interleukins BCLL subgroup 2 1.83 0.0157 0.0586 




favoring leishmania parasite 
infection 
BCLL subgroup 2 1.79 0.0132 0.0617 
IL4 and IL13 signaling BCLL subgroup 2 1.76 0.0183 0.0645 
Cytokine signaling in immune 
system 
BCLL subgroup 2 1.77 0.0346 0.0651 
Post translational protein 
modification 
BCLL subgroup 2 1.67 0.0350 0.0981 
L1CAM interactions BCLL subgroup 2 1.60 0.0562 0.1289 
Fc epsilon receptor FCERI 
signaling 
BCLL subgroup 2 1.59 0.0537 0.1291 
Peptide ligand binding receptors BCLL subgroup 2 1.56 0.0482 0.1438 
G alpha 12 13 signaling events BCLL subgroup 2 1.55 0.0569 0.1466 




BCLL subgroup 2 1.49 0.0660 0.1731 
Signaling by VEGF BCLL subgroup 2 1.41 0.1078 0.2321 
Diseases of metabolism BCLL subgroup 2 1.41 0.1111 0.2349 
Signaling by WNT BCLL subgroup 2 1.39 0.1019 0.2369 
Signaling by nuclear receptors BCLL subgroup 2 1.40 0.1091 0.2372 
Infectious disease BCLL subgroup 2 1.38 0.1333 0.2380 
Asparagine N linked glycosylation BCLL subgroup 2 1.38 0.1222 0.2397 
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Metabolism of RNA Control B cells -3.19 <0.0001 <0.0001 
Cell cycle Control B cells -2.83 <0.0001 <0.0001 
Cell cycle mitotic Control B cells -2.61 <0.0001 0.0012 
RNA polymerase ii transcription Control B cells -2.37 <0.0001 0.0037 
DNA repair Control B cells -2.27 <0.0001 0.0052 
M phase Control B cells -2.29 <0.0001 0.0052 
Mitotic G phase and G-S 
transition 
Control B cells -2.27 0.0020 00.0058 
Cell cycle checkpoints Control B cells -2.31 0.0019 0.0061 
S phase Control B cells -2.03 0.0061 0.0152 
Separation of sister chromatids Control B cells -2.06 0.0062 0.0156 
Transcriptional regulation by 
TP53 
Control B cells -2.04 0.0039 0.0159 
Mitotic metaphase and anaphase Control B cells -2.05 <0.0001 0.0159 
Neddylation Control B cells -1.93 0.0019 0.0256 
Rho GTPases activate formins Control B cells -1.81 0.0257 0.0456 
Antigen processing ubiquitination 
proteasome degradation 
Control B cells -1.78 0.0218 0.0516 
HIV infection Control B cells -1.77 0.0150 0.0519 
Regulation of TP53 activity Control B cells -1.75 0.0298 0.0532 
Mitotic prometaphase Control B cells -1.72 0.0307 0.0572 
Cellular responses to external 
stimuli 
Control B cells -1.65 0.0267 0.0808 
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Metabolism of carbohydrates Control B cells -1.48 0.0751 0.1629 
TNFR2 non canonical NFKB 
pathway 
Control B cells -1.48 0.0731 0.1662 
Cilium assembly Control B cells -1.41 0.0891 0.2074 

























Supplemental table S9. List of genes differentially expressed between BCLL subgroups by RNA Seq that 
were also measured in the NanoString experiment. The adjusted p value and fold change from the RNA 





SUPPLEMENTARY MATERIAL FOR CHAPTER 4 
 
Routine and expanded immunoglobulin PCR for antigen receptor rearrangements (PARR) methods 
Routine PARR primers 
The Colorado State University-Clinical Immunology laboratory routine PARR assay detects 
complete immunoglobulin (IG) heavy chain rearrangements composed of a V (variable) gene, D 
(diversity) gene and J (joining) gene, and incomplete IG heavy chain rearrangements composed of a D 
gene and J gene. For complete IGH-VDJ rearrangement amplification in our routine PARR assay, forward 
primers bind the framework 1 region of immunoglobulin heavy variable (IGHV) genes in the 
predominant IGHV3 gene family. The majority of IGHV genes in the canine immunoglobulin locus belong 
to subgroup IGHV3 (previously the VH1 family), and four studies demonstrate that IGHV3 genes 
predominantly rearrange.94,99,100,121  Two reverse primers target the three major immunoglobulin heavy 
joining (IGHJ) genes of the six IGHJ genes annotated in the locus.98,121 For incomplete IGH-DJ 
rearrangements in the routine PARR assay, forward primers bind the most commonly rearranged 
immunoglobulin heavy diversity (IGHD) genes (IGHD2, IGHD3, and IGHD4) of the six IGHD genes 
annotated in the locus.94,98,99 The forward IGHD primers are paired with the reverse IGHJ primers used to 
detect complete IGH-VDJ rearrangements. Primer sequences and amplification methods are described 
in the supplemental material in Colopy et al.123  
Expanded immunoglobulin PARR reaction 
 An expanded primer set was designed to detect additional IG gene rearrangements in three 
separate reactions (Supplemental table S10). To detect additional complete IGH-VDJ rearrangements, 
IGHV3 subgroup primers binding framework region 3 were designed to target additional IGHV3 genes 
which do not have conserved homology in the framework 1 region. Two additional primers target 
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framework 2 of the functional gene in the IGHV1 subgroup (IGHV1-30) and the one functional gene in 
the IGHV4 subgroup (IGHV4-1), respectively, increasing the IGHV genes targeted. For incomplete IGH-DJ 
rearrangements, six IGHD primers were designed so that all six IGHD genes are targeted. To detect IG 
light chain rearrangements, primers were designed to amplify the kappa deleting element (Kde) and IG 
lambda (IGL) rearrangements. Five forward primers and a reverse primer were designed to bind a subset 
of IGLV and IGLJ genes. 
 For each of the three reactions in the expanded PARR assay, 100-500 ng of DNA was amplified 
with the QIAGEN Multiplex PCR Master Mix kit (QIAGEN, Hilden, Germany) in a 25 µL volume reaction. 
Primer sequences and primer concentrations are provided in Supplemental table S10. Primer sets were 
labeled with FAM fluorescent dyes. The PCR cycling conditions were identical to those used for routine 
canine PARR, and fragment analysis on an ABI 3130xl system (Applied Biosystems, Foster City, CA) and 
data analysis with GeneMarker software (Soft Genetics, State College, PA) were performed as previously 
described.123 
Supplemental table S10. PCR for antigen receptor rearrangements (PARR) primers for amplification of 









Sequence (5’ – 3’) Primer 
concentration 
(nM) 
Reaction 1: complete IGH-VDJ rearrangements  
267TAG IGHV  CATAACCGATTCACCATCTCCAGAGA 400 
193f IGHV  AAGGGCCGATTCACCATCTC 400 
V80_165 IGHV  TGGGAGGGGACTGGAATGGAT 100 
V51_190 IGHV  CTGGGTACGACAGGCTYCAG 100 
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Brd3 IGHJ FAM ACCTGAGGAGACGGTGACC 250 
Brd4 IGHJ FAM TGAGGACACGAAGAGTGAGG 250 
Reaction 2: incomplete IGH-DJ rearrangements  
1pq4 IGHD  ACTGTGGTACTACTGTACTGATGAT 125 
2pq1 IGHD  AAGGAACATTGCACTGTGCTACTA 125 
3rb1-flap IGHD  TCAAAGGGTGTCACACAGTGTATA 125 
4pq2-flap IGHD  CTGGTCTGTGTCACGGTGGTATAGTA 125 
5pq3-flap IGHD  AAGGCCTGAGGCAGTGTGAGTTCTA 125 
6pq2-flap IGHD  GTTTGGCCCAGGTAGGAACCACAGTGCTAAC 125 
Brd3 IGHJ FAM ACCTGAGGAGACGGTGACC 250 
Brd4 IGHJ FAM TGAGGACACGAAGAGTGAGG 250 
Reaction 3: Kde and IGL rearrangements  
48F Kde FAM TGGCGATCTTTTGTCAGGACTG 250 
306R Kde  TGCAAAAATGTCATGGGGCTCT 250 
46F IGLV  CAGAGGGTCACCATYTCCTGC 250 
425F IGLV  AGACTGTCACCATCTCCTGT 250 
422F IGLV  AGGGACAGTCACACTCACAT 250 
420F IGLV  CTGGAAGAGTCGGTCAAGC 250 
426F IGLV  AAGACAGCCACCATCACMTG 250 






Expanded immunoglobulin PARR analysis 
 Complete IGH-VDJ (reaction 1) and incomplete IGH-DJ (reaction 2) rearrangements amplified 
with expanded primers were interpreted with the same diagnostic criteria used for IGH-VDJ and IGH-DJ 
rearrangements in the routine assay, respectively. For IG light chain rearrangements (reaction 3), Kde 
and IGL reactions were defined as clonal by 1-2 tall narrow peak(s) >8,000 in amplitude in the absence of 
a robust polyclonal base. These loci have limited junctional diversity compared to complete V-D-J 
rearrangements from IG heavy chain loci, and they are more challenging to interpret.9 For example, in 
this assay polyclonal Kde results frequently have 1-2 peaks which are 2x the height of the other peaks 
forming the base. Therefore, we use more stringent criteria to define clonality in these loci and only 
interpret a peak as clonal if there is minimal to no polyclonal base. Representative clonal and polyclonal 
results for Kde and IGL loci in the expanded PARR assay are shown in Supplemental figure S1.       
 
Supplemental figure S1. PCR for antigen receptor rearrangements (PARR) clonal and polyclonal results 
for kappa deleting element (Kde) and immunoglobulin lambda (IGL) light chain reactions. The size of the 
PCR products is on the horizontal axis and abundance is on the vertical axis. Two clonal results and two 
polyclonal results are shown for each reaction. Clonal results (top) have 1-2 tall narrow peaks with a 




Expanded immunoglobulin PARR primer testing 
The expanded IG PARR primers were tested on 10 negative control and 10 positive control 
samples. For negative controls, routine PARR and PARR with expanded IG primers were performed on 
peripheral blood samples from ten healthy control dogs with no evidence of lymphoproliferative disease 
by flow cytometry. All three expanded IG reactions were polyclonal in all 10 cases. Ten randomly 
selected small breed BCLL patients that were clonal with routine PARR were tested with expanded IG 
primers. Results are presented in Supplemental table S11. All 10 cases were clonal with the expanded 
complete IGH-VDJ reaction (100%), and 7 cases were clonal with the light chain reaction (70%). Four 
cases were clonal with the expanded incomplete IGH-DJ reaction (40%). One of these cases had a clonal 
incomplete rearrangement on routine PARR, two cases had suspicious peaks that did not reach clonal 
criteria on routine PARR, and one case had polyclonal incomplete rearrangements on routine PARR. Of 
the six cases with polyclonal expanded incomplete IGH-DJ results, 1 was considered clonal with routine 
PARR IGH-DJ primers, 1 had a suspicious peak that did not reach clonal criteria, and 4 were polyclonal. 
Supplemental table S11. PCR for antigen receptor rearrangements (PARR) results for 10 B-cell chronic 













Light chain loci 
(expanded 
assay) 
1 Clonal Clonal Clonal Clonal Clonal 
2 Clonal Clonal Clonal Polyclonal Clonal 
3 Clonal Clonal Polyclonal Clonal Clonal 
4 Clonal Clonal Polyclonal Polyclonal Polyclonal 
5 Clonal Clonal Polyclonal Polyclonal Polyclonal 
6 Clonal Clonal Polyclonal Polyclonal Clonal 
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7 Clonal Clonal Polyclonal Polyclonal Polyclonal 
8 Clonal Clonal Possible clonal Clonal Clonal 
9 Clonal Clonal Possible clonal Clonal Clonal 









AA, Amino acid 
AIR, Airedale Terrier 
BASS, Bassett hound 
BCLL, B-cell chronic lymphocytic leukemia 
BCR, B-cell receptor 
BDC, Bearded Collie 
BIC, Bichon frise 
BOR, Border collie 
BOST, Boston terrier 
BOX, Boxer 
CBC, Complete blood count 
CCR, Chinese crested 
CDR, Complementarity determining region 
CDR3, Complementarity determining region 3 
CDT, Coton de Tulear 
CKP, Cockapoo 
CLL, Chronic lymphocytic leukemia 
CLL-IPI, Chronic lymphocytic leukemia international prognostic index 
COC, Cocker spaniel 
CRN, Cairn terrier 
CSH, Chihuahua shorthair 
CSU-CI, Colorado State University-Clinical Immunology 
D, Diversity 
DACH, Dachshund 




FC, Fold change  
FDR, False discovery rate 
FPKM, Fragments per kilobase million 
FR, framework region 
FS, Forward scatter 
GLDR, Golden retriever 
GSEA, Gene set enrichment analysis 
GWAS, Genome-wide association study 
IF, Immunofixation 
IG, Immunoglobulin 
IGH, Immunoglobulin heavy chain 
IGHD, Immunoglobulin heavy diversity 
IGHJ, Immunoglobulin heavy joining  
IGHM, Immunoglobulin heavy constant mu 
IGHV, Immunoglobulin heavy variable  
IGK, Immunoglobulin light chain kappa 
IGL, Immunoglobulin light chain lambda 
IMGT, International ImMunoGeneTics 
IQR, Interquartile range 
J, Joining 
JRT, Jack Russell terrier 
KDE, Kappa deleting element 
LAB, Labrador retriever 
LBD, Labradoodle 
MAST, Mastiff 
MFI, Median fluorescence intensity 
MIX, Mixed breed 
MLT, Maltese 
MST, Median survival time 
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MTD, Maximum tolerated dose 
N, Number 
NA, Not applicable 
NES, Normalized enrichment score 
NEWFIE, Newfoundland 
NHL, Non-Hodgkin lymphoma 
P, Pseudogene 
PARR, PCR for antigen receptor rearrangements 
PBLEB, Polyclonal B-cell lymphocytosis in English bulldogs 
PBS, Phosphate buffered saline 
PE, Protein electrophoresis 
PIT, Pit bull terrier 
POM, Pomeranian 
PPBL, Persistent polyclonal B-cell lymphocytosis 
RALD, Ras-associated autoimmune lymphoproliferative disorder 
RAT, Rat Terrier 
RIN, RNA integrity number 
RNA Seq, RNA Sequencing 
RS, Recombination sequence 
SHI, Shih Tzu 
SLL, Small lymphocytic lymphoma 
SNP, Single nucleotide polymorphism 
STS, Schnauzer 
TCR, T-cell receptor 
TIBT, Tibetan terrier 
TRB, T-cell receptor beta 





WET, Soft Coated Wheaten Terrier 
